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H uman ageing is accompanied by characteristic metabolic and endocrinechanges, including altered hormone profiles, insulin resistance and
deterioration of skeletal muscle. Obesity and diabetes may themselves drive
an accelerated ageing phenotype. Untangling the causal web between ageing,
obesity and diabetes is a priority in order to understand their aetiology and
improve prevention and management.
The role of biological ageing in determining the risk of obesity and associated
conditions has often been examined using mean leukocyte telomere length
(LTL), a marker of replicative fatigue and senescence. However, considering
phenotypes which represent different domains of biological and functional
ageing as exposures for obesity and related traits could allow the elucidation
of new understudied phenotypes relevant to cardio-metabolic risk in the wider
population.
This PhD considers the causal role of (1) hand grip strength (HGS), a marker
of overall strength and physical functioning, and (2) resting energy expenditure,
an indicator of overall energy metabolism and the major component of daily
energy expenditure, in cardio-metabolic risk. I also characterise a new and
readily-quantifiable marker of age-related genomic instability, mosaic loss of
the Y chromosome (mLOY). Observational evidence implicates each of these
phenotypes in cardio-metabolic conditions and intermediate phenotypes. How-
ever, it is not possible to infer causality from these observational associations
due to confounding and reverse-causality. Mendelian randomisation offers a
solution to these limitations and can allow the causal nature of these relation-
ships to be investigated. Using population-based data including UK Biobank,
this thesis presents the first large-scale genetic discovery effort for each trait
and provides new biological insight into their shared and separate aetiology. I
used identified variants to investigate the bidirectional causal associations of
each trait with cardio-metabolic outcomes, intermediate phenotypes and other
related traits such as frailty and mortality. In total I identified 16 loci for hand
grip strength, 19 for mLOY, and one signal for REE. I have shown that HGS is
likely to be causally linked to fracture risk, and I have identified the important
shared genetic architecture between mLOY, glycaemic traits and cancer. I
have also demonstrated that at least one known genetic variant contributing to
obesity risk acts partially via reduced REE.
Overall the findings of my PhD contribute to our wider understanding of the
aetiological role of ageing processes in metabolic dysfunction, and have impli-
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Common abbreviations and acronyms used throughout this thesis are specified
with a brief description below. Other abbreviations are defined on an ad-hoc
basis throughout the main text.
REE Resting energy expenditure, the minimum 24-hour energy requirement of a
wakeful, fasted adult at complete physical and mental rest
PAEE Physical activity energy expenditure, 24-hour energy expenditure due to skeletal
muscle contraction (volitional and non-volitional)
TEF Thermic effect of food, the 24-hour uplift in energy expenditure corresponding to
post-absorptive digestion of food and assimilation of nutrients
TEE Total energy expenditure, the sum of REE, TEF and PAEE
HGS Maximal isometric hand grip strength across both hands, unless otherwise spec-
ified
mLOY Mosaic loss of the Y chromosome
T1D/T2D Type 1/Type 2 Diabetes Mellitus
GWAS Genome-wide association study (from array genotyping)
EDTA Ethylenediaminetetraacetic acid, a preservative used in blood sampling
1000G 1000 Genomes reference panel
HRC Haplotype Reference Consortium
LD Linkage Disequilibrium
HLA Human Leukocyte Antigen complex (Major Histocompatibility Complex) at chro-
mosome 6p21. As specified throughout this document, this region is often dis-
counted from genetic discovery and downstream analyses due to structural com-
plexities
HWE Hardy-Weinberg Equilibrium
DXA Dual X-ray Absorptiometry, the gold standard for assessment of compartmen-
talised and tissue-specific body masses
UKB UK Biobank cohort
GEFOS GEnetic Factors for OSteoporosis Consortium
CHARGE Cohorts for Health and Ageing Research in Genetic Epidemiology Consortium
CARDIoGRAMplusC4D Coronary ARtery DIsease Genome wide Replication and Meta-analysis plus
Coronary Artery Disease Consortia
GIANT GEnetic Investigation of ANthropometric Traits Consortium
SNP Single nucleotide polymorphism (usually biallelic)
CI Confidence interval
MR Mendelian randomisation
EPIC European Prospective Study of Nutrition and Cancer
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O besity, type 2 diabetes (T2D) and associated cardio-metabolic disorders are amongst the mostpressing of threats to global public health. In 2012, more than a third of adults and 17% of children
were clinically obese in the United States1 on the basis of body mass index (BMI) ≥30kg/m2. This level
is rapidly being approached by the United Kingdom and other European countries2, and represents only
the uppermost subset of the considerably larger overweight population. Excess weight (BMI≥25kg/m2)
affects more than half of adults in the US, for example, with the burden concentrated in those of middle
and older age1. Moreover, obesity and its related conditions are now a truly globalised epidemic as the
epidemiological transition sees their prevalence rising rapidly throughout the developing world3–5. The
burden which these conditions place on quality of life is immense, and their economic and social con-
sequences unsustainable in even the most developed nations6,7. There is, therefore, a clear imperative
to advance our understanding of their aetiology, with a view to improving translational prevention and
management.
1.1 Introduction
Age is an established risk factor for non-communicable disease, but, biologically, individuals age at dif-
ferent rates. Indeed, ageing is a composite of multiple processes which should be considered as sepa-
rate concepts to chronological age. These domains reflect aspects of biological, physiological and func-
tional ageing which are not adequately summarised by lifespan alone8–11. The theorised link between
metabolism and ageing extends back many years to the ’Rate of Living’ hypothesis - the first to speculate
on possible associations between elevated metabolic rate and decreased lifespan12. Whilst the major
principles of this hypothesis are now considered largely inaccurate13, later hypotheses - namely that age-
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ing is driven by oxidative damage resulting from metabolic production of reactive oxygen species (ROS)14
- remain central to our concept of ageing8. The close relationship between ageing and metabolism is
now well established. Data from in vitro and in vivo models and human populations suggests that age-
ing is characterised by a range of metabolic alterations, including (i) changes in circulating growth and
steroid hormones such as insulin-like growth factor I, (ii) altered body composition as a result of increased
adiposity and sarcopenia (age-related degeneration of skeletal muscle), (iii) increased insulin resistance,
and (iv) mitochondrial dysfunction15. It has been argued that the established cellular hallmarks of age-
ing universally have important metabolic repercussions, and are major aetiological drivers of age-related
metabolic dysfunction15,16.
In recent years there has been substantial interest in characterising the aetiological role of biological and
functional ageing in the development of obesity, T2D, and associated conditions at population level. Bio-
logical ageing has most commonly been modelled using leukocyte telomere length (LTL). Telomeres are
highly repetitive sequences which cap the ends of chromosomes and play a crucial role in maintaining
the stability of genomic DNA17. To overcome the ’end-replication problem’ - the fact that the end-most
sections of genomic DNA cannot be copied in full by the cell’s replicative machinery18 - telomeres are
progressively degraded with successive cell divisions until, at a threshold level of shortening, the cell
enters senescence18,19. Shortening can be observed in humans at population level20 and, as a com-
bined indicator of both senescence and oxidative stress21, is conventionally considered a good marker of
biological age11.
Population-based studies have observed a moderate association between lower LTL and obesity22,23,
glycaemic traits and diabetes24–26 and coronary heart disease27; the cross-sectional design of much of
this work, however, makes the establishment of causal directionality in the exposure-outcome association
particularly challenging. Altered physiological milieu associated with cardio-metabolic outcomes (such as
chronic low-grade inflammation or hyperglycaemia), for example, may in fact act as a driver of telomere
attrition, rather than the reverse, highlighting the issues raised by confounding and reverse causality when
considering LTL as an observational exposure. Studies of alternative ageing metrics such as hand grip
strength - a widely used proxy for functional ageing prospectively associated with mortality risk, diabetes
and CHD - are inherently prone to the same set of limitations.
Modern genetic methods offer a robust solution to the limitations of observational epidemiology in estab-
lishing causality. The principle of Mendelian randomisation (MR) leverages the fact that alleles contribut-
ing to variation in a phenotypic trait are randomly and independently allocated at conception, to model
genetically-predicted variation in that trait at population level. Given that an individual’s allele allocation
is fixed throughout the lifespan, and not susceptible to external confounders according to the classical
definition of confounding, the association between this genetically-modelled trait and an observed out-
come of interest can be interpreted causally. MR and its many extensions have gained traction as an
22
epidemiological tool in recent years, and are now a widely-accepted method for causal inference.
Mendelian randomisation approaches considering LTL as a causal exposure for cardiometabolic condi-
tions do exist28,29, and have provided some initial insights into these conditions as downstream effects of
biological ageing processes. Sixteen common variants (10 independent loci) for LTL have been identified
to date28, primarily in a large cohort of 48,000 Europeans30, but further progress in modelling telomere
length as a causal exposure will require this instrument to be substantially expanded in order to increase
the variance explained, as power in MR is partially a function of the phenotypic variance accounted for
by the instrument. A sufficiently expanded discovery effort is precluded by the availability of additional
samples with intersecting LTL quantification and genome-wide genotyping. In addition, it could be argued
that LTL is a relatively abstract concept in terms of modelling age and, importantly, is non-modifiable.
Considering the specific role of other physiological and metabolic correlates of human ageing may allow
us to focus more closely on the underlying biology predisposing to metabolic dysfunction.
In this thesis, I present an alternative approach to investigating the role of ageing in cardiometabolic
dysfunction, focussing on selected markers of physiological ageing and physical functioning: hand grip
strength, resting energy expenditure, and mosaic loss of the Y chromosome, an emerging marker of stem
cell dynamics and genomic instability with age. Observational evidence suggests an association between
each of these phenotypes and metabolic conditions, but the underlying genetic variants in each case are
poorly characterised, and robust establishment of causal direction has so far not been possible. Each trait
may also be of relevance as a continuous risk factor in the extended population, not restricted to those of
older age.
Using large population-based studies such as UK Biobank, this PhD focusses on new genetic discovery
for each REE, HGS and mLOY and applies a range of downstream analyses based on tissue enrichment,
expression profiles, and pathway analysis to gain detailed biological insight into each trait. These discov-
ery efforts represent the largest and most informative genome-wide association studies (GWAS) to date
for these phenotypes, and allow me to investigate the shared genetic architecture of ageing phenotypes
with cardiometabolic traits. As an adjunct to this, I conduct detailed observational mediation analyses to
establish whether known genetic variants for BMI exert their effect on adiposity through population-level
variation in REE.
Where possible, variants identified are utilised as instrumental variables to allow them to be modelled as
causal exposures for cardiometabolic traits, intermediate phenotypes (e.g. continuous glycaemic traits)
and other potential outcomes of interest such as mortality, within a Mendelian randomisation framework.
To fully detangle the causal direction of the ageing-metabolism association, the role of selected metabolic
traits as causal drivers of these ageing traits is also considered.
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1.2 Hand Grip Strength
Muscle strength is a key determinant of quality of life amongst the elderly31,32, an established frailty
marker33,34, and a prospective predictor of physical decline35,36, functional limitation37,38 and loss of in-
dependence in activities of daily living38,39 in middle- and older age. Most commonly, limb strength is
assessed at population scale and in the clinic using isometric hand grip strength (HGS) - an accessible
and readily-applied measure which correlates with other indices of skeletal muscle strength40,41 includ-
ing knee extensor force (Pearson’s ρ ~0.7). Decreased HGS forms part of the consensus definition of
sarcopenia42 - pathological age-related reduction in muscle mass and function - and, as a commonplace,
easily-assessed quantitative indicator of strength, has been suggested as an ideal phenotype to facili-
tate genetic characterisation of late-life physical functioning phenotypes43. Efforts to identify underlying
genetic variants have so far been few and far between, despite the commonplace measurement of HGS
as a functional phenotype. Various candidate approaches have highlighted the possible role of a hand-
ful of genes based on hypothesised biological priors, but GWAS approaches have yet to be applied in
sufficiently-powered samples to rigorously implicate variants in a hypothesis-free manner44.
Lower HGS robustly predicts all-cause mortality35,45–48 independently of changes in muscle mass, and
has recently been characterised as a prognostic indicator of CHD with potential clinical utility in low-
resource settings49. Strong observational links with age-related morbidity and mortality have strength-
ened the perception of HGS as a marker of ageing. However, the capacity of HGS to reflect underlying
undiagnosed and early pathological processes through reverse causation - for example in the case of
diabetes50–52 and obesity53,54 - highlights the need to unpick directionality in the association of HGS with
health outcomes. Based on data from Scandinavian conscripts, it has also been suggested that - out-
side the more commonly-studied timeframe of middle and older age - adolescent grip strength may be an
important predictor of mortality over the lifecourse55.
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1.3 Resting Energy Expenditure
1.3.1 Definition and Measurement
Resting energy expenditure (REE) is defined as the energy required by a fasted adult to maintain physi-
ological homeostasis and vital functions whilst wakeful, and physically and mentally at rest, in a thermo-
neutral environment56–59. REE corresponds to the baseline minimum energy requirement to sustain life
without the additional energy costs attributable to movement or digestion and assimilation of nutrients. It
should be differentiated from the basal metabolic rate, which refers to the baseline energy requirement of
an individual whilst asleep. Dependent on how sedentary a lifestyle an individual leads, REE contributes
around 60% of total daily energy expenditure (TEE)56, which otherwise comprises energy expenditure re-
sulting from contraction of skeletal muscle (physical activity energy expenditure, PAEE) and the energetic
cost of digestion (thermic effect of food, TEF; Figure 1.1). For purposes of thermoregulation, energy may
additionally be expended as non-shivering or shivering thermogenesis, which are regarded as subsets of
REE and PAEE for most intents and purposes. Taken in the context of total energy intake, REE forms
one side of overall energy balance. Intuitive interest in REE as an aetiological factor for weight gain and
cardiometabolic dysfunction has been driven by the fact that obesity is a condition of chronic energy bal-
ance, and REE constitutes the majority of daily energy expenditure. Its complex association with both
body composition and ageing (discussed in detail below) highlights the gains which might be made by
genetic characterisation and causal inference of this trait.
The definitive measure of REE is direct calorimetry, which assesses energy use by direct measurement of
radiated heat, based on the thermodynamic principle that all energy utilised by endotherms is ultimately
lost as heat60,61. The accepted gold-standard for assessment of REE in a clinical and research setting,
however, is indirect calorimetry: measurement of the relative fractions of inspired and expired O2 and CO2
to derive metabolic O2 consumption (VO2) and CO2 production (VCO2). In turn, these parameters are
used to calculate REE according to standard formulae which account for substrate use by calculation of
the respiratory exchange ratio (V CO2V O2 ) and correspondingly assign a caloric equivalent to VO2 based on
findings from bomb calorimetry of macronutrients62.
1.3.2 Non-Genetic Determinants
Age, Sex and Body Composition Nearly a century of research begun by the 1918 work of Harris and
Benedict63 supports the central and highly intuitive role that body size - and composition - plays in the
determination of REE. REE is predominantly determined by fat-free mass (FFM)64,65, is lower in women
relative to men63,66,67, and inversely related to age, independent of sex-related differences in body com-
position or overall changes in relative fat and fat-free compartments68–70. Age-related decreases in REE
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Figure 1.1: Contribution of
REE to total daily energy ex-
penditure. REE contributes
around 60% of total daily en-
ergy needs, dependent on activ-
ity levels. The remainder of total
energy expenditure comprises
the thermic effect of food (TEF)
and physical activity energy ex-
penditure (PAEE). PAEE can
be split into incidental move-
ment attributable to daily liv-
ing (Non-exercise energy ex-
penditure, NEEE), and volitional
exercise-induced energy expen-
diture (VEE) resulting from de-
liberate exertion.
might be explained by changes in the metabolic rate of specific organs over the lifecourse68, whilst abso-
lute fat mass may also play an important independent role71, though literature is inconsistent72. Effects
on REE observed per unit fat mass are considerably less than for FFM, reflecting the known disparity
in the metabolic activity of these tissues. For example, in a healthy cohort of 150 adults, Johnstone and
colleagues73 have reported that dual x-ray absorptiometry (DXA)-derived fat-mass explains 6.7% variance
in REE (p<0.01), in contrast to 63% explained by FFM.
Ancestry REE is lower in black, relative to Caucasian, individuals, independent of body composition74–76.
A particular body of evidence supports this observation amongst African-American women77–83, who rep-
resent a demographic of special interest due to their disproportionate predisposition to obesity, and in-
creased risk of weight gain84, for which REE has been hypothesised as an aetiological driver85. Lower
REE amongst blacks is suggested to be mediated by decreased functional organ mass by comparison to
whites86. Differences in REE continue to be observed when ethnicity is modelled as a continuous trait.
Amongst African-Americans, REE is lower with higher African admixture87, whilst increased European
admixture correlates with increased REE88, suggesting an underlying genetic component to the ethnic
observation.
Stimulants and Alcohol Nicotine is acutely thermogenic89–91, yet the influence of long-term smoking
status is relatively under-studied. Adjusted for body composition parameters, existing work suggests that
REE is greater in current relative to never smokers amongst obese African-American83 and Caucasian92
populations, albeit in small samples. Most recently, Blauw et al.93 have replicated this finding in 6,673
Dutch nationals, reporting that elevated REE is restricted to smoking in the current vs. never subcohort,
with no continuous effects per pack-year smoked. Similarly, alcohol91,94 and caffeine89,95,96 intake are
associated with short-term increases in REE, but the effect of habitual intake as a lifestyle exposure
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remains to be elucidated. Nonetheless, these correlates highlight the need to ensure that participants in
whom REE is measured are free of stimulants and alcohol57.
1.3.3 Genetic Determinants
Family and twin studies ranging from the mid-1980s to the present72,97–99 consistently estimate the herita-
ble component of REE at around 30%, yet underlying variants remain uncharacterised. Existing literature
for the most part comprises candidate gene studies utilising biologically plausible genes identified by prior
work in animal models or high-profile obesity-related genes in humans100–106. Though significant gene-
REE associations are reported in a number of cases, this work is afflicted by the standard limitations of
early candidate gene studies, being underpowered, lacking replication of findings in appropriate indepen-
dent samples, and accounting for neither key confounders such as body size, age and sex, nor multiple
testing.
Whilst hypothesis-free approaches are not altogether absent, they have been of limited value and mostly
pre-date the modern GWAS era. Genome-wide linkage studies utilising microsatellite panels have previ-
ously been conducted in French Canadians107, Nigerians108 and (for baseline metabolic rate as opposed
to REE) Pima Indians109. The Pima Indian population has also recently provided a modern GWAS for
objectively-measured REE110 (n=507), implicating a variant intronic in GPR158. Even this latest effort is
notably underpowered for genome-wide discovery, and an absence of replication in comparable popula-
tions limits interpretation and highlights the need for further discovery work pooling many thousands of
samples with objective assessments of REE.
1.3.4 REE as an Aetiological Factor
The intuitive role of REE in cardiometabolic disease (particularly obesity) is clear, and has generated in-
terest for many decades. A popular historic approach has been to quantify REE in so-called ’post-obese’
subjects relative to never-obese controls; such studies report lower REE amongst previously obese partic-
ipants who have returned to normal weight111. These retrospective observational approaches are partic-
ularly prone to confounding by ’adaptive thermogenesis’; change in REE corresponding to altered energy
intake, which exceeds the change attributable to changes in body composition alone112–115. Indeed, neg-
ative energy balance at the level required for safe weight loss induces adaptive responses which persist
over subsequent periods of weight maintenance116–118. Studies reporting lower REE amongst obese rel-
ative to normal weight participants119,120 are liable to reverse causation, even after adjustment for body
composition. REE prospectively predicts weight gain during follow-up of American Indians independent of
age, sex and body composition121, and Italians122 normalised for fat-free body mass, but not amongst a
multi-ethnic cohort of American men123, the largest such study to date. The complex relationship of REE
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with body mass, and its vulnerability to confounding and reverse causation, highlight the advances which
might be made through the application of techniques for robust causal inference.
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1.4 Mosaic Loss of Y Chromosome
Of the three main phenotypes considered within this thesis, mosaic loss of Y (mLOY) has the least devel-
oped body of literature concerning a possible aetiological role in cardiometabolic dysfunction; but, as an
outcome of genomic instability, has a strong theoretical basis as an ageing phenotype8.
mLOY is a post-zygotic aneuploidy acquired during the lifecourse, and involving complete loss of the
Y chromosome in a proportion of somatic cells, resulting in genomic mosaicism for the Y chromosome.
mLOY constitutes one of a wider set of post-zygotic variations with relatively high prevalence at population
level, which are increasingly recognised as of relevance to disease processes124. Described for many
decades125,126, Y mosaicism in peripheral blood is the most common chromosomal aneuploid event in
humans by an order of magnitude and is strongly associated with age. More than one fifth of men aged
>80 years had detectable Y mosaicism in peripheral blood in a recent study, though mLOY of some extent
is commonly observed from middle age onwards127. Y loss represents a binary event at the cellular level
(lost/retained), but can be expressed as a proportion of affected blood cells at the individual level128, using
fluorescence estimates of Y chromosome abundance from standard genome-wide genotyping arrays.
The high prevalence of mLOY clearly demonstrates that peripheral blood cells are able to survive in the
absence of the Y chromosome, and offers a unique scenario in which a severe chromosomal defect is
able to be observed and quantified at population scale in apparently healthy men.
Whilst conventionally considered an innocuous age-related phenomenon rather than an aetiologically-
significant factor for health129,130, the recent recognition that greater mLOY is associated with prospec-
tive risk of Alzheimer’s disease127, non-haematological cancers131–133 and mortality131 has ignited in-
terest in mLOY as both an important biological correlate of ageing, and an independent exposure for
disease risk124,128. Large-scale autosomal mosaicism has also been associated with cardiovascular out-
comes amongst people with diabetes134, highlighting the potential aetiological importance of mLOY in
cardiometabolioc dysfunction. However, the fact that mLOY is a post-zygotic mutation and consequently
subject to confounding in the same way as any other observational exposure - for example by behavioural
factors such as smoking135 - prevents robust examination of mLOY as a causal exposure for these traits
in current work.
The ease with which mLOY can be assessed, and the fact that it can be derived from existing large scale
genome-wide genotype data, makes it a particularly attractive phenotype for future work, and particularly
for very large scale genetic discovery. Identification of autosomal variants underlying mLOY in men may
provide fundamental insights into the common biology of genomic instability in both sexes, and its inter-
section with disease risk, whilst allowing the significance of chromosomal mosaicism as an age-related
causal disease exposure to be formally assessed.
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1.5 Summary of Rationale and Objectives
The rationale and areas of opportunity for this thesis can be summarised as follows:
1. Ageing is a complex and multi-factorial exposure which is inherently of interest in disease risk, and
is closely associated with obesity and related cardiometabolic dysfunction.
2. Understanding the directionality of ageing as an exposure or outcome of disease will have transla-
tional benefit.
3. Hand grip strength, resting energy expenditure, and Y chromosome mosaicism each represent dif-
ferent functional and biological aspects of ageing, and are observationally implicated in the aetiol-
ogy of cardiometabolic disease either directly or (in the case of mLOY) through related phenomena.
4. Considering these wider functional and biological phenotypes of ageing will allow relevant biology
and physiology to be more closely interrogated, and will facilitate the study of these phenotypes as
exposures for disease in the wider population, and outside the immediate context of ageing.
5. Standard observational approaches preclude causal inference given their liability to reverse causa-
tion and confounding.
6. Mendelian randomisation offers a solution robust to these limitations.
7. Highly-powered and informative genetic discovery efforts for HGS, REE and mLOY are absent in
the literature, and will provide new and valuable insights into the biology of these traits.
Through application of genome-wide discovery efforts in very large-scale population-based data including
UK Biobank and very deeply phenotyped cohorts such as the Fenland Study, this thesis will characterise
common genetic variants underpinning variation in these phenotypes. Detailed downstream analyses will
be used to prioritise genes at identified loci and to maximise biological insight. Variants implicated will be
applied as instrumental variables to facilitate causal inference of each phenotype on key cardiometabolic
outcomes and intermediate traits, and allow the directionality of known observational associations to be
examined under a bidirectional Mendelian randomisation framework.
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Chapter 2




The work presented in this thesis utilises large observational cohorts as the principal data source for
genetic discovery and associated analyses. Whereas cohorts used for replication and functional insight
or follow-up vary between chapters, and dependent on the availability of necessary phenotype data,
a core of studies are common throughout. Brief procedural details of these cohorts - particularly the
genotyping, quality control and imputation protocols for extracted DNA - are provided here. Elements of
the study which are particularly salient to certain chapters (such as the assessment of chapter-specific
phenotypes) are discussed more fully in the relevant chapter.
2.1.1 UK Biobank
First conceptualised in the early 2000s as a joint venture of the UK Medical Research Council and the
Wellcome Trust136,137, UK Biobank (ukbiobank.ac.uk) is a large population-based observational cohort
designed to facilitate highly-powered research of the aetiology and mechanisms of chronic disease, with
a particular focus on genetics138,139. The study contains more than 500,000 British participants who
have provided a broad range of health data at high resolution, including biological samples (blood, saliva,
urine), detailed physiological and anthropometric measures, and information on lifestyle factors. Most
recently, in collaboration with a UK-wide working group, UKB has delivered objective assessments of car-
diorespiratory fitness and physical activity from triaxial wrist-mounted accelerometry in nearly a fifth of its
participants. Additionally, the study is integrated into the reporting frameworks of the UK National Health
Service (NHS), for automated and ongoing linkage and ascertainment of healthcare events, outcomes
and mortality. UKB has the particular distinction of being fully open access for research undertaken in the
public interest.
Recruitment and Initial Assessment
Between 2006-2010, a total of 503,325 middle- and older-aged (40-69 years) British residents were
recruited from centralised NHS primary care registrations. Upon enrollment, participants attended an
initial assessment visit at one of 22 centres located throughout England, Scotland and Wales, during
which a comprehensive catalogue of anthropometric, physical, lifestyle and behavioural exposures were
assessed, and biological samples (blood, urine and saliva) were drawn. UK Biobank provides a cen-
tralised catalogue of data collected, and detailed protocols for each variable, on its Data Showcase
(ctsu.ox.ac.uk/crystal). Overarching protocols for the study have been described previously139. Briefly,
UKB used a touch screen-delivered questionnaire to initially assess lifestyle factors including diet (food
frequency questionnaire, FFQ) and habitual physical activity (modified short-form Recent Physical Activity
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Questionnaire, RPAQ140), self-reported medical history, psychosocial factors and sociodemographics, as
well as cognitive function. Aspects of this touch screen questionnaire were clarified and expanded upon
during a personal interview with trained personnel. Basic physical measures - for example heart rate,
blood pressure, bone mineral density, hand grip strength and anthropometric phenotypes (e.g. height,
weight) were assessed by a research nurse using standard equipment, and blood samples were drawn.
Participants provided their own urine and saliva samples whilst at the assessment location. Standard-
isation of assessment by reference to centrally-issued standard operating protocols was mandated by
UKB to minimise random and systematic error, and optimise comparability of measures across the net-
work of research staff and assessment centres within which the study operated. All participants provided
informed consent at the start of their assessment visit. UKB attained ethical approval from the UK Na-
tional Research Ethics Committee North West and was conducted in full compliance with the principles
of the World Medical Association Declaration of Helsinki. A relatively low response rate of 5.5% during
recruitment141 (likely due to the untargeted, systematic canvassing of eligible individuals within certain
geographic locale, and high participant burden of enrolment by contrast to some other cohorts) means
that UKB demonstrates a degree of healthy-volunteer effect, and should not be interpreted as a represen-
tative sample of the UK population (see Chapter 7). Such limitations, however, do not preclude valid and
generalisable assessment of epidemiological associations if there is sufficient variability in phenotypes
within the cohort.
Anthropometric measures Weight was measured as part of bioimpedance assessment using a BC418MA
Body Composition Analyser (Tanita Europe BV, Amsterdam, the Netherlands), with the participant dressed
in light clothing. Standing height was measured on a rigid stadiometer (Seca, Birmingham, UK).
Genetic Data
The analyses presented in this thesis primarily use imputed data from UKB’s interim genotyping release
(May 2015), restricted to biallelic SNPs with MAF ≥0.1%. This release covers approximately the first 30%
of the cohort; the remaining participants were released in July 2017, however, this largely fell outside the
timeframe available for analysis within the scope of this PhD. Genotyping and imputation were conducted
using a central pipeline in collaboration with industrial and academic partners, and overseen by UKB.
DNA Extraction and Genotyping To ensure the preservation and long-term stability of biosamples,
UKB devised and applied a standardised sample-handling protocol for blood encompassing prescribed
procedures for the sampling process itself and initial handling at the assessment location, followed by
temperature-controlled shipping to central -80◦C and -196◦C archives across primary and back-up sites142.
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DNA was extracted from EDTA buffy coat using standard approaches with a particular focus on between-
batch consistency before shipping to Affymetrix Research Services (Santa Clara, CA) for centralised
genotyping. Samples were genotyped at >800,000 loci on one of two custom-configured arrays (UK
Biobank Axiom array or UK BiLEVE Axiom array) with 95% common content designed to optimise the
quality and quantity of variants for imputation, whilst directly genotyping selected exome content and rare
coding variants.
Imputation After restriction to biallelic SNPs with MAF ≥0.1 and additional genotyping quality control,
including the removal of SNPs with missing data, multiallelic variants, and 1,037 sample outliers, a subset
of 641,081 autosomal SNPs from 152,256 samples were available for imputation, which was conducted
centrally on behalf of UK Biobank at the Wellcome Trust Centre for Human Genetics, University of Ox-
ford. SNPs were pre-phased using SHAPEIT3 software143, and imputed (using a modified version of
IMPUTE2) to a merged reference panel containing combined haplotypes from the UK10K consortium144
and 1000 Genomes consortium, Phase III145. This approach has previously been shown to provide a high
quality imputation reference in populations of mixed ancestry143. Full details of the genotyping and QC
protocol applied (biobank.ctsu.ox.ac.uk/crystal/docs/genotyping_qc.pdf), and the phasing and imputation
approach (biobank.ctsu.ox.ac.uk/crystal/docs/impute_ukb_v1.pdf) are available centrally from UKB.
Subsetting Unrelated Europeans To account for relatedness and population structure within the geno-
typed sample, UKB centrally defined a subset of unrelated European participants which complied to a
strict white European genetic ancestry based on principal components analysis, and were free of overt
relatedness. This subsample was used in sensitivity analyses and methods within which population struc-
ture could not otherwise be accounted for, as indicated throughout.
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Box 2.1 | Fenland Study: A priori exclusion criteria
• Clinical diagnosis of diabetes mellitus
• Terminally ill with prognosis of less than one year
• Suffering from a psychotic illness
• Pregnant or breastfeeding
• Unable to walk unassisted
2.1.2 The Fenland Study
Coordinated from the MRC Epidemiology Unit, Cambridge, phase one of the Fenland study (Fenland)
is a population-based cross-sectional cohort designed to enable enhanced investigation of the joint and
separate effects of genetic and lifestyle factors on intermediate traits relevant to T2D, obesity, and related
metabolic disorders. To achieve this, the study combines large sample size with very complete and
detailed phenotyping, with a particular focus on metabolic profiling and the assessment of continuous
intermediate traits which offer power advantages for analysis and interpretation, by comparison to binary
disease classifications. Fenland was the first cohort to implement truly population-scale assessment of
objective resting energy expenditure by indirect calorimetry as a standard element of the baseline visit,
and remains unique in the volume of calorimetry data it holds.
Recruitment and Initial Assessment
Over the course of ten years from 2005, 12,342 British adults aged 30-55 years were recruited from NHS
primary care practice lists in Cambridge and rural Cambridgeshire, and attended an initial assessment
visit at one of three MRC Epidemiology Unit field centres located in Wisbech, Ely or Cambridge. To facili-
tate robust study of the early pathogenesis of chronic conditions before clinical intervention or confounding
by comorbidities, recruitment was focussed on younger and middle-aged participants free of pre-existing
conditions. Potential participants were identified by their general practitioner and approached for inclusion
(n=46,020; 27% response rate). Individuals were excluded from further consideration if they fulfilled any
one of the criteria outlined in Box 2.1.
Anthropometric Measures Extensive compartmentalised body composition was obtained by dual x-
ray absorptiometry (DXA), the de facto gold standard. Compartment-specific (fat, lean, bone) masses
were measured on a Lunar Prodigy device (GE Healthcare, Buckinghamshire, UK), processed using
proprietary software, and manually partitioned into trunk and peripheral compartments. Total body weight
was measured using callibrated scales, and standing height using a rigid stadiometer.
36
Indirect Calorimetry Participants were requested to fast and refrain from intake of thermogenic stim-
ulants (caffeine, nicotine) from 22.00 on the evening preceding their assessment. Indirect calorimetry
was assessed approximately one hour into the visit; in the intervening time, participants had generally
been sedentary and physically at rest. With the participant fully reclined, open-circuit indirect calorimetry
(Jaeger Oxycon Pro, CareFusion) was assessed for six consecutive minutes using continuous flow (breath
by breath) sampling. The participant breathed normally through a fitted facemask, and remained wakeful,
still and quiet throughout. Live output was monitored by trained research personnel throughout to ensure
data quality. Observed oxygen consumption (VO2) and carbon dioxide elimination (VCO2) were cleaned
and applied to derive resting energy expenditure (kcal/day) by a standardised protocol using established
formulae based on the calorimetric equivalents of the cardiorespiratory parameters. Full details of this
process are provided in Chapter 4).
Genetic Data
DNA was extracted from EDTA whole blood by standard technique at Whatman Biosciences (Cambridge,
UK), and array-genotyped at the MRC Epidemiology Unit on one of three commercial platforms; the
majority on the UK Biobank Axiom array (Affymetrix) utilised for UK Biobank’s centralised genotyping
effort (n=9,368), or, alternatively, on Human Genome-wide SNP 5.0 (Affymetrix, n=1,402) and Infinium
CoreExome-24 (Illumina, n=1,664) arrays. Standard proprietary calling algorithms were used. After sam-
ple quality control (sample call rate ≥95%, heterozygosity thresholds), and omission of variants demon-
strating deviation from Hardy-Weinberg equilibrium (pHWE=5×10-6), variants were imputed (IMPUTE2)




EPIC-Norfolk is one of the two UK-based subcohorts contributing to the European Prospective Study on
Nutrition and Cancer (EPIC), a multi-centre prospective cohort totalling 500,000 participants throughout
ten Western Europe and Scandinavian countries146. EPIC was established in 1989 with the objective
of investigating the role of diet, lifestyle and environment in the development of chronic conditions, with
a particular focus on cancer. With detailed phenotyping spanning multiple prospective timepoints, EPIC
and each of its sub-cohorts have become valuable resources for chronic disease epidemiology and the
exploration of genetic risk.
Recruitment and Initial Assessment
EPIC-Norfolk147 comprises 25,639 British adults aged 40-79 years, recruited from general practice lists
(n=35) in Norwich and surrounding Norfolk between 1993 and 1997. All registered individuals in the
prescribed age range were canvassed for participation unless flagged as unsuitable by the practitioner:
of the 77,630 approached, 30,445 consented to participate, and 25,639 were ultimately enrolled148, a
response rate of 33%. Participants attended a initial first health-check (1HC) upon recruitment, during
which a standard range of anthropometric and physical measures were taken, lifestyle exposures were
assessed and blood was sampled. Since the first health check, participants have routinely been invited
to re-attend for assessment on two occasions; three, thirteen, and twenty years after their initial baseline
assessment. Given its relatively static population and the oversight of care provision by one NHS Trust,
Norfolk was selected as the recruitment setting with the intention of minimising participant attrition and
maximising outcome ascertainment over decades of follow-up; full details of participant response rates
and characteristics between health checks have been published previously148. The assessment process
in subsequent health checks retains the standard elements of the baseline visit but has been expanded
and developed to include new measures with time. For example, assessment of hand grip strength as an
important indicator of overall strength with aging was introduced in the third health check (3HC, n=8,623,
response rate of 46.9% amongst the 18,380 surviving individuals consented before 1HC, who had not
previously withdrawn consent or been lost to follow-up148). The third health check is the primary source of
data for this thesis. There was approximately equal attrition of men and women from the study between
1HC and 3HC, but those attending both 3HC and 1HC were significantly younger, leaner, more educated,
of higher socioeconomic status, more physically active, and less likely to smoke that those who attended
1HC alone148, highlighting a healthy cohort effect which becomes more pronounced throughout the course
of follow-up.
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Anthropometric Measures With the participant dressed in light clothing and barefoot, weight was mea-
sured to the nearest 0.2kg using a digital scale (Salter, UK), and standing height (nearest mm) with a rigid
stadiometer147.
Genetic Data
DNA was extracted from EDTA buffy coat using standard methods. Samples were genotyped at >800,000
SNPs on the UK Biobank Axiom Array (Affymetrix) at the MRC Epidemiology Unit. After removal of SNPs
failing Hardy-Weinberg equilibrium (p≤5×10-6), variants were pre-phased (ShapeIT v2.r790) and imputed
(IMPUTE v2.3.13) to 1000G Phase III individuals (October 2014).
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2.2 Methods
Each of the chapters of this thesis follow a broadly similar analytical trajectory comprising genetic discov-
ery, followed by independent replication of variants where appropriate data are available, and downstream
analyses to (i) provide biological insight (ii) infer causality, and (iii) investigate shared genetic architecture.
In the interests of brevity and to reduce duplication of content, the methods applied commonly within this
analytical pipeline, including detailed discussion of their rationale and context, are provided as a single
point of reference here. Details of methods which do not fall into this overarching pipeline of genetic
discovery and application (for example derivation and measurement of chapter-specific phenotypes) are
outlined in each chapter, as are specific analytic details which vary between cohorts and analyses.
2.2.1 Genetic Discovery and Meta-Analysis
Linear Mixed Models
Linear mixed models (LMMs) offer a robust solution to handle confounding arising from sub-ethnic popu-
lation stratification and cryptic relatedness in genome-wide association studies, and confer power advan-
tages in large population-based cohorts149. Discovery analyses presented in this thesis were preferen-
tially run using LMM implemented in BOLT-LMM (v2.2). Primary analyses assumed additive (per-allele)
effect and were restricted post-analysis to biallelic variants with MAF≥0.1% and imputation quality (IM-
PUTE ’info’ parameter) ≥0.4. Independent loci were defined on the basis of physical proximity, using
a 1mb window centred on the index SNP (i.e., 500kb flanking each side). For replication cohorts and
meta-analytical discovery approaches (e.g., REE discovery, Chapter 4) used in this thesis, SNP associa-
tions were most commonly calculated externally, and therefore used a range of approaches and softwares
aligned with the collaborators’ usual analysis pipeline. External study-specific methods are detailed on a
chapter-by-chapter basis.
Heritability Estimation
Unless otherwise specified, narrow-sense heritability (h2) was estimated using a Restricted Estimate
Maximum Likelihood variance components analysis implemented in an extension of the algorithm used
for main association analyses, BOLT-REML (v2.2). This approach is based on the same principles as
conventional methods of heritability estimation such as genomic-relatedness-based restricted maximum-
likelihood approaches150, but incorporates speed enhancements when working with large datasets151. As
an alternative for meta-analytical discovery samples combining data from multiple cohorts, heritability was
estimated using LD Score Regression152–154.
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Distinguishing Inflation from Polygenicity
Genomic inflation provides an indication of residual population stratification present in GWAS, and is
conventionally expressed as a genomic control factor (λGC); the observed divided by the expected median
of the χ2 distribution155,156. This value can be used to assess the degree of residual confounding from
population structure, and to correspondingly correct the genome-wide test statistics. Given that apparent
inflation of λGC can, however, be attributable to complex polygenicity of the trait157, the intercept from LD
Score Regression (LDSC) has recently been suggested as a measure of inflation robust to this effect154.
We calculated both the standard λGC and LD score regression intercept using recently-described LDSC
software (v1.1.0), based on pre-calculated European LD scores154 derived using the 1000G European
subset. To avoid confounding by imputation quality, calculations were restricted to variants available in
Hapmap Phase III, as recommended by the program developers. Statistically significant inflation was
defined on the basis of a significant LD score regression intercept at α ≤0.05, and summary statistics
were adjusted manually for the intercept point estimate in such cases. Details are provided on a case-by-
case basis throughout.
Meta-Analysis
When (i) generating a combined discovery sample or (ii) calculating combined p-values for stage one
variants replicated in external (European) cohorts, variants were meta-analysed using a fixed-effects,
inverse variance-weighted approach implemented in METAL158. Genomic control factors (defined as the
intercept from LD-Score Regression) were applied during the meta-analysis process, if required. Given
that a standard fixed-effect is underpowered for meta-anlysis of estimates across ethnically-discordant
groups159, specific methods developed to maximise power in transethnic analyses were applied where
necessary, as discussed in Chapter 4.
Linkage Structure and Secondary Signals
To examine local LD structure, regional plots were generated in LocusZoom160 using LD reference values
from 1000G Phase I Europeans. To investigate the presence of multiple independent signals at a locus as
appropriate, conditional analyses were run on each discovery locus prior to replication. Using approximate
conditional analyses in Genome-wide Complex Trait Analysis161,162 (GCTA, v1.25.3), variant p-values
at each locus were conditioned on the genotype of the index variant and their conditional p-values re-
examined using the genome-wide threshold to define the presence of a secondary signal.
41
2.2.2 LD Score Regression
Using genome-wide summary statistics from discovery (either in UKB alone or meta-analysed discov-
ery in the case of REE), the LD Score Regression method recently described by Bulik-Sullivan and
colleagues154 was applied, as appropriate, to (i) estimate genetic correlation between the trait of interest
and other phenotypes and (ii) derive tissue-specific partitioned heritability of traits based on pre-calculated
European LD scores. To avoid confounding by imputation quality, all LDSC analyses were restricted to
variants available in HapMap Phase III.
Tissue-specific Partitioned Heritability
Partitioned heritability can provide an indication of whether certain cell types are enriched for functional
gene categories which disproportionately contribute to the heritability of a phenotype163. In this way, over-
represented effector tissues important within the aetiology of the phenotype can be identified. LDSC is
distributed with eight curated tissue classes, each of which contain functional categories of variants which
act in a manner specific to that tissue. Partitioned heritability analyses were run separately for each tissue
class, adjusting in each case for heritability explained by each functional category of variants across the
genome (that is, in a non-tissue-specific manner). A Bonferroni-corrected p-value accounting for eight
tests was used to define statistical significance.
Genetic Correlations
To gauge the shared contribution of variants across the genome to the trait of interest (e.g. hand grip
strength) and other phenotypes, we calculated genetic correlations (rG) from LD score regression153.
Analyses were run using either the standalone LDSC executable or the LD Hub facility164, a web appli-
cation which aggregates published genome-wide summary statistics from large consortia, for rapid calcu-
lation of rG). Correlations were run in a hypothesis-free manner restricting to potentially correlated traits
of biological relevance, and using a Bonferroni-corrected p-value adjusted for the number of independent
tests to define significance. Exact details are provided in each chapter.
2.2.3 Imputed Transcriptome Analyses
To explore the potential functional significance of variants in gene expression, and to prioritise functional
genes falling within identified loci, a number of variant- and gene-centric expression analyses were un-
dertaken. Initially, lead variants (or their best proxy, r2≥0.8) were looked up in cell types relevant to the
trait (see Chapter methods) in the GTEx resource165 to identify cis-eQTL associations. Variants passing
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GTEx criteria for tissue-specific eQTL association, and additionally high LD (r2≥0.8) with the best eQTL
for the transcript in question in the tissue of interest were considered eQTLs.
To supplement this variant-centric approach, three new methods for integrating genome wide summary
statistics with expression associations from independent samples were applied: TWAS, SMR and MetaX-
can. By utilising established eQTL data sets as reference, these approaches are able to effectively model
expected variation in the transcriptome of the GWAS sample based on variation in autosomal variants
across the genome (genetically-predicted gene expression, GPGE), and subsequently test for indepen-
dent associations between imputed transcript levels and the phenotype of interest.
SMR Summary Mendelian Randomisation (SMR) uses summary-level gene expression data to map
potentially functional genes to trait-associated SNPs166, and investigate whether trait associations at a
locus are driven by differential expression, under the assumption of a single causal variant/eQTL. Using
publicly-available whole blood eQTL data from Westra and colleagues167, we tested for associations be-
tween transcript abundance in whole blood and our GWAS traits. A conservative significance threshold
was set at p=4.9×10-6, reflecting the number of transcripts tested.
TWAS The recently-described Transcriptome-wide Association Study (TWAS) approach168 was used to
infer gene expression associations in whole blood data sets (Young Finns Study and the Netherlands Twin
Registry cohorts). The threshold for significance was set to correct for the number of studies and genes
(p=1×10-5).
MetaXcan MetaXcan, a meta-analysis extension of the PrediXcan method169 modified to take summary
statistics as input in place of individual-level data170, was used to infer associations between tissue-
specific genetically-predicted gene expression (GPGE) derived from GTEx165, and GWAS traits consid-
ered in this thesis. PrediXcan is a gene-based data aggregation and integration method which incorpo-
rates data from observed gene expression and GWAS to translate evidence of association between a
phenotype and a variant to the gene level. Briefly, PrediXcan first imputes gene expression at an individ-
ual level using prediction models trained on directly-measured transcriptomic data sets with intersecting
genome-wide genotyping, before regressing the phenotype of interest on imputed GPGE. MetaXcan ex-
tends the application of PrediXcan to allow inference of the direction and magnitude of GPGE-phenotype
associations using only GWAS summary statistics, which is advantageous when SNP-phenotype associ-
ations are obtained from meta-analysis, and when individual-level data are not available. Pre-calculated
tissue-specific expression prediction weights generated from GTEx were downloaded from the PredictDB
resource (http://predictdb.org/) as transcriptome reference. Tissue-specific analyses were run, restricting
to tissues selected on the basis of biological relevance to the trait under consideration. The threshold for
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statistical significance was conservatively set using a Bonferroni correction considering each gene-based
association in each tissue as a separate and statistically independent test. Further details on the selection
of tissues, and corresponding Bonferroni thresholds, are supplied in each chapter.
2.2.4 Pathway Analyses
Trait associations across the genome were tested for enrichment of genes falling within known biological
pathways, or sharing common functional annotation using the Meta-Analysis Gene set ENrichment of
varianT Associations (MAGENTA). By using pre-specified gene set definitions as reference, MAGENTA
applies a gene set enrichment analysis (GSEA)-based approach which has been previously described171.
Briefly, each autosomal gene is mapped to a single index SNP, defined as the SNP with the lowest as-
sociation p-value within a 100kb upstream and 40kb downstream window. After adjustment for possible
confounders including gene size, SNP density and LD, this p-value (which represents a gene score) is
ranked relative to all scored genes in the genome. At a given significance threshold (95th or 75th per-
centile), the observed number of gene scores ranked above the threshold in a given pathway is calculated
and compared to the expected number of gene scores above this threshold under a null hypothesis, based
on the distribution of one million randomly-permuted pathways of identical size. This process generates
an empirical permutation-based GSEA p-value for each pathway.
Enrichment was assessed in a hypothesis-free manner across gene sets drawn from six public databases
of gene ontology (GO), functional annotation and canonical or curated pathways: GO Terms, the Protein
Analysis through Evolutionary Relationships (PANTHER) database, Ingenuity, the Kyoto Encyclopaedia
of Genes and Genomes (KEGG), Biocarta, and Reactome pathways (downloaded via the Molecular Sig-
natures Database, mSigDB, July 2011). Analyses were restricted to 3,216 gene sets with an effective
size ≥10 genes after filtering of proximal genes and genes not containing variants for analysis. Genes
in the HLA region were excluded due to difficulties in accounting for gene density and linkage structure.
For some phenotypes, custom gene sets of particular biological or mechanistic relevance were addition-
ally defined and tested. Details are provided on a chapter-by-chapter basis. Pathway significance for
hypothesis-free tests was defined using a FDR≤0.05 at either threshold, considering each pathway as a
statistically independent test. In hypothesis-driven gene set testing, a pathway GSEA p-value accounting
for the number of candidate pathways tested was applied.
2.2.5 Gene-based Association
By aggregating the contribution of multiple variants within a gene to variation in a phenotype, gene-
based testing is can be used to prioritise genes from genome-wide summary statistics. Against the
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Box 2.2 | Assumptions of Mendelian randomisation
1. The instrument is robustly associated with the exposure
2. The instrument is associated with the outcome only via the modeled
exposure
3. The instrument is independent of factors confounding the observa-
tional association between the exposure and the outcome
backdrop of a lower burden of correction for multiple-testing, genes containing multiple associated variants
which do not exceed the genome-wide threshold for significance can be highlighted. Such approaches
have previously been shown to be effective when considering protein-coding variation in exome-based
analyses172, and are widely used to assess candidates of particular biological interest in GWAS summary
statistics. Recently, and with the release of packages to streamline the analytic process173, application of
systematic gene-based testing across the genome (genome-wide gene association study, GWGAS) using
summary statistics has increased substantially, particularly in very large-scale studies such as UKB174–177
In these analyses, a combination of these two approaches were applied. For hypothesis-driven inves-
tigation of gene associations, the VErsatile Gene-based Association Study (VEGAS) algorithm178 was
used, calculating LD from HapMap Europeans and restricting to directly typed and well-imputed (info≥0.8)
variants. For GWGAS, we applied the newly-described MAGMA permutation-based approach173, using
1000G Phase 3 as the LD reference. In all cases, conservative Bonferroni correction accounting for the
number of tests run, and assuming all tests were independent, was used to account for an α ≤0.05.
2.2.6 Mendelian Randomisation
Mendelian randomisation (MR) provides a solution to circumvent many of the issues of confounding and
reverse causation which can affect the robust inference of directionality and causality in classical observa-
tional epidemiology. Conceptualised as a ’natural randomised trial’179 (Fig 2.3), MR applies Mendel’s first
and second laws (that alleles independently segregate during meiosis and are randomly assigned at con-
ception) to model genetically-predicted variation in an exposure using variants as a genetic instrument.
As alleles are fixed for the lifespan, and therefore cannot in theory be confounded by known or unknown
factors, associations between the instrument and an observed outcome can be interpreted causally, given
that assumptions hold180,181 (see Box 2.2, Fig 2.3).
Constructing Scores
Additive genetic risk scores were calculated as the sum of aligned (e.g. effect-increasing) alleles at SNPs
associated with the exposure, and expressed as either (i) a per-allele score or (ii) a weighted score.
For the latter, each allele dosage was weighted by its effect on the exposure, allowing the effect of the
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Figure 2.3: Concept and theory of Mendelian randomisation. Left: MR is conceptualised as analogous to an intervention-based
RCT. Random assignment at conception of risk alleles for the exposure, X, leads to variation in genetically-determined levels of X
within the population, for which altered phenotypes in the outcome Y can be observed. Right: Under observational epidemiology,
the association between an exposure X and an outcome Y is subject to known, unknown, and residual confounding (U). When
genetic variants associated with X can be used as an instrumental variable Z, the direct relationship between Z and Y (red arrow)
is theoretically unconfounded and, subject to the assumptions of MR, can be used to infer causality in the X-Y association. After
Hingorani & Humphries179, Lawlor et al.180
instrument to be interpreted per genetically-predicted change in the exposure. Effect weights were most
commonly drawn from combined stage one + two analyses. Further details follow in the Methods sections
of each chapter. Scores were restricted to variants passing the genome-wide threshold for significance to
minimise the risk of pleiotropy and weak instrument issues.
Main Analyses
We applied two-sample MR, in which causal associations are investigated in a second sample indepen-
dent of the population used to derive the genetic risk score182,183. Where outcome and genotype were
available in an intersecting sample, MR was implemented using individual participant data (IPD) in an
appropriate study cohort with the required phenotypes available, regressing the outcome on individually-
derived genetic scores. For the most part, however, we applied the recently-described summary statistic
approach, which extends the two-sample approach to leverage summary data of the score-exposure and
score-outcome association184,185. The score-outcome effect is regressed on the score-exposure associ-
ation for each variant, and the resulting β provides an indication of the overall causal estimate. Given
that summary statistics can be sourced from publicly-available consortium meta-analyses representing
the largest possible sample size for many traits, the range of outcomes and exposures for causal infer-
ence is substantially expanded. Assuming that the outcome and exposure associations are drawn from
ethnically- and demographically-similar populations, summary statistic MR increases power whilst min-
imising the risk of a false positive due to weak instrument bias183. Bias from weak instruments shifts the
estimate toward the null in this context (i.e. it is conservative), in contrast to one-sample approaches, in
which weak instruments artificially inflate the causal estimate.
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Summary-statistic MR was implemented using either in-house scripts, or the MR-Base two-sample MR
package for R186, which streamlines the process of extracting exposure or outcome data from published
summary statistics, aligning alleles between the exposure and outcome, and identifying suitable prox-
ies for instrumental variants. Where effect estimates were drawn from consortia meta-analyses, full
details are provided in each chapter. Inverse variance-weighted (IVW) regression was applied as the
standard model. This approach weights the regression at each variant by the precision of its effect on
the outcome, and thus ensures that the contribution of each variant to the overall causal estimate is
decreased where there is increased error in its causal estimate. Where a variant was not available in out-
come summary statistics, we used its nearest proxy (r2≥0.8) defined from 1000G using either LDLink187
(https://analysistools.nci.nih.gov/LDlink/) or the in-built functionality of MR-Base.
Sensitivity Analyses
Amongst the assumptions required for an MR to be valid and informative, only the first (robust associa-
tion between the instrument and the modelled exposure) can be tested directly. Approaches to indicate
whether an assumption may have been violated, and to mitigate for it in sensitivity analyses, are available,
as detailed below. These stages were pursued only when MRs indicated a statistically significant result
(accounting for multiple testing), based on IVW estimation.
Directional Pleiotropy Horizontal pleiotropy - when a variant is associated with an outcome via multiple
biologically heterogeneous pathways - can lead to violation of assumptions in MR, specifically if the com-
bined pleiotropic effect of a score is directional183. Directional pleiotropy occurs when there is residual
association between the gene score and the outcome, which persists after the effect of the score on the
exposure has been accounted for, implying that the residual effect acts through pathways external to the
modelled exposure188. Under this situation, the causal estimate from MR is biased away from the null. To
circumvent possible issues of directional pleiotropy in our instruments, we applied MR-Egger189, a mod-
ification of Egger’s regression190 which relaxes the strict set of assumptions normally required for IVW
MR, and does not restrain the intercept to the origin. By allowing variants to violate the second assump-
tion of MR (Box 2.2), the intercept generated by MR-Egger provides a formal assessment of directional
pleiotropy, and the corresponding β indicates a causal estimate robust even if all variants in the score
influence the outcome through directionally pleiotropic pathways.
Multiple Invalid Instruments To allow for a situation in which some variants violated more than one
assumption of MR, a weighted median approach was applied191. By weighting the causal estimates
toward their median, this approach provides consistent causal estimates when as many as 50% of the
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H and grip strength is a widely-used proxy of muscular fitness, a marker of frailty and predictor of arange of morbidities and all-cause mortality. To investigate the genetic determinants of variation in
grip strength, we performed a large-scale genetic discovery analysis in a combined sample of 195,180 in-
dividuals and identify 16 loci associated with grip strength (p≤5×10-8) in combined analyses. A number of
these loci contain genes implicated in structure and function of skeletal muscle fibres (ACTG1), neuronal
maintenance and signal transduction (PEX14, TGFA, SYT1), or monogenic syndromes with involvement
of psychomotor impairment (PEX14, LRPPRC and KANSL1). Mendelian randomisation analyses are
consistent with a causal effect of lower genetically-predicted grip strength on higher fracture risk. In con-
clusion, our findings provide new biological insight into the mechanistic underpinnings of grip strength and
the causal role of muscular strength in age-related morbidities and mortality. This chapter contains work





Muscle strength, measured by isometric hand grip strength, is an accessible and widely-used proxy of
muscular fitness. Lower grip strength is associated with impaired quality of life in older adults, and is
an established marker of frailty, predicting physical decline and functional limitation in daily living35,38,39.
The value of grip strength as a clinical predictor of fracture risk has been demonstrated in different
populations192,193, and higher grip strength has been found to be prognostic of walking recovery after
hip fracture surgery in later life194. Grip strength has also been shown to predict cardiovascular disease
(CVD) and all-cause mortality over many years of follow-up45,49,55. Whilst it remains unclear whether
these prospective associations with fracture risk, CVD and mortality are causal - or reflect early manifes-
tation of underlying disease processes - the role of muscular strength as a predictor of functional capacity
highlights the importance of understanding its aetiology.
Grip strength is highly heritable (h2=30-65%)195–197. Whilst candidate gene approaches have implicated
multiple loci in this phenotype, including thermogenic and myogenic factors198,199, there remain few ro-
bustly replicated associations. Two genome-wide association studies in up to 27,000 individuals have
been reported to date44,200, yielding one intergenic genome-wide significant association200 at rs752045.
Here, in a combined sample size of 195,180 individuals, including 142,035 individuals from the UK
Biobank (UKB) cohort138, we identified 16 genome-wide significant loci associated with grip strength.
We also performed Mendelian randomisation (MR) analyses, which showed no evidence for causality in
the associations of grip strength with cardiovascular disease or all-cause mortality, but were suggestive
of a causal effect of muscular strength on fracture risk.
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3.2 Methods
Assessment of Grip Strength and Covariates Isometric hand grip strength was measured at UKB
baseline using a calibrated Jamar J00105 hydraulic hand dynamometer with peak force indicator (Lafayette
Instrument Company, IN, USA), adjusted to the individual’s hand size. With the participant seated, elbow
bent, and forearm horizontal and supported, one measurement was taken per hand, and maximal hand
grip (kg) was taken as the higher of the two readings. The protocol for height and body mass measure-
ment has previously been described in Chapter 2. Phenotyping details for each of the stage two cohorts
are detailed in Supplementary Table 1.
Genotyping and Imputation Imputed variants from UKB’s interim genotyping release (May 2015) were
used for stage one association analyses: full details of the underlying genotyping and imputation protocols
applied centrally by UKB have been detailed in Chapter 2. Stage II cohorts applied imputation in line with
their usual practices - full details are provided in Supplementary Table 1.
17q21.31 Haplotype Imputation and Analyses In collaboration with colleagues at the University of Le-
icester (L. Wain, M. Tobin, N. Shrine, see Section 3.5), nine structural haplotypes previously reported at
the 17q21.31 cytoband were imputed according to existing protocols201–203. Imputation was based on a
haplotype reference panel from Boettger and colleagues202, which uniquely coded each structural haplo-
type using a combination of twelve surrogate, virtual binary markers. In addition, the file contained 6,302
flanking variant haplotypes. IMPUTE v2.3.2 was used to impute the genotypes of the surrogate markers
against the reference panel. The panel contained 284 genotyped variants within the reference region,
pre-phased with SHAPEIT v2.837. Variants within the copy-number variable region, with MAF <0.01, or
evidence of deviation from Hardy-Weinberg equilibrium pHWE=1×10-6 were excluded. Surrogate markers
were subsequently decoded into the corresponding nine structural haplotypes for analysis. Association of
haplotypes (inverted versus non-inverted, continuous structural variant [α/β/γ] copy number, and nine
common haplotypes as a categorical exposure) with grip strength was modelled using linear regression
adjusted for age, sex, height (m), BMI (kg/m2) and genotyping chip in up to 111,860 unrelated genetic
white Europeans defined centrally by UKB.
Genome-wide association analyses of grip strength 142,035 UKB participants had imputed genetic
data, grip strength and full covariate availability for genome-wide association analyses; all were of self-
identified white ancestry, with the majority (94.6%) reporting as white British. Discovery analyses for
maximal grip strength (n=142,035) were run using a Bayesian linear mixed model (LMM) adjusted for
age (years), sex, height (m) and BMI (kg/m2), implemented in BOLT-LMM software (v2.2), as described
in Chapter 2. Primary analyses assumed additive (per-allele) effect. Analyses were restricted to biallelic
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variants with MAF≥0.1% which had been directly typed, or imputed with imputation quality (IMPUTE2
info)≥0.4.
Independent loci were defined based on proximity using a 1mB window around the index variant reaching
genome-wide significance. Independent lead variants (n=21) were followed-up in up to 53,145 individuals
from international collaborating cohorts (stage two). In cases where an index variant was not typed or
imputed at sufficient quality, appropriate proxies were defined as the variant with the next-lowest p-value
within 500kb of the index (Supplementary Table 4). Each stage two cohort accounted for population
structure according to its usual practice. Full details of the analytical approach and model specification of
each replication cohort are summarized in Supplementary Table 1. Stage I and II results for each of the
21 variants were combined by inverse variance-weighted fixed-effect meta-analysis using METAL. Sixteen
loci reached genome-wide significance in combined meta-analysis and were considered to be associated
with grip strength.
To examine local linkage disequilibrium structure of replicated loci, regional plots for each of the 16 repli-
cated loci were generated in LocusZoom using LD reference values from the CEU panel of 1000G Phase
1. To investigate possible independent signals at each of the 16 replicated loci, approximate conditional
analyses were undertaken using Genome-Wide Complex Trait Analysis software (GCTA, Version 1.25.2).
LD-Score Regression Using genome-wide summary statistics from our UKB phase one analyses,
the recently-described LD Score Regression method described by Bulik-Sullivan and colleagues (imple-
mented in LDSC software, v1.0.0) was used to (i) estimate genetic correlation between grip strength and
other phenotypes, and (ii) derive tissue-specific partitioned heritability of grip strength. The main princi-
ples and practical considerations of this approach have been described in Chapter 2 - details specific to
the grip strength analyses are provided here.
Genetic Correlations
Genetic correlations of grip strength were calculated with CHD risk, lean mass index (LMI),
fat mass index (FMI) and bone mineral density (BMD) measured at the forearm, femoral
neck or lumbar spine. For CHD and BMD, publicly available GWAS summary statistics from
the CARDIoGRAMplusC4D204 and GEFOS205 consortia, respectively, were used. Summary
statistics for LMI and FMI were generated de novo by conducting GWAS in a combined
sample of 12,851 individuals from the Fenland Study and EPIC-Norfolk. Details of these
cohorts are provided in Chapter 2, and descriptive details of anthropometric parameters are
provided in Supplementary Table 2. LMI and FMI (kg/m2) were defined as DXA-derived
lean mass or fat mass, respectively, divided by the square of DXA-derived height (GE Lunar
Prodigy processed using Lunar EnCORE v14.1, GE Healthcare). GWAS were conducted
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separately in each cohort using BOLT-LMM as for the main hand grip analyses. FMI analyses
were adjusted for age and sex. Because of the sex specific distribution of the phenotype,
LMI analyses were run sex stratified and adjusted for age. Results from both cohorts were
combined by fixed-effect inverse variance-weighted meta-analysis using METAL.
Tissue-specific Partitioned Heritability
Partitioned heritability was run individually for each of the eight curated tissue classes dis-
tributed with LDSC, adjusting in each case for heritability explained by each functional cate-
gory of variants across the genome (that is, in a non-tissue-specific manner).
Integration of Expression Data To investigate the direct associations of gene transcript levels with
hand grip, and prioritise genes falling within the 16 identified loci, we combined variant-centric and wider
genome-wide approaches. Initially, a look-up of all 16 replicated grip strength variants or their best proxy
(r2>0.8) was conducted in skeletal muscle, transformed fibroblasts, nervous system and brain regions in
the GTEx resource to identify eQTL associations. Variants passing GTEx criteria for tissue-specific eQTL
association, and in high LD (r2≥0.8) with the best eQTL for the transcript in question in the tissue of in-
terest were considered significant eQTLs. To consider the combined effect of genetically-predicted gene
expression on hand grip across the genome, we additionally took advantage of SMR and MetaXcan ap-
proaches, using transcriptome reference from Westra and colleagues (whole blood), and multiple tissues
from GTEx, respectively. This process is detailed fully in Chapter 2. We conservatively considered pre-
dicted expression of a gene to be associated with grip strength at a MetaXcan p-value≤2.52×10-7, taking
each gene association in each tissue as an independent test for the purposes of Bonferroni correction
Gene Set Enrichment Analyses Genome-wide discovery results from the UKB cohort were tested for
enrichment of pre-specified gene sets based on common functional annotation or known biological path-
ways in MAGENTA (v2.4)171. Enrichment was assessed in a hypothesis-free manner across gene sets
drawn from six public databases of gene ontology, functional annotation and canonical/curated pathways,
as described in Chapter 2. In collaboration with colleagues at the Broad Institute (D.G. MacArthur, M. Lek,
see Section 3.5), custom sets were defined from literature review, incorporating genes with known func-
tion in pathways or processes relevant to muscle development and maintenance (Supplementary Table
11. Given their established pro-atrophic role and candidacy as a potential drug target to maintain muscle
mass and function, genes involved in the transduction of myostatin/activin signalling via activin A type II
receptors (ACVR2A and ACVR2B) were defined from Han et al.206. Monogenic genes implicated in mus-
cular dystrophies and myopathies were based on Kaplan & Hamroun (2014)207, with additional manual
curation (M. Lek) to include collagen IV-opathies, congenital myopathies and glycogen storage diseases
which may present which present with a similar pattern of limb-girdle muscle weakness.
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Gene-based Tests Genes involved in myostatin/activin signalling via activin type II receptors (FST,
MSTN, ACVR2A, ACVR2B) and known atrophy effectors (TRIM63, FBXO32) were identified from literature206,208
and defined as candidate genes for grip strength based on their biological prior for an involvement in skele-
tal muscle trophism. Gene-based association tests were performed for each candidate using the Versatile
Gene-based Association Study (VEGAS) algorithm178, calculating LD from HapMap Europeans. VEGAS
was applied to the grip strength discovery-phase association results across the whole genome, restricting
to directly typed and well-imputed variants (IMPUTE info>0.8).
Role of Variants in Muscle Structure & Histology To identify whether grip strength variants were as-
sociated with elements of muscle histology, the association of the 16 replicated HGS variants with muscle
histology parameters was examined in 656 men from three independent cohorts of Swedish ancestry
(see Supplementary Note). In collaboration with colleagues, the additive association of each of the 16
lead SNPs with percentage of (i) type I fibres, (ii) type IIA fibres and (iii) type IIB fibres from muscle biopsy,
as well as capillary density (calculated as the number of capillaries divided by the total number of fibres)
was calculated. Phenotypes were inverse-normalized prior to analysis. To better quantify power in this
sample, formal power calculations were performed using Quanto (biostats.ucsc.edu/Quanto.html).
Mendelian Randomisation Summary statistic MR (see Chapter 2) was used to examine sex and growth
hormone-related phenotypes as causal exposures for grip strength. Primary analyses comprised of the
standard inverse variance-weighted approach; as sensitivity analyses for robust causal inference, het-
erogeneity was assessed using Cochran’s Q-statistic, and MR-Egger, weighted median, and penalised
weighted median estimators of causal effect were applied. The advantages of this approach are de-
tailed elsewhere in this thesis. Additive genetic instruments weighted for the effect of each variant on
the intermediate phenotype were constructed for circulating sex hormone-binding globulin (SHBG)209,
dehydroepiandrosterone sulphate (DHEA-S)210, insulin-like growth factor I (IGF-1)211, fasting insulin212,
and insulin secretion213 on the basis of published findings. Full details of each instrument are contained
in Supplementary Table 17. Grip strength effect estimates were obtained from the stage one discovery
GWAS in UKB.
To infer causality in the association of grip strength with CHD, myocardial infarction (MI), fracture risk, BMD
(forearm, lumbar spine, femoral neck), LMI and FMI, summary statistic MR was implemented as above,
using the 16 identified loci as instrumental variable for genetically-determined grip strength. Summary
statistics for BMD, CHD, LMI and FMI were the same as those used in genetic correlations. Summary
statistics for MI were obtained from CARDIoGRAMplusC4D204. Fracture risk utilised summary statistics
from an ongoing analysis by GEFOS (Supplementary Note), as well as individual participant-level data in
EPIC-Norfolk. Where HGS variants were not available in outcome phenotype summary statistics, proxies
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were defined as the variant with the next-lowest association p-value for HGS within 500kb of the index in
stage one analyses.
Re-weighting MRs incorporating EPIC-Norfolk outcomes
Because EPIC-Norfolk was included in genomewide association meta-analyses for FMI and
LMI outcomes, and provided data for the individual participant-level analyses of fracture
risk, the HGS instrument was re-weighted using effect estimates exclusive of EPIC-Norfolk
samples for the summary statistic analyses of FMI/LMI, and the individual participant level
analyses (Supplementary Table 5. For the latter, unconditional logistic regression adjusted
for age and sex was used to model the association of an individually-calculated genetic
risk score for HGS with fracture risk. This analysis was then meta-analysed (fixed effects)
together with results from the summary statistic HGS-fracture risk MR in GEFOS to provide
a single result.
All-cause mortality
To test the causal relationship of HGS with all-cause mortality, genetically-determined HGS
was modelled on a per-individual basis in EPIC-Norfolk (nTotal=21,043, nDeceased=5,699), us-
ing effect estimates from combined stage one plus two analyses, and excluding estimates
derived from EPIC-Norfolk, as above. The association of the genetic risk score to mortal-
ity was tested under a Cox proportional hazards model, adjusted for age and sex. Pro-
portional hazards were confirmed using standard technique (Schoenfeld residuals, Kaplan-
Meier curve).
Parental Lifespan
To enhance power, and in line with previous work214, an individual participant level MR of
HGS-parental lifespan, as a proxy for survival, was conducted in UKB. The concept of explor-
ing genetic associations by proxy for conditions or traits which are rare, lethal or for which the
accrual of cases within a standard observational cohort setting carries an unacceptable time
overhead (for example, mortality) is gaining traction in the literature, and has been shown not
only to recapitulate signals obtained from standard approaches, but also to confer significant
power advantages in discovery approaches215. In collaboration with P. Joshi, parental lifes-
pan and vital status (paternal nTotal=133,123, nDeceased=102,072; maternal nTotal=133,123,
nDeceased=102,072) were regressed on the genetically-predicted handgrip of offspring (mod-
elled as previously, inclusive of EPIC-Norfolk estimates) using Cox proportional hazards, in
effect imputing parental genotype at each HGS variant from that of the offspring. The effects
generated reflect the influence of offspring genotype on parental longevity, and the expected
allele dosages in the parental generation are half the observed dosages in offspring. Effect
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estimates per parental allele are correspondingly twice that observed per offspring allele. For
clarity, the inferred effect on parental lifespan per parental allele is presented in this work.
Association of Loci with Elite Athletic Status Using data from four multi-ethnic cohorts of elite ath-
letes (Japanese nAthletes=54, nControls=406; African American nAthletes=79, nControls=391; Jamaican nAthletes=88,
nControls=87; European nAthletes=395, nControls=726; see Supplementary Note), the association of the 16
replicated HGS loci with odds of attaining elite athletic status was assessed by conditional logistic regres-
sion relative to age-, sex-, and ethnicity-matched controls. Analyses were performed separately in each
cohort before meta-analysing to provide a single point of reference.
Tests of Model Fit To test for departure from additivity in the main grip strength stage one analyses,
we applied a dominance deviation approach including two terms for ’best guess’ genotypes (i.e. allele
codings restricted to integers, rather than allowing continuous terms reflecting the uncertainty in genotype
introduced by imputation). One term encoded the major allele homozygotes, heterozygotes, and minor
allele homozygotes as 0,1,2, respectively, and the other as 0,1,0, to test the hypothesis that heterozygotes
have mean grip strength values intermediate between the two heterozygote terms. The second model
allows departure from additivity to be detected.
Checks for Allele Selection by Age Given that observational grip strength is strongly predictive of lon-
gitudinal mortality45, two complementary analyses were run in UKB to ensure that strength increasing
alleles from combined stage one plus two analyses were not under selection by age. Modelling each
variant as strength-increasing allele dosage, the linear association of age with allele dosage was quanti-
fied, considering age as the dependent variable. To gauge whether allele dosage was predicted by age,
the inverse of this regression was subsequently run, considering age as the independent variable. This
approach has recently been applied to test for selection of variants by age in the Genetic Epidemiology
Research on Ageing (GERA) cohort216. Analyses were restricted to centrally-defined unrelated white




3.3.1 Multiple novel loci are associated with grip strength
In stage one analyses, we tested the association of >17 million variants (minor allele frequency (MAF)
≥0.1%, imputation quality >0.4), in 142,035 white European individuals from UK Biobank with maximal
grip strength. Genome-wide SNP-based heritability was estimated at 23.9% (SE 2.7%). Twenty-one loci
showed genome-wide significant associations (p≤5×10-8) in stage one (Supplementary Figure 1), and
were subsequently followed up in stage two analyses of up to 53,145 individuals from 8 additional studies
(Supplementary Table 1, Supplementary Note) including the Cohorts for Heart and Aging Research in
Genomic Epidemiology (CHARGE) consortium200. Twelve loci were independently replicated (directional
consistency with stage one, p <0.05) in stage two cohorts (Supplementary Table 5) and 16 loci contained
genome-wide significant associations (p≤5×10-8) in combined analyses. Effect sizes on grip strength
ranged from 0.14-0.42 kg per allele under an additive model (Table 3.1, Supplementary Table 5). Given
the discordance in sample size between stage one and two analyses, and in the interests of maximising
power, we considered there to be evidence of association at any locus reaching genome-wide significance
in combined analyses, and pursued all 16 in downstream analyses. Lead SNPs at the 16 grip strength-
associated loci included common variants ( MAF≥5%) in or near POLD3, TGFA, ERP27, HOXB3, GLIS1,
PEX14, MGMT, LRPPRC, SYT1, GBF1, KANSL1, SLC8A1, IGSF9B, ACTG1, a low-frequency variant
(MAF 3%) in DEC1, and a further common variant falling within the human leukocyte antigen (HLA)
region (Table 3.1, Supplementary Figure 2). Approximate conditional analyses identified no additional
signals at genome-wide significance at these 16 loci after conditioning on their respective lead SNPs.
At two loci, we saw evidence for a departure from additivity (p=3.13×10-3) under a dominance devia-
tion model (Supplementary Figure 3); at the GBF1 locus, there was evidence of a dominant effect of
the grip strength-raising A allele (pdomdev=2.3×10-3), and at the SYT1 locus, evidence for a recessive
effect of the grip strength-raising A allele pdomdev=3.0×10-3. No individual variants showed significant
effect modification by age or sex. The association of the 16-variant genetic score (modelled as the sum
of the grip strength-increasing allele dosage at each variant per individual) showed no interaction with
age (pinteraction=0.30), but was stronger in men than in women (men: β = 0.20 kg per grip strength-
increasing allele, p=2.38×10-48; women: β = 0.13 kg per grip strength-increasing allele, p=3.61×10-43;
pinteraction=1.56×10-5 (Figure 3.1). Age at recruitment was independent of strength-increasing allele
dosage at each of the sixteen SNPs from combined analyses. Equally, allele frequency at each SNP
was not predicted by age, suggesting that there is no selection of alleles by age at these loci216. We did
not replicate the previously-reported association at rs752045 with grip strength200 (β per minor allele =
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Figure 3.1: Association of the HGS 16-SNP score with grip strength by age and sex strata
Association of the grip strength-increasing genetic score showed no interaction with observed grip strength by age
(pinteraction=0.30), but was stronger in men than women (pinteraction=1.56×10-5) in a subset of 111,860 unrelated UKB participants
from stage one analyses. Associations shown are from linear regression
A number of associated loci contained genes with biologically plausible roles in strength and neuromuscu-
lar fitness, through effects on the structure and function of skeletal muscle (ACTG1), excitation-contraction
coupling (SLC8A1), evidence for neurotrophic roles (TGFA), or involvement in the regulation of neurotrans-
mission (SYT1). ACTG1 (Actin, γ1A) encodes a key component of the costamere, a protein complex lo-
calised to the Z-disc of skeletal muscle which physically tethers myofibrils to the cell membrane and trans-
mits contractile force generated at the sarcomere to the extracellular matrix via the dystrophin glycoprotein
complex (DGC)217,218. Monogenic loss of elements of the DGC results in muscular dystrophies219, whilst
Actg1 knock-out mice display overt muscle weakness, progressive myopathy and decreased isometric
twitch force220. SLC8A1 encodes a transmembrane Na+/Ca2+ exchanger which is vital to restoring Ca2+
concentration to pre-excitation levels in excitable cells. Muscle-specific overexpression of SLC8A1 has
been shown to induce dystrophy-like skeletal muscle pathology221. Synaptotagmin-1, encoded by SYT1,
is an integral synaptic membrane protein which regulates Ca2+-dependent neurotransmitter release at the
presynaptic terminal222, and is implicated in development of neuromuscular junction pathology in rodent
models of spinal muscular atrophy223. TGFA encodes transforming growth factor α, a well-characterised
growth factor which plays a key neurotrophic role in the central and peripheral nervous systems224, and is
upregulated during the acute injury response of motor neurons, promoting neuronal survival225,226.
Three lead variants for grip strength map to or near to genes implicated in monogenic syndromes charac-
terised by neurological and/or psychomotor impairment (Table 3.1, Supplementary Figure 2). rs10186876
(pCombined=9.75×10-11) lies 15kb upstream of LRPPRC (leucine-rich pentacotripeptide-containing), which
has been implicated in the French-Canadian variant of Leigh Syndrome (Mendelian Inheritance in Man
(MIM) ID: 220111), a cytochrome C oxidase deficiency with features including developmental delay, hy-
potonia and weakness227. Mutations in PEX14 (Peroxisomal Biogenesis Factor 14) (intronic lead vari-
ant rs6687430) underlie certain forms of Zellweger Spectrum Peroxisomal Biogenesis Disorder (MIM:
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Table 3.1 | Sixteen HGS loci reaching genome-wide significance in combined analyses
Stage One (UKB) Stage Two Cohorts Combined
rsID Gene? All. EAF Effect SE p Effect SE p Effect SE p N
rs958685 TGFA A/C 0.52 0.154 0.026 2.8 x 10 -9 0.164 0.04 3.8 x 10-5 0.157 0.022 4.8 x 10-13 191,754
rs72979233 POLD3 A/G 0.76 0.210 0.03 3.7 x 10-12 0.112 0.041 5.8 x 10-3 0.175 0.024 5.0 x 10-13 192,490
rs11614333 ERP27 C/T 0.62 0.181 0.027 5.0 x 10-11 0.117 0.04 3.5 x 10-3 0.16 0.023 1.6 X 10-12 195,154
rs2288278 HOXB3 A/G 0.66 0.162 0.027 3.0 x 10-9 0.147 0.04 2.8 x 10-4 0.157 0.023 3.8 x 10-12 195,133
rs4926611 GLIS1 C/T 0.64 0.173 0.027 1.3 x 10-10 0.115 0.041 5.1 x 10-3 0.156 0.023 4.8 x 10-12 192,964
rs6687430 PEX14 G/A 0.46 0.15 0.026 7.6 x 10-9 0.124 0.04 1.7 x 10-3 0.142 0.022 5.6 x 10-11 195,176
rs10186876 LRPPRC A/G 0.36 0.162 0.027 2.7 x 10-9 0.113 0.041 6.2 x 10-3 0.147 0.023 9.8 x 10-11 192,490
rs374532236 MGMT T/C 0.38 0.157 0.027 5.5 x 10-9 0.121 0.042 4.2 x 10-3 0.147 0.023 1.1 X 10-10 189,701
rs10861798 SYT1 A/G 0.43 0.145 0.026 4.3 x 10-8 0.159 0.047 7.4 x 10-4 0.148 0.023 1.3 x 10-10 189,160
rs78325334 HLA Region T/C 0.84 0.228 0.038 2.4 x 10-9 0.113 0.05 0.024 0.186 0.03 9.6 x 10-10 193,127
rs2273555 GBF1 A/G 0.61 0.153 0.027 9.1 x 10-9 0.096 0.041 0.019 0.136 0.022 1.1 x 10-9 191,754
rs80103986 KANSL1 A/T 0.81 0.201 0.033 1.8 x 10-9 0.098 0.052 0.059 0.171 0.028 1.2 x 10-9 193,090
rs2110927 SLC8A1 C/T 0.27 0.161 0.029 4.4 x 10-8 0.098 0.045 0.029 0.142 0.025 7.7 x 10-9 192,490
rs6565586 ACTG1 A/T 0.25 0.169 0.03 2.2 x 10-8 0.096 0.064 0.14 0.156 0.027 1.2 x 10-8 187,072
rs72762373 DEC1 A/G 0.03 0.424 0.078 4.9 x 10-8 0.359 0.255 0.16 0.418 0.074 1.8 x 10-8 152,162
rs34845616 IGSF9B A/G 0.25 0.168 0.03 1.7 x 10-8 0.07 0.049 0.15 0.141 0.025 2.7 x 10-8 189,666
All, alleles (effect/other); EAF, effect allele frequency; N, sample size; HLA, Human Leukocyte Antigen
Results are sorted by combined stage one + stage two p-value
? Nearest gene to the index variant
Stage one analyses include 142,035 participants
Effect estimates are in kg, per additional effect allele
614887), a syndrome characterised by absence of functional peroxisomes and systemic neurological
impairment228. Finally, rs80103986 is intronic in KANSL1, which has been implicated in the complex
impaired-psychomotor phenotype of Koolen-de Vries syndrome (MIM: 610443)229. Further, the signal
at KANSL1 is in a large linkage disequilibrium (LD) block also containing MAPT (rs754512, pdiscovery =
3.7×10-8), which encodes the microtubule-associated τ protein. MAPT has been implicated in a suite of
so-called tauopathies characterised by progressive neurological deficit, and is also a well-characterised
risk locus for Parkinson’s disease230. 17q21.31 has a complex haplotype structure comprising an in-
version and three structural copy number variants arising from duplication events, which has previously
been shown to be of relevance to health201. After imputing the nine common structural haplotypes at this
locus201–203, the inverted haplotype was associated with lower strength by reference to the non-inverted
(β = -0.17kg, p=3.85×10-6), independent of age, sex, height and BMI (Supplementary Table 6). This
association appeared to be driven by the inverted α2.γ2 structural variant (β = -0.18 kg, p=1.24×10-5).
In sensitivity analyses, we re-tested associations of the 16 grip strength variants in UKB after exclusion
of up to 8,676 individuals with T1D, cancer, or other prevalent disease with potential to influence muscle
strength. No loci showed significant attenuation of effect relative to overall analyses (Supplementary
Tables 7, 8).
3.3.2 Signals are enriched for biologically relevant tissues
To identify enrichment of association signals across different tissues and identify likely effector tissues, we




































































Figure 3.2: MetaXcan-predicted as-
sociation of imputed gene transcript
levels with grip strength across
biologically-relevant tissues in GTEx
Data are shown for all genes at which
altered transcription was significantly
associated with grip strength in at least
one biologically-relevant tissue, after
accounting for multiple testing. Data are
z-scores of transcript level association
with higher handgrip strength, clustered
by tissue. Direction of z-score indicates
whether higher or lower gene expression
is associated with higher grip strength.
Absolute z-score > 1.96 indicates nominal
significance at p≤0.05, and ≥4.94
indicates significance after adjustment for
multiple testing (p≤7.91×10-7). NAcc,
Nucleus accumbens.
discovery phase. After adjustment for multiple testing across nine distinct tissue types (p < 0.0056), we
observed significant enrichments of associations with grip strength in tissue-specific regulatory regions for
a number of tissues, including bone/connective tissue (p = 2.03×10-10), skeletal muscle (p = 1.88×10-9)
and the CNS (p = 7.37×10-8). Enrichments at weaker levels of statistical significance were also observed
in cardiovascular and gastrointestinal tissue, as well as the adrenal/pancreas axis, and ’other’ tissues
(Supplementary Figure 4).
3.3.3 Integration of gene expression data
Guided by tissue-specific enrichments, we sought to identify putative effector transcripts underlying these
associations by investigating associations of lead SNPs or their proxies (r2>0.8) with transcript levels in
brain, tibial nerve and skeletal muscle in GTEx. The grip strength-increasing allele at ACTG1 (rs6565586)
was associated with lower expression of ACTG1 in skeletal muscle (pEXP-Lead=3.81×10-13,
pEXP-Best eQTL=2.64×10-13, r2=0.85). At LRPPRC (rs10186876), the strength-increasing allele was associ-
ated with higher LRPPRC expression levels in cerebellum (pEXP-Lead=6.35×10-7, pEXP-Best eQTL=9.35×10-8,
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r2=0.93) and cerebellar hemisphere (pEXP-Lead=1.29×10-6, pEXP-Best eQTL=3.62×10-8, r2=1.00), which ap-
pears directionally concordant with previously-characterised loss of function and otherwise damaging
mutations associated with the disease phenotype of French-Canadian Leigh Syndrome231. At rs1161433
(ERP27 locus), the grip strength-increasing allele was associated with higher levels of MGP expression
in tibial nerve (pEXP-Lead=5.90×10-10, pEXP-Best eQTL=2.19×10-12, r2=0.84). MGP (Matrix Gla Protein) is a
well-characterised inhibitor of vascular tissue and cartilage calcification, and consequently acts as a key
regulator of bone formation232.
We also performed integrated transcriptome- and genome-wide analyses using MetaXcan and SMR ap-
proaches. Accounting for 5,973 independent expression probes (Bonferroni-corrected p=8.37×10-6), and
potential coincidental overlap of eQTL signals with GWAS loci, SMR analyses using whole blood tran-
scriptome data167 suggested correlation between higher grip strength and lower expression levels of
ERP27(pSMR=2.50×10-9) and KANSL1 (pSMR=3.05×10-7), both of which are implicated genes from our
GWAS analysis.
MetaXcan analysis identified 25 protein-coding transcripts implicated in grip strength at Bonferroni-corrected
significance in at least one of twelve biologically-relevant tissues from the GTEx resource (neuronal, mus-
cle, connective, androgenic tissues and whole blood; transcripts showed concordantly altered expression
across a number of these candidate tissue types (Figure 3.2, Supplementary Table 9). For LRPPRC,
for example, we observed association of higher expression levels across a number of brain tissue types,
tibial nerve, whole blood and testis, with higher grip strength. Higher MAPT expression in multiple brain
regions known to be implicated in motor coordination (cortex, cerebellum and cerebellar hemisphere) was
also associated with higher grip strength.
3.3.4 Pathways underlying variation in grip strength
Hypothesis-free gene set enrichment analysis (GSEA) based on gene-sets of common functional anno-
tation, or belonging to pre-defined canonical pathways (Supplementary Table 10, indicated five-fold en-
richment of association in/near genes implicated in ’positive regulation of protein catabolic process’ (gene
ontology (GO): 1903364, false discovery rate (FDR)=0.026), and nominal enrichment of associations near
genes implicated in ’dual excision repair in global genomic nucleotide excision repair’ (Reactome: R-HSA-
5696400, FDR=0.047). Given the identification of established psychomotor disease loci amongst index
variants for grip strength, we additionally interrogated our association results for enrichment of genes
known to be implicated in monogenic myopathies and dystrophies (Supplementary Tables 10 and 11).
Grip strength associations were nominally enriched in the myopathy-linked gene set (p=0.017), but not at
loci implicated in dystrophic conditions (p=0.47).
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3.3.5 Insights into overlap with pro-atrophic signalling
Myokine signalling via activin type II receptors (ActRII) has been recognised as a key pathway by which
muscle mass might be preserved in many clinical contexts206,208: yet, we saw no evidence for enrich-
ment of associations around genes in a custom-defined pathway of myostatin/activin signalling through
ActRII206 (Supplementary Table 10 and 11). We also performed gene-based association analyses us-
ing VEGAS for genes encoding receptors and ligands in the ActRII signalling pathway, as well as known
atrophy effectors (Supplementary Table 12). Two genes (ACVR2B and FBXO32) showed a significant as-
sociation with grip strength (p<0.0071, accounting for seven gene-based tests) (Supplementary Table 12).
ACVR2B, for which we found the strongest evidence for gene-based association (p=0.0002), encodes the
principal transmembrane receptor of myostatin: the target of BYM338, a monoclonal antibody-based in-
hibitor of ActRIIB, which has shown early promise in reversing muscle atrophy and promoting hypertrophy
in phase I trials233,234. FBXO32 encodes the E3 ubiquitin ligase Atrogin-1/MAFbx, which is recognised as
fundamental effector of atrophy206. These associations are an indication of notable biology at ACVRB2
and FBXO32, though the fact that the VEGAS algorithm calculates gene-level association as the mean of
variant associations within the gene means that gene associations may be influenced by single variants,
and results must therefore be interpreted with care.
3.3.6 Implication of loci in elite athletic performance
Whilst low grip strength is normally considered a marker of frailty, we also investigated the role of grip
strength-associated SNPs in the opposite extreme of physiology: elite athlete status. We examined the
association of grip strength-associated SNPs with odds of being an elite sprint/power athlete in a meta-
analysis of four studies of sprint and power athletes (nAthletes=616, nControls=1610) (see Methods and
Supplementary Note for further details of methods and participants). Among the 14 available SNPs, we
saw no evidence of association with elite athlete status (Supplementary Table 13). Previously, a nonsense
mutation (R577X) in ACTN3, which encodes the actin-binding protein α-actinin 3 in skeletal muscle, has
been associated with elite athlete status235. We found a nominally significant association of the stop-gain
variant (T allele) with lower grip strength (additive: β = -0.062 kg, p = 0.018) (Supplementary Table 14)
although we found no evidence for any departure from an additive genetic model at this locus (dominance
deviation model p = 0.72; Supplementary Figure 5).
3.3.7 Variant association with muscle histology
We also examined whether the lead SNPs at grip strength-associated loci were associated with muscle
fibre type and capillary density in a small sample in which muscle fibre type histology and genome-wide
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data were available (13 of 16 SNPs were available; Supplementary Table 15). Allowing for 13 tests
(p=3.8×10-3), the grip strength-raising allele at TGFA was associated with a lower proportion of type I
(slow-twitch oxidative) muscle fibres (β=-0.16, p=3.3×10-3), and a tendency towards higher proportion
of type IIB (fast-twitch glycolytic) muscle fibres (β=0.16, p=5.5×10-3) (Supplementary Table 15). We
acknowledge limited power in this small sample to identify modest effect sizes. Given a minor allele
frequency of 0.1 and a sample size of 656 individuals, we estimated 80% power to detect an effect size of
~0.35 SDs.
3.3.8 MR of intermediate phenotypes on muscle strength
Given the roles of sex- and growth hormones and related phenotypes in muscle growth and development236–238,
we performed summary statistic MR to test whether genetically-determined sex hormone binding globulin
(SHBG), dehydroepiandrosterone sulphate (DHEA-S), insulin and insulin-like growth factor-I (IGF-I) lev-
els were associated with grip strength. Using genome-wide significantly associated SNPs for SHBG209,
DHEA-S210 and IGF-1 levels211, we saw no evidence for a causal association with grip strength (Supple-
mentary Table 16). We saw some indication of causality of insulin resistance and fasting insulin levels
in grip strength (Supplementary Table 16) in inverse-variance and median-weighted analyses, although
the considerable heterogeneity in inverse-variance weighted results warrants a cautious interpretation
(Supplementary Table 16, Supplementary Figure 6).
3.3.9 Muscle strength as a possible causal exposure
Using a MR approach, we investigated the potentially causal role of muscular strength in both mortality
and disease outcomes, utilising the 16 replicated loci as an instrumental variable to model genetically-
determined grip strength as a proxy of wider muscular strength.
Mortality We found no evidence for a causal relationship between muscular strength and all-cause
mortality in 21,043 participants (5,699 deaths) drawn from the EPIC-Norfolk cohort (hazard ratio (HR) per
kg higher grip strength 0.96 (95%CI 0.91, 1.03), p = 0.265; Figure 3.3A). However, given wide CIs we also
sought to improve power using a recently published approach applying data on parental lifespan214 as a
proxy for longevity. Using this approach in UKB (102,072 paternal deaths, 83,315 maternal deaths), we
again found no evidence for causality, with greater precision (HR [95% CI]: 1.00 [0.98, 1.03], p = 0.739)
(Figure 3.3A).
Coronary Heart Disease We next investigated a causal role for grip strength in cardiovascular disease































































Figure 3.3: Mendelian randomisation of grip strength to mortality, morbidity and anthropometric phenotypes
(a) Mortality and parental lifespan in UKB & EPIC-Norfolk; (b) Forearm, lumbar spine and femoral neck bone mineral density
in GEFOS; (c) Coronary heart disease and myocardial infarction in CARDIoGRAMplusC4D and all-fracture risk in GEFOS +
EPIC-Norfolk; (d) lean mass and fat mass indexes in the Fenland Study + EPIC-Norfolk (n=12,851). Error bars reflect 95% CI
tion (MI; 43,677 cases, 128,199 controls) from the CARDIoGRAMplusC4D Consortium204 (Figure 3.3C).
We found no evidence for a causal relationship between grip strength and CHD (odds ratio (OR) per
genetically predicted kg higher grip strength 0.99 (95% CI 0.94, 1.03), p = 0.631) or MI (OR 0.98 (95%
CI 0.93, 1.03), p = 0.433; Supplementary Table 18). This result was further supported by cross-trait LD
Score regression results showing no significant genetic correlation between grip strength and CHD (rG=
-0.045, p = 0.362; Supplementary Table 19).
Fracture risk and bone mineral density We performed MR analyses of fracture risk using a meta-
analysis of (1) summary statistics MR results for fracture risk from the GEFOS consortium (20,439 cases,
78,843 controls; Supplementary Note, Supplementary Table 18) and (2) logistic regression results from
association of the weighted grip strength genetic score with fracture risk in the EPIC-Norfolk study (1,002
cases, 20,042 controls). Meta-analysis results suggested a causal association of genetically-predicted
higher grip strength with lower risk of fracture (OR per genetically predicted kg higher grip strength 0.95
(95% CI 0.90, 0.99), p = 0.02) (Figure 3.3B). Summary statistic MR of genetically-determined grip strength
on publicly available bone mineral density (BMD) GWAS results205 did not show significant associations
between grip strength and BMD (Figure 3.3C, Supplementary Table 18). However, we did find positive
genome-wide genetic correlations of bone mineral density with grip strength (femoral neck BMD: rG =
0.123, p=9.5×10-3; lumbar spine BMD: rG = 0.156, p=6×10-4; Supplementary Table 19), supportive of a
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role for genetically predicted higher grip strength in fracture risk.
Similar to the BMD results, MR analyses of genetically-determined grip strength on meta-analysed GWAS
results comprising 12,851 participants from the Fenland and EPIC-Norfolk cohorts did not show significant
associations between grip strength and lean mass index (LMI) or fat mass index (FMI) (LMI β = .072
kg/m2, p = .074; FMI β = .013 kg/m2, p = .878) (Figure 3.3D, Supplementary Table 18). We did observe,
however, a significant genetic correlation between grip strength and LMI (rG = 0.258, p=2.8×10-5), but not
FMI (Supplementary Table 19).
3.4 Discussion
We have identified 16 loci associated with maximal hand grip strength at genome-wide significance. A
number of the lead variants were located within or close to genes implicated in structure and function of
skeletal muscle fibres, neuronal maintenance, and signal transduction in the central and peripheral ner-
vous systems. Partitioned heritability analyses indicated significant tissue-specific enrichment of skeletal
muscle, central nervous system, connective tissue and bone in the genome-wide grip strength results.
We observed evidence of shared genetic aetiology of lean mass and grip strength levels, while pathway
analyses indicated a role for genes involved in regulation of protein catabolism in the aetiology of grip
strength.
Due to the well-established observational associations of higher grip strength with reduced risk of mor-
tality and incident CHD it has been hypothesised that improvement of muscle strength might increase
longevity and reduce risk of adverse cardiovascular events49. Our MR analyses do not find evidence
supportive of a causal role of muscular strength in mortality risk, nor in risk of cardiovascular events
(CHD and MI), leaving open the possibility that these observational associations may be attributable to
confounding and/or reverse causality. In the absence of causality, it is likely that apparent prospective as-
sociations between hand grip strength and cardiovascular disease are driven by a subset of undiagnosed
participants amongst whom early, sub-clinical disease processes in the pathogenesis of CHD and related
conditions have begun to adversely influence grip strength, whether through direct atrophic pathways or
indirect loss of muscle condition, perhaps due to reduced physical activity. Regardless, this does not
negate the importance of maintaining strength and muscle mass during ageing as a strategy to maintain
physical function205, and we acknowledge the potential limitations of our MR, especially to conclude on
the absence of a causal association given a null result. For example, the limited variance in intermediate
traits explained by genetic variants leaves uncertainty over the presence of a small causal effect. Thus,
expanded genetic discovery efforts and greater availability of large-scale studies of disease outcomes
will improve the precision of MR analyses in future. We saw evidence for shared genetic aetiology of
bone mineral density and lean mass with grip strength, and MR results suggested a causal role for higher
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muscular strength in lower risk of fracture. Collectively, these results suggest that the determinants of
muscular strength are shared with the determinants of fracture risk and are consistent with those from
intervention studies to increase muscle strength, which have been shown to improve functional capacity
and reduce the rate of falls239, as well as attenuating the rate of functional decline and increased frailty
which often follows major fracture among the elderly240. Despite the established decline in grip strength
with increasing age, we did not observe heterogeneity in the effect of grip strength-associated variants
with grip strength by age. The cumulative effect of the genetic score was greater in men than women,
however, perhaps suggesting differences in the underlying genetic component of muscle strength by sex.
We saw evidence of enrichment of associations with grip strength around genes implicated in myopathies.
We also noted three loci with genome-wide significant associations containing genes (KANSL1, PEX14
and LRPPRC) implicated in rare, severe clinical syndromes characterised by phenotypes of progressive
psychomotor impairment, muscle hypotonia and neuropathy227,229. Within the UKB discovery cohort, the
association of all three loci with grip strength persisted at genome-wide significance even after sensitivity
analyses restricted to participants without any form of self-reported condition which might affect muscle
mass or function. Whilst these clinical conditions represent the extreme phenotype of highly deleterious
rare mutations in these genes, we demonstrate that proximal common variants are likely to underpin more
subtle population-level variation in strength in healthy populations.
Finally, we found that common variation at ACVR2B, the principal receptor of myostatin and activin in
skeletal muscle, is associated with population-level variation in grip strength. Ongoing clinical trials and
development of pharmaceutical agents targeting this pathway have demonstrated potential to reverse
atrophy, and improve muscle function in numerous clinical contexts, both within and separate from the
context of frailty and ageing233,234. Most notably, Bimagrumab (a monoclonal antibody antagonist of
ActRII) has progressed to Phase III for the treatment of spontaneous inclusion body myositis234 (a rare
and severe myopathy), and trials are progressing for related indications including cachexia, hip fracture
and chronic obstructive pulmonary disease233. Our association of common variation in ACVR2B with
muscle strength provides some level of genetic support for pharmaceutical targeting of ActRII in this
context.
In conclusion, we identified 16 loci robustly implicated in grip strength and provide insight into the un-
derlying biology of this important, widely studied, yet poorly characterised trait. MR analyses suggest no
causal role for muscular strength in mortality, but do provide evidence for a causal role in fracture risk,
highlighting the importance of interventions to improve muscle strength as a means to reduce fracture
risk and resultant morbidities. Further genetic and functional work to characterise these loci will elucidate
new pathways involved in the regulation of muscle strength and inform the development of drugs to tackle
muscle wasting and weakness.
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Chapter 4
REE-Gen: A Global Effort to Identify and




R esting energy expenditure (REE) constitutes the majority of daily total energy requirements, isa cornerstone of basic metabolism and energy balance, and may be of aetiological importance
to weight gain and obesity. A number of genes have been pursued as candidates influencing REE,
but genetic variants influencing REE are poorly characterised. To identify these variants, we performed
a large genetic discovery analysis in up to 11,164 European individuals, and identified one common
locus to the 3’ of GOT2 associated with REE, independently of body size. GOT2 is an indispensable
component of the malate-aspartate shuttle, which translocates high energy electrons from glycolysis in
the cytoplasm, to the mitochondrial matrix, where they enter the electron transport chain. By inclusion
of a further 700 transethnic samples, we additionally identify two further signals for REE, which offer
high biological plausibility for an involvement in energy metabolism. REE associations across the genome
were nominally enriched for major biochemical respiratory processes independent of age and sex, and
showed intuitive positive genetic correlation with body size parameters. We present the first large-scale





Resting energy expenditure (REE) is the minimum level of energy required by an adult to maintain vital
function whilst at rest, it forms the main component of total daily energy expenditure in all but the most
physically active individuals56. REE varies primarily as a function of age, sex and basic anthropometric
factors, driven by body size, and has typically been considered a fixed energy cost for an individual
of given body size and composition64–70. Family and twin studies97–99 have consistently estimated the
heritable component of REE at 30%, yet no underlying variants have been characterised. Whilst certain
candidate genes (e.g. UCP1, UCP3, MC4R) have been reported as associated with REE in specific
populations100–106, the current literature is based on nominal significance thresholds (p<0.05), and is
underpowered for genetic effect.
As a major component of energy balance, REE has clear theoretical implications in obesity. However,
observational approaches to assess whether REE plays a role in weight gain have been inconclusive, and
are limited by their high potential for confounding, especially when using retrospective methods. Amongst
known loci for BMI and adiposity, the mechanisms by which variants aetiologically underpin higher body
size and fat mass are unknown. Whether variants are linked to positive energy balance through increased
energy intake, or decreased expenditure - and whether their effects act through behavioural or physiolog-
ical routes - is unclear. Recent work in mice and human cell lines provides an initial suggestion that FTO
may mediate higher BMI through decreasing net thermogenesis241, yet further work is required.
To characterise genetic variants associated with REE independently of body size, we conducted a genome-
wide association study (GWAS) of REE measured by indirect calorimetry in up to 11,164 Europeans, and
an additional transethnic sample of 697.
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4.2 Methods
For each contributing cohort (Supplementary Table 20), cardiorespiratory exchange was measured in
rested and overnight-fasted individuals by open circuit indirect calorimetry under thermoneutral climate-
controlled conditions, according to best practice57. After quality control to ensure steady-state respiration
(a prerequisite for the accurate inference of REE57), REE was derived from observed respiratory ex-
change parameters using established equations62,242. For the Fenland Study, respiratory exchange data
collected over the course of recruitment was processed, cleaned and used to derive REE de novo for the
purposes of this work, as detailed below. For other cohorts, REE phenotypes were based on the existing
measurement, quality control, and derivation procedures applied by each study; exact details of these
protocols are outlined in Supplementary Table 20.
Fenland: Measurement of cardiorespiratory exchange at rest
In the Fenland study, participants provided measurements approximately an hour into the assessment
visit, having primarily been seated and at rest for that time. After a short period of acclimation, respiratory
exchange was quantified (Jaeger Oxycon Pro, Carefusion, CA) using breath-by-breath (BxB) sampling
with a facemask interface, for six consecutive minutes. Heart rate was measured contemporaneously
using two independent devices: (i) a telemetric sensor (Polar, Warwick, UK) providing real-time read-out
of pulse, and (ii) the ActiHeart combined heart rate/activity monitor (CamNTech, Cambridge, UK) set to
sample RR interval at 15s epochs The participant was supine, still and wakeful throughout.
Running quality assurance of data Real-time output was monitored by trained personnel throughout
the test to identify instability in the measured phenotypes, and HR was tracked to ensure steady-state
at resting levels (per a baseline reference measure). Participants with erratic or inconsistent breathing
profile, respiratory exchange, or elevated HR were reminded to relax, and breathe normally. Testing
duration may have been extended at the operator’s discretion should the six-minute protocol be judged
insufficient to gauge stable exchange phenotypes from normal breathing. In case of anomalies indicative
of equipment error, malfunction or sampling line leaks, the test was paused and errors rectified, before
resuming for a further six minutes.
Pre-test calibration The Oxycon Pro was calibrated for (i) ambient condition sensing (air temperature,
atmospheric pressure and humidity), (ii) volume measurement, and (iii) gas analysis, on a standard sched-
ule according to manufacturer instructions. All calibrations were run twice daily, with additional calibration
for volume and ambient conditions between participants. Analyser calibration used gas of standard com-
position (15% O2, 5% CO2, 80% N2; BOC Industrial Gases, Guildford, UK). Volume calibration was via a
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Fenland: Derivation of resting energy expenditure
Cardiorespiratory exchange data collected within Fenland is uniquely large, and gathered in a research
context distinct to the clinical environment from which calorimetry usually originates. By contrast to the
clinical setting57, Fenland applied a shorter, standard measurement protocol centred on maximising data
quality whilst minimising inconvenience to the participant. Output was monitored to ensure quality, yet
testing duration was standardised and interpretation of data was not contemporary with the test. Efficient
processing of this data necessitated the development of a novel quality control and interpretation pipeline.
The procedure was split into two parts (Supplementary Figure 7): within-participant cleaning and smooth-
ing of the BxB time-series, followed by cohort-level masking of participants with inadequate or poor-quality
data.
Within-participant filtering Under BxB sampling, exchange data are continuously assessed and re-
ported by breath, in contrast to mixing-chamber protocols, which collect and sample expired air at fixed
intervals, introducing a degree of averaging. To manage the noisier nature of BxB output (Figure 4.1), an
initial within-participant cleaning stage was constructed to retain stable, physiologically plausible breaths
representative of underlying respiratory exchange at rest. Absolute and distribution-based filters were ap-
plied (Table 4.1) to remove physiologically spurious breaths, anomalies (e.g. coughs, sneezes, hiccups),
hardware error, and exchange parameters suggestive of non-resting states. BxB filtering focused first
on removal of non-valid breaths, and secondly on ensuring steady-state exchange within the remaining
time-series (Supplementary Figure 7).
Restriction to valid breaths To remove physiologically implausible breaths within each individual’s
timeseries of breaths (Supplementary Figure 7), VO2 was normalised to body weight and restricted to
the range 1 - 6mL/kg/min. Thresholds were selected to maintain true variation and avoid artificial trun-
cation of the distribution within the range of plausible VO2 values at rest, whilst ensuring that extreme
and erroneous values were removed. Missing values of VO2/kg and VCO2/kg were dropped by default.
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Figure 4.1: Breath by breath VO2 timeseries in two participants with differing degrees of data noise prior to filtering. Data are
observed body mass-adjusted VO2 reported by breath. Red trace (right axis), rolling coefficient of variation (CV) of VO2 for
consecutive 15s epochs. Upper plot, six-minute timeseries from a participant with mean VO2 correspondonding to the standard
MET (3.5mL/kg/min). Lower plot, equivalent timeseries for a participant with a high mean observed VO2. Combined, these plots
demonstrate the variability in the stability of observed respiratory exchange parameters which must be consistently processed
to retain breaths representative of underlying respiration.
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Figure 4.2: Population trend in VO2 & VCO2 over duration of indirect calorimetry. Data shown are population-level means of
individual-level means calculated using unsmoothed valid breaths, with 95% CI. Time is calculated relative to the full test duration
of each participant. A and B, Trend over six-minute test duration; C and D, Detail of trend over last 120s of protocol by 15s epoch.
Breath-wise respiratory exchange ratio (RER) was limited to the range 0.6-1.2. RER usually equates to
the true respiratory quotient (RQ) of 0.7-1.0 at cellular level - however there is a need to allow for physi-
ological processes such as bicarbonate buffering which increase the gradient between the RQ and RER.
Anomalous breaths and those registered in error were further flagged by removing breaths corresponding
to an outlying respiratory minute volume (VE), more than 3 SDs from the participant’s mean, and those
with extreme inspiratory and expiratory durations (TIN and TEX, respectively; Table 4.1).
Metabolic representativeness of remaining breaths was assessed on the basis of their end-tidal partial
pressure of CO2 (pEtCO2, the concentration carbon dioxide in the breath at the end of exhalation); values
reflecting hypo- or hyperventilation (i.e. respiratory exchange in excess or deficit of underlying metabolic
requirements) were removed. pEtCO2 is applied as a proxy indicator of arterial oxygen tension (paCO2),
and has a clinically-acceptable range of 30-45mmHg corresponding to a normal paCO2 range of 35-
45mmHg, accounting for the established arterial-end tidal oxygen gradient. In the interest of conserving
observations whilst ensuring that true hyperventilation was removed, the minimum limit applied was low-
ered to 25mmHg. The upper limit remained unchanged, as CO2 retention exceeding this threshold would
correspond to clinical ventilatory failure.
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Phenotype stability Steady-state respiration is a prerequisite to accurate interpretation of indirect calorimetry57.
As an initial step in identifying population-level stabilisation of respiration, minute-by-minute mean VO2 and
VCO2 were calculated for each participant based on valid breaths from the previous stage, and averaged
across the whole test population (Figure 2.2, panels A-B). Each minute was defined relative to the end-
time of the participant’s test to account for differing test durations. At population level, VO2 and VCO2
continued to decrease substantially over the first three to four minutes of rest, and begin to plateau from
minute five (Figure 2.2, panels C-D). Individual time-series were therefore truncated to the last 120s.
A five-breath rolling median was applied to all physiologically-valid breaths in this timeframe to generate
a smoothed time-series and reduce the influence of remaining phenotype fluctuations. To systematically
address instability in the time-series, smoothed VO2 and VCO2 were regressed separately on underlying
time within each individual, and mean VO2 and VCO2 values of valid breaths across the 120s calcu-
lated by participant. Breaths with a residual VO2 or VCO2 exceeding 10% of the participant mean VO2
or VCO2, respectively, were identified as contributing to substantial fluctuation in the phenotype, and re-
moved, leaving a final cleaned time-series of smoothed breaths judged to be physiologically plausible and
metabolically representative (Supplementary Figure 7).
Between-participant filtering Based on the requirement for steady-state respiratory exchange, par-
ticipants with a substantial directional trend in cleaned VO2 or VCO2 were removed from the analytical
dataset (Supplementary Figure 7). To achieve this, cleaned VO2 and VCO2 for each participant was
regressed on underlying time, and participants with an outlying β-coefficient (>3 SDs from the mean pop-
ulation β, and with a significant Bonferroni-corrected p-value at α=0.05) omitted. Participants with <6 or
>50 breaths were dropped. To ensure representativeness, participants were additionally dropped if this
cleaned time-series represented <50% of all valid breaths taken in the last 120s of the test (i.e. those
remaining after restricting to valid breaths).
Calculation of REE from standard equations For participants passing all stages of QC, total daily
resting energy expenditure (kcal/24hr) was derived according to the Abbreviated Weir formula, an adapta-
tion of Weir’s classic formula which omits the physiologically negligible contribution of protein metabolism
to energy expenditure62,243. After calculation, REE was converted to kJ/day (1 kcal = 4.184 kJ).
REE = 1.44(3.9V O2 + 1.1V CO2)
NEO and the Pima Indian study used slight, but very closely aligned, variations of the above formula
derived by Elia and Livesey244, and Lusk242, respectively.
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Cross-sectional analyses in Fenland
To check associations of REE with known correlates, we ran initial cross-sectional analyses with age, sex,
bodyweight, height and compartmentalised lean, fat and bone masses using linear regression (Stata 14;
StataCorp, TX, USA) in a subset of Fenland samples only (n=7,689; corresponding to the analytic set
used in Chapter 5). All models were adjusted for ambient temperature, calorimeter device and whether
or not the participant has ingested as standard dose (75g) of glucose as part of an oral glucose tolerance
test prior to measurement of respiratory parameters. Tissue-specific masses were measured by dual
x-ray absorptiometry (DXA; Lunar Prodigy, GE Healthcare), processed using manufacturer’s proprietary
software, and manually partitioned into trunk and peripheral (limbs) compartments.
European association analyses & signal selection
Two variant discovery models were run: the first adjusting for age and sex, and the second for age, sex
and bodyweight (kg). To account for between study-heterogeneity, we obtained the residual of REE for
each model from linear regression adjusted for the model terms and study-specific covariates as detailed
in Supplementary Table 20. Residuals were transformed to obtain a distribution of mean 0 and standard
deviation 1.
Genome-wide associations of autosomal SNPs with transformed residuals were calculated separately
in each contributing European study - Fenland, the Baltimore Longitudinal Study of Ageing (BLSA), the
Netherlands Epidemiology of Obesity study (NEO), and the Quebec Family Study (QFS) - and additionally
for each genotyping array within cohorts where multiple arrays were used. Details of each study are pro-
vided in Supplementary Table 20; a standardised analysis plan was followed by each collaborating cohort
(Appendix 1). Linear mixed models (LMM) implemented in BOLT-LMM were applied preferentially; oth-
erwise, study-specific measures to account for population structure were applied (Supplementary Table
20). SNPs with MAF <0.5% or imputation quality < 0.4 were excluded post-analysis. Fixed effects (in-
verse variance-weighted) meta-analysis of European cohorts was conducted in METAL without genomic
correction. Variants with an association p≤5×10-8were considered genome-wide significant. Indepen-
dent loci were defined on physical distance using a 500kb window either side of the index SNP. To confirm
the absence of inflation in the association results, LD Score Regression intercept was calculated using
LDSC via LD-Hub. Regional plots were produced for significant loci using LocusZoom with 1000G as LD
reference.
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Addition of trans-ethnic samples
Inclusion of diverse ancestral samples in GWAS may increase power to detect variant effects, yet can
be adversely affected by between-study heterogeneity159. We performed a trans-ethnic meta-analysis
by including REE data from two multi-ethnic cohorts: Pima Indians in Arizona (Pima, n=509) and the
Nigerian individuals enrolled in the International Collaborative Study on Hypertension in Blacks (ICSHIB;
n=188). See Supplementary Table 20 for descriptive details of these cohorts, and their protocol for REE
derivation.
Genome-wide associations were calculated separately in ICSHIB and Pima data, adjusting for age, sex,
study-specific covariates and population structure. After restricting to variants available in the European
meta-analysis, results were meta-analysed together with the European discovery summary statistics in
METASOFT245 using (i) standard fixed-effects, (ii) Han and Eskin’s modified random effects model (robust
to heterogeneous direction of effect between studies)245, and (iii) a binary effects model which increases
power where a variant has an effect in some cohorts but not others246. After removing variants not
available in either Pima or ICSHIB, trans-ethnic association results were available for 3,916,937 variants.
Metabolome Look-ups
Associations of rs61520068 with circulating metabolite levels were extracted from the GWAS summary
statistics of two UK cohorts with metabolomic profiling. Metabolite measures were measured in up to
9,363 Fenland participants using the targeted Biocrates AbsoluteIDQ p180 Kit (Life Sciences AG, Aus-
tria), and up to 5,841 individuals from EPIC-Norfolk using the untargeted Metabolon Discovery-HD4 plat-
form (Metabolon, NC, USA). In each study, separate GWAS analyses were run for each metabolite level
(log-transformed and standardised) using BOLT-LMM (or SNPTEST where BOLT-LMM failed due to in-
valid heritability estimates). Models were adjusted for age and sex (and batch within EPIC-Norfolk). In
Fenland, analyses were performed separately within two separate genotyping arrays, and meta-analysed.
These analyses form part of an ongoing large-scale systematic genetic discovery effort for metabolites
overseen by L. Lotta and I. Stewart, and were used by kind permission. Conservative Bonferroni correc-
tion, considering each tested metabolite as an independent statistical test, was applied within each array
to define statistical significance.
Signal annotation & expression-based analyses
HaploReg247 was used to functionally annotate REE variants from European and trans-ethnic discovery
(and their proxies; r2≥0.8), including details on cis-eQTLs. Expression-based analyses were expanded to
leverage associations with REE across the genome using imputed transcriptome-based models (TWAS,
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MetaXcan, and SMR) based on expression in whole blood, and across multiple tissues from GTEx, as
described in Chapter 2
Gene Set Enrichment Analyses
To test for biological and functional enrichment of associations with REE across the whole genome, we
conducted hypothesis-free pathway-based analysis using MAGENTA, as previously described. Statistical
enrichment of a pathway was defined as a permutation-based false discovery rate (FDR) ≤0.05 across all
pathways. Taking a hypothesis-driven approach, associations with REE across the genome were addition-
ally tested for enrichment of candidate pathways involved in cellular processes of glycolysis and aerobic
respiration. Pathways were identified by querying mSigDB for key respiratory processes (Supplementary
Table 24). Twenty-one pathways with >10 genes were identified; significant enrichment was defined using
a conservative p-value threshold ≤(0.05/21), though nominal associations at p<0.05 were also reported
given that adjustment for each pathway as an independent test is likely to be over-conservative when the
contents of the gene sets are overlapping between pathways and between versions of the same pathway
drawn from different databases.
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4.3 Results
Of the 10,079 participants for whom indirect calorimetry measures were available in Fenland, REE was
derived for 9,372 participants (92.9%; 91.1% of original men , and 93.6% of original women), who retained
valid, steady-state respiratory time-series after restriction to valid breaths and removal of individuals with
unstable phenotypes. Univariate anthropometric and respiratory phenotypes amongst this analytic sub-
cohort are summarised in Supplementary Table 21. On average, participants passing quality control were
somewhat overweight (mean BMI 26.8±4.7kg/m2), with mean age 48.9 years. The 707 excluded partici-
pants weighed less on average (mean body mass 74.4kg vs. 78.1kg in the analytic set, p<0.001), and had
a correspondingly decreased BMI. Age did not differ between quality control successes and failures. Over
the last 120s of measurement, our observed VO2 was concordant with expected ranges from literature248.
In men and women combined, mean REE was 1748.17±432.55kcal/24hr; REE was normally distributed
overall, and within the sexes (Supplementary Figure 8).
Of the 9,372 with derived REE, array genotyping and full covariate data was available in 8,491 participants;
once combined with data from contributing discovery-stage cohorts (NEO, QFS, BLSA), objective REE
was available in up to 11,164 individuals of European descent from Fenland, plus three additional cohorts
in the Netherlands, Canada and United States. Based on a subset of data from the Fenland study we
confirmed known observational associations of REE, which was negatively correlated with age, higher
in men relative to women, and cross-sectionally predicted by body size, including separate independent
effects of lean mass and fat mass (Supplementary Table 22).
4.3.1 A common variant near GOT2 is associated with REE
To identify novel genetic associations with objectively-assessed REE from indirect calorimetry, I performed
a genome-wide association study of REE in up to 11,164 individuals of European descent, with and with-
out adjustment for body mass (Supplementary Figure 9). Whole genome heritability of REE adjusted
for age and sex was estimated at 14.3% (2.3% after adjustment for bodyweight) using LD score regres-
sion. After accounting for multiple testing, heritability was not enriched for any particular tissue based on
partitioned heritability analyses.
We identified one common (MAF = 0.50) intergenic signal for REE, independent of age and sex (rs61520068,
p=4.11×10-8), to the 3’ of GOT2 (Mitochondrial Glutamic-Oxaloacetic Transaminase II), associated with
a 0.08 SD increase in REE per effect allele (Figure 4.3). No signals reached genome-wide significance
upon additional adjustment for bodyweight. Association p-values were not significantly inflated in either
model on the basis of LD-score regression intercept, and apparent inflation of GC was attributable to
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Figure 4.3: Regional association of rs61520068 with REE in European discovery analyses adjusted for age and sex
sence of any secondary signal at rs61520068. rs61520068 was not a significant cis-quantitative trait locus
for either tissue-specific gene expression or methylation based on look-ups in GTEx (via the HaploReg
browser) and the BiOS QTL Browser (http://www.genenetwork.nl/biosqtlbrowser/), and we additionally
found no evidence of association with circulating metabolite levels in either the Fenland or EPIC-Norfolk
cohorts. Summary statistics from the initial (age- and sex-adjusted) model were used as the main source
of associations for subsequent analyses.
4.3.2 Genetic signals are independent of major confounders
To check that the signal at rs61520068 was not influencing REE through an underlying association with
body size, we looked up the variant in the most recent consortium-based GWAS for BMI249, height250,
hip and waist circumferences251, and body fat percentage252, and confirmed an absence of signal within
a 2mb window around the variant (Supplementary Figure 10). Additionally, GOT2 encodes aspartate
aminotransferase (AST), which is routinely used as a clinical indicator of liver function. As compromised
liver function may confound observed genetic associations with metabolic function, we further confirmed
that rs61520068 was not associated with plasma AST in the EPIC-Interact cohort253,254 in standard asso-
ciation analyses assuming additive effect and accounting for age, sex and population structure (p=0.59,
n=15,332).
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4.3.3 Transethnic analyses implicate additional intronic signals
The addition of ethnically-diverse samples to GWAS may offer power benefits for variant discovery by
exploiting differences in allele frequency, but requires tailored approaches to appropriately handle hetero-
geneity and population structure. We performed a trans-ethnic GWAS by meta-analysing Native American
(n=509) and black African (n=188) individuals from two additional studies together with our main European
population. A combination of meta-analysis techniques optimised to detect consistent and inconsistent
directions of effect between ethnicities, as well as lack of effect in some ancestries, were applied to max-
imise power. These included fixed effects, Han and Eskin’s modification of random effects and binary
effects approaches, respectively245,246.
Combined analyses revealed two additional intronic signals at genome-wide significance (p≤5×10-8)
in HCRTR2 (rs12527963), and VTCN1 (rs12034996), with frequencies varying from 0.01-0.50 between
ancestries (Supplementary Table 23). The lead variant at VTCN1 remained significant after adjustment of
REE for bodyweight (pBinary=3.43×10-9). The European signal near GOT2 fell just short of genome-wide
significance in transethnic analyses adjusted for age and sex (pHan-Eskin=3.86×10-7, pBinary=1.15×10-7),
but the magnitude and direction of its effect remained concordant with the European discovery model. This
attenuation of statistical significance likely reflects the increased heterogeneity of transethnic analyses.
4.3.4 Enrichment for respiratory processes
Hypothesis-free gene set enrichment analyses (GSEA) using MAGENTA did not indicate statistically-
significant enrichment of European REE associations across the genome for underlying canonical bi-
ological pathways or gene ontology groupings. To more closely investigate enrichment of association
for specified biological processes and phenotypes relevant to energy balance and REE, we undertook
hypothesis-driven GSEA using curated gene sets from mSigDB implicated in cellular respiration or its
sub-processes (Supplementary Table 24). Suggestive enrichment of associations for genes involved in
the citrate cycle (KEGG TCA Cycle p=0.022; GO TCA Cycle Enzyme Complex p=0.034), and implicated
in the mitochondrial electron transport chain (Biocarta, p=0.0499) was observed, though should be in-
terpreted with caution as these associations do not survive strict correction for multiple testing across
21 pathways (p=0.002). Nonetheless, there would appear to be biologically interesting enrichment at
these pathways, especially considering the high level of correlation between their constituent genes, such
that adjustment for 21 independent tests is likely over-conservative. Enrichment for the GO TCA Cycle
Enzyme Complex term was statistically strengthened after adjustment for bodyweight (p=0.008).
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4.3.5 Gene-based variant and expression analyses
Genome-wide gene-based association analyses are increasingly being applied to supplement variant-
centric approaches in genetic discovery, and are particularly attractive due to their lower burden of mul-
tiple testing. Using MAGMA to test the mean association of all SNPs in each gene with REE across
the genome, PRKCSH (glucosidase II β-subunit) showed gene-level association with REE, independent
of body weight (pMAGMA=1.50×10-6). We further applied a range of integrated transcriptome analyses
(MetaXcan,SMR,TWAS) to gauge whether altered expression of genes in whole blood and a range of
tissues was associated with REE. These approaches did not, however, implicate transcript levels in any
tissue with REE.
4.3.6 Shared genetic basis with cardiometabolic phenotypes
In light of the fact that European discovery efforts identified only one variant at genome-wide significance
in age and sex-adjusted models, formal assessment of REE as a causal exposure using MR techniques
was not possible. Whilst the construction of polygenic instruments containing only variants associated
with the modelled phenotype at sub-genomewide significance has been advocated255, the risks of violat-
ing major assumptions of MR analyses by such an approach are very high. Selecting variants falling below
the genome-wide threshold may weaken the assumption of robust association between the instrument and
modelled intermediate, and also markedly increases the likelihood for pleiotropy and heterogeneity which
cannot appropriately be mitigated through the use of sensitivity analyses. For this reason, we consid-
ered the shared genetic architecture of REE with selected anthropometric, cardiometabolic and ageing
phenotypes, using associations across the whole genome (Supplementary Table 25). After accounting
for multiple testing, REE (age and sex-adjusted) showed positive genetic correlation only with body size
phenotypes, including standing height (p=3.10×10-8) and BMI (p=1.18×10-7). These findings are con-
cordant with the observation that body size is the primary driver of whole-body energy requirements, and
highlight the close relationship between these phenotypes. No further associations were observed, how-
ever. Genetic correlations using genome-wide associations for REE further adjusted for body mass were
not possible, as the narrow-sense heritability observed in this model fell below the threshold required for
correlation analyses by LD Score Regression.
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4.4 Discussion
We have identified one common signal for REE in Europeans at genome-wide significance, and a fur-
ther two signals after inclusion of 700 individuals of Native American or African ancestry. Associations
appear to be independent of confounding by body size. Signals fall in or near to genes implicated in cellu-
lar respiration (GOT2, SLC38A7 ), T cell-mediated immunity (VTCN1) and orexigenic factors (HCRTR2).
Across the genome, associations with REE are nominally enriched for the two major processes of aerobic
respiration: the citrate cycle and the mitochondrial electron transport chain.
GOT2 encodes the mitochondrial form of glutamic-oxaloacetic transaminase, a core component of the
malate-aspartate shuttle (MAS). This process vitally facilitates translocation of the high-energy reducing
equivalents generated in glycolysis to the mitochondrial matrix, where they enter the electron transport
chain (Figure 4.4). The intrinsic role of GOT2 in electron transfer gives a high biological prior for as-
sociation with REE. GOT2 knockdown in lung cancer cells lines has previously been demonstrated to
reduce ATP production by nearly a half256, and decrease mitochondrial aspartate availability257, whilst
GOT2 acetylation regulates the rate of the MAS in non-cancer cells258. Of note, the GOT2 locus also
partially contains SLC38A7, which encodes the major mitochondrial transporter of glutamine. Glutamine
is the precursor amino-acid of glutamate, the substrate of GOT2 in the MAS, where it is converted to
α-ketoglutarate and feeds into the citrate cycle. Neither GOT2 - nor any other gene - is functionally im-
plicated by rs61520086, but, in the absence of alternative means to prioritise genes, the fact that GOT2
is the only gene wholly contained within the 1mB locus centred on the index (Figure 4.3 strengthens its
position as a gene of interest at this locus.
Transethnic analyses shed further light on potential genetic signals underlying REE: in particular, the
implication of the neuropeptide orexin (HCRTR2) was of interest. Orexin (also known as hypocretin) is
most well-characterised as a regulator of food intake, appetite and wakefulness260–263, though a direct
role in thermogenesis and adipocyte browning has been described more recently. Orexin is necessary for
brown fat differentiation264, reverses brown adipose dysfunction in ageing mice265, and has been shown to
be a key modulator of non-shivering thermogenesis in brown adipose tissue264,266,267. Whilst transethnic
analyses in this case do add further biological insight, the low additional sample size contributed by
transethnic samples to this analysis and the relatively low frequency of the identified variants means
that these associations should be interpreted with caution pending further replication in diverse ancestral
samples
This work represents the largest genetic discovery of objectively-assessed REE to date - and the first in
Europeans - with a combined sample size exceeding other recent GWAS efforts by more than twenty-
fold110. Through concerted international collaboration, the pooled sample used in these analyses incor-
porates the majority of REE data available from indirect calorimetry (with array-based genotyping also
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available) on a global scale. Nonetheless, the absolute sample size used here is relatively small and it
must be acknowledged that - despite best efforts - these analyses are likely to be underpowered. Lim-
ited discovery of associated variants has precluded the intended formal assessment of REE as a causal
exposure, and the subsequent use of genetic correlations to assess shared genetic architecture of REE
with cardiometabolioc traits across the genome only confirms known observational drivers of REE, rather
than providing new insight.
Given that all available data have been utilised to maximise discovery sample size, our capacity to
replicate associations in independent samples has been restricted. Follow-up of our identified locus at
GOT2 should be pursued in further work, though enhanced discovery efforts with improved sample size
should be prioritised in order to maximise identification of independent variants for REE and generate
a robust instrument for REE. This, however, represents a medium to long-term objective, as it will re-
quire substantial new phenotyping efforts in many thousands of individuals, or de novo genotyping of
existing large population-based samples with REE already assessed. A particular frustration amongst
existing population-based cohorts with indirect calorimetry measures (e.g. POUNDS-LOST268, Health-
ABC) is that the availability of biosamples suitable for genotyping is limited, having been stored only for a
small proportion of the population (POUNDS-LOST), or otherwise not made collaboratively available to us
(Health-ABC). In the short term, functional validation of the major genes implicated here by knock-down
or knock-out in cell lines or animal models likely represents the next immediate avenue to investigate the
role of these genes in energy expenditure. Dedicated systems (e.g. Seahorse Analysers, Agilent Tech-
nologies, Santa Clara, CA) allowing the direct effect of cellular perturbations on the respiratory profile of
cell lines to be quantified through direct measurement of oxygen consumption and respiratory intermedi-
ates, are in wide research use, and could be applied to such knock-down cell lines in collaboration with
partners.
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Figure 4.4: The malate-aspartate shuttle (MAS). As the inner mitochondrial membrane is impermeable to reduced cofactors,
the MAS represents the main mechanism by which reducing equivalents for respiration are translocated between the cytosol
(shaded blue) and the mitochondrial matrix (shaded orange). NADH oxidation in the intermembrane space is coupled to NAD re-
duction in the matrix, regenerating NADH for oxidative phosphorylation, and maintaining the cytoplasmic supply of NAD required
for glycolysis. Glutamic-oxaloacetic transaminase is denoted here as cytosolic/mitochondrial aspartate aminotransferase, mAs-
pAT. α-KG, α-ketoglutarate; MDH2, malate dehydrogenase; GAA, glutamate-aspartate antiporter; MKA, malate-α-ketoglutarate
antiporter; cAspAT, cytosolic/mitochondrial aspartate aminotransferase. Reproduced from Menzies et al.259
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4.5 Contributions
The full list of contributors to the work presented in this chapter is as follows:
Raymond R. Noordam, Christian Couture, Paolo Piaggi, Toshiko Tanaka, Bamidele Tayo, Ruifang
Li-Gao, Jennifer Schrack, Richard Cooper, Amy Luke, Claude Bouchard, Louis Pérusse, Clifton Bog-
ardus, Leslie Baier, Dennis O. Mook-Kanamori, Luca A. Lotta, Isobel Stewart, Kate Westgate, Robert
A. Scott, Søren Brage, Nicholas J. Wareham.
D.J.W.: Conceived project, prepared overall consortium analysis plan, and performed main analyses.
Constructed and applied systematic processing and quality control pipeline for raw respiratory exchange
parameters to obtain analytic REE phenotype, according to best practice. Co-ordinated de novo formation
of the REE-Gen consortium from international collaborators in 2015 and maintained engagement and
compliance of collaborators to the analysis plan and its deliverables over the course of the PhD. Prepared
the manuscript.
Provision of discovery GWAS summary statistics from additional discovery cohorts: R.R.N, D.O,M-K.
(NEO Cohort); C.C., C.B., L.P. (QFS Cohort); T.T., J.S. (BLSA Cohort); P.P., C.B., L.B. (Pima Cohort); B.T.,
A.L., R.C. (ICSHIB Cohort). Metabolite GWAS data and look-up in EPIC-Norfolk data: L.A.L., I.S. Indirect
calorimetry measurements and technical assistance with REE derivation: S.B., K.W. Guidance, support








N inety-seven genetic loci have been identified for body mass index (BMI), yet the mechanisms un-derpinning genetic risk for obesity are poorly characterised. Whilst some variants are thought to
play a role in behavioural determinants of energy intake, consideration of the mediating role of energy ex-
penditure has been incomplete. This is particularly true in the case of resting energy expenditure (REE),
which represents the majority of daily energy expenditure and is typically considered non-modifiable for
an individual of given body size and composition. Common BMI variants in FTO and MC4R have been
reported to exert some of their effect on body weight via REE both in model organisms and small hu-
man studies, yet these findings lack replication. To inform the mechanistic basis of genetic obesity risk,
this chapter details the first systematic assessment of the association of all BMI-increasing variants with
REE in a large population-based cohort, and assesses the potential of REE as a mediating factor of 95
known biallelic risk loci for obesity, both in combination, and on a variant-by-variant basis. Obesity is in-
terpreted with a particular focus on adiposity, using DXA-derived body fat percentage (BFP). One variant
near MTCH2 associated with higher adiposity as gauged by BMI and BFP was associated with lower daily
REE after accounting for body size (β = -73.72 kJ/24hr per BMI-increasing allele, p=4.65×10-4). We did
not replicate previously-published associations of common BMI-associated variation near FTO and MC4R
with REE.
BMI-increasing genetic variation near MTCH2 (mitochondrial homolog carrier 2) appears to influence BFP
partially via lower genetically-determined REE. Our results do not support previous work suggesting that




Large-scale genetic discovery has identified many common single nucleotide polymorphisms (SNPs) as-
sociated with BMI, with 97 independent loci reaching genome-wide significance in the most recent Eu-
ropean meta-analysis totalling more than 500,000 individuals249. This literature has provided valuable
insight into the underlying genetic aetiology of body composition and obesity, and allowed shared genetic
architecture with other relevant traits to be interrogated. Yet, the biological mechanisms by which BMI-
associated variants predispose to obesity - and specifically whether they act through modulation of energy
intake or energy expenditure - remain poorly understood.
Current population-based work has largely assessed the role of BMI-associated genes in energy intake,
on the hypothesis that - in the context of a ubiquitous obesogenic environment - genetic risk for obesity op-
erates through central regulation of eating behaviour269. In support of this, when modelled as a combined
genetic risk score, the additive effect of BMI-increasing variants is associated with higher emotional and
uncontrolled eating in US adults270. FTO has been associated with diminished satiety responsiveness
in children271, binge-eating in adolescence272, and poorer cognitive restraint270 and disinhibition273 in
adults. MC4R is associated with uncontrolled eating274 and shows sex-specific effects on emotional eat-
ing in adults275. Examination of the mediating role of energy expenditure (both REE and physical activity
energy expenditure, PAEE) in genetic BMI risk has similarly been restricted mainly to FTO variants276. As
the predominant component of total daily energy expenditure56 (and largely considered fixed for an individ-
ual of given body size and composition) REE has long been recognised as a possible risk factor for weight
gain, though observational studies have often been confounded or subject to reverse causation95,277,278.
Recently, in detailed work using rodent models and human cell lines, Claussnitzer and colleagues have
reinvigorated discussion that REE may be a mechanistic factor in FTO-associated BMI risk by suggesting
that FTO influences adipocyte differentiation and browning, and upregulates cellular thermogenesis241.
This finding is, however, at odds with previous - albeit small - population-based samples which report no
association between FTO and REE after accounting for the confounding effect of body size276. Reduction
of REE (normalised to body weight) has also been implicated as a potential route by which variation near
MC4R (melanocortin 4 receptor) may predispose to higher BMI in the Pima People of Arizona103.
Whilst these candidate genes have received considerable attention, their reported effect on REE is incon-
sistent between evidence from animal models, cells lines and human cohorts, remains to be replicated in
large population-based samples, and must be interpreted in the context of the wider genetic component
of obesity risk. The extent to which known BMI-associated variants aside from FTO and MC4R influence
energy balance through REE in human populations is unknown. To characterise whether genetic pre-
disposition to obesity operates through REE, we systematically examined, for the first time, whether the
effect of all known BMI-increasing variants on adiposity was mediated by objectively-measured REE in up
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to 7,689 middle- to older-aged British adults from the Fenland Study.
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5.2 Methods
Obtaining a measure of REE independent of body size REE was derived from respiratory param-
eters at rest as described in the previous chapter. REE is confounded by body size, and appropriate
adjustment is necessary to gain physiologically valid and comparable findings of genetic associations
with REE, but discussion of how best to normalise REE for body size has been ongoing in the literature
for many years276. Taking BMI as an aggregate measure of overall body size, we generated residuals
(REERES) by linear regression of whole-body REE (kJ/24hr) on BMI (kg/m2), adjusting for age, sex and
technical artefacts of the calorimetry measurement (calorimeter device ID, ambient test temperature). As
participants were administered a standard 75g oral glucose tolerance test (OGTT) at the outset of the
assessment visit, we additionally adjusted this regression for OGTT test status (received/not received).
Of those participants with genotyping, up to 7,689 had derived REE and complete data for all residualised
covariates, and were used in analyses.
Association of adiposity with known BMI variants Ninety-five biallelic variants associated with BMI
in the latest GIANT consortium discovery effort249 were extracted from imputed genotypes for each of the
participants with REE and complete covariate data, and expressed as the BMI-increasing allele dosage,
using the BMI-increasing allele reported by GIANT. The association of allele dosage at each variant with
(i) REE residualised only for age, sex, OGTT and technical parameters (REEAS), (ii) REERES, (iii) BMI
residualised for age and sex and (iv) DXA-derived body fat percentage residualised for age and sex,
was assessed by linear models additionally adjusted in each case for genotyping array and four topmost
genomic principal components as a indicator of underlying population structure. To consider the combined
additive effect of all 95 variants in aggregate, we additionally tested for association between each of these
phenotypes and a genetic risk score (GRS95) comprised of the BMI-increasing allele dosage summed
across all 95 variants within each participant.
Identifying variants potentially affecting adiposity through REE According to the logic of Baron and
Kenny279, for REERES to potentially act as a mediator of genetic association with body fat percentage, it
must be associated with both allele dosage at the variant, and independently with BFP. Amongst those
variants associated at nominal significance (p≤0.05) with BFP, we defined a subset of variants at which
the observed effect on adiposity was potentially mediated by REE as variants which were additionally
associated with REERES after accounting for 95 independent tests (p=5.26×10-4).
Mediation analyses of adiposity To assess the possible mediating effect of variant-BFP association
by REERES, three individual linear regressions were run within a Sobel-Goodman testing framework. The
direct effect of allele dosage on BFPAS was drawn from the set of regressions previously performed,
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and the indirect effect via REERES was gauged by regressing REERES on allele dosage, and repeating
the regression of BFPAS on dosage with additional adjustment for REERES. All models were additionally
adjusted for genotyping array and the four genomic PCs, as previously. Mediation was formally quantified
using a parametric Sobel-Goodman test, comparing the direct and indirect effect (via REERES) of the
variant on BFPAS.
Sensitivity analyses To increase the statistical power and robustness of mediation analyses, standard
errors and the indirect effect of rs3817334 on BFP via REERES were bootstrapped (1000 iterations, case
resampling) to produce normal distribution-based, percentile-based and bias-corrected 95% confidence
intervals, in line with best practice for assessing mediation.
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5.3 Results
Accounting for age and sex, whole-body REE (kJ/24hr) was associated with higher BMI (β = 2.93 kg/m2
per SD increase in REE, p<5×10-300). After removing the variance in REE attributable to BMI by resid-
ualisation (REERES), no statistical association existed between REERES and BMI (p=1.00), and REERES
was normally distributed, suggesting that the linear model applied provides a measure of REE adequately
adjusted for the important effect of body size on REE, and offers a good indication of whether an individual
has a particularly high or low REE given their size. Importantly, higher REERES was associated with lower
BFP (β=-0.58% per SD increase in REERES, p=2.53×10-11, consistent with the hypothesis that low REE
normalised for body size is an aetiological factor for higher body fat accumulation.
Of the 95 variants considered, only one associated with REE independently of age and sex after account-
ing for multiple testing (rs7138803, β=102.6 kJ/24hr per BMI-increasing allele, p=3.93×10-5, Supple-
mentary Table 26. This locus (FAIM2) was also one of the most significantly-associated with higher BMI
(p=8.08×10-5). On adjustment of REE for BMI, four variants were associated with REERES at nominal
significance (p≤0.05), including rs7138803 (β=49.93, p=0.02), and variants in or near CALCR, ERBB4
and FPGT-TNNI3K. One variant (rs3817334, MTCH2) survived Bonferroni correction and was associated
with a decrease of 73.72 kJ/24hr in REERES per BMI-increasing allele (p=4.65×10-4). All five variants
associated with REERES had consistent directions of effect between the age and sex-adjusted model, and
after additional adjustment for BMI. Of the five, only the MTCH2 and FAIM2 loci were associated with
BMI or BFP after accounting for age and sex. Aggregated dosage across all 95 variants expressed as
an additive genetic risk score was strongly associated with higher REEAS, BMI and BFP, but showed no
statistical association with REERES, highlighting the extent to which the association with higher REEAS is
likely driven by larger body size (Supplementary Table 26).
For REE to be considered a possible mediator of genetic adiposity risk (higher BFP), BMI-increasing vari-
ants must be associated with both BFP and REE. To ensure adequate power, we restricted downstream
mediation analyses to variants associated with REERES after accounting for multiple testing, and nomi-
nally associated with BFP. Only rs3817334 fulfilled this criterion (βBFP=0.24% per BMI-increasing allele,
p=0.023), and was taken forward for statistical examination as a mediator.
5.3.1 A variant near MTCH2 predisposes to adiposity via lower REE
Using Sobel’s test, we observed evidence for partial mediation of the genetic effect of rs3817334 on
BFP by REERES (pMediation=1.39×10-3). This association was independent of the underlying correlation
between body size and REE. Specifically, higher genetically-determined BFP at rs3817334 was mediated
by lower REE (βIndirect of rs3817334 on BFP via REERES = 0.033% per additional BMI-increasing allele,
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Table 5.1 | Mediation analyses of genetic risk on body fat percentage
REERES (kJ/24hr) BFP (%) BFP adj. REERES (%) Mediation
Beta SE p-value Beta SE p-value Beta SE p-value pSobel Beta SE
rs3817334
-73.72 21.05 4.65E-04 0.24 0.11 0.023 0.207 0.105 0.049 1.39E-03 0.033 0.010
REERES is REE residualised for age, sex, BMI (kg/m2), ambient temperature during calorimetry, calorimeter device ID, and
OGTT test status (Y/N). Betas are effect per BMI-increasing allele as defined from GIANT Consortium meta-analyses, in the
units indicated. In mediation analyses, Beta and SE refer to the indirect additive effect per BMI-increasing allele on BFP via
REERES.
95% CI 0.013, 0.053%), corresponding to approximately 13.7% of the genetic predisposition to higher
BFP at rs3817334 being transmitted through REERES.
5.3.2 Sensitivity Analyses
In sensitivity analyses, we sought to improve power in our mediation analyses by bootstrapping to gener-
ate non-parametric standard errors and 95% CIs of the indirect effect of rs3817334 on BFP via REERES.
Bias-corrected and percentile-based 95% CIs were not materially different from normal-based CIs, and
did not alter interpretation.
5.3.3 Functional profiling of the MTCH2 locus
To examine the effect of rs3817334 on gene expression, we performed a look-up of the variant in the
GTEx resource, which has systematically identified expression quantitative trait loci (eQTLs) for genes in
a range of human tissues. The BMI-increasing allele (T) at rs3817334 was associated with higher MTCH2
transcript levels in skeletal muscle. Using data from the Exome Aggregation Consortium (ExAC)280, we
additionally identified a common missense variant in MTCH2 (rs1064608)) which is in strong LD with
rs3817334. (r2=0.80 in 1000G Phase 3 CEU reference panel).
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5.4 Discussion
Our study is the first to systematically assess the role of REE as an aetiological factor across all estab-
lished genetic risk loci for obesity. We report that genetic risk for increased adiposity at rs3817334 - an
intronic variant in MTCH2 - is mediated in part by lower residual REE after accounting for the known
correlations between REE and body size.
MTCH2 encodes mitochondrial carrier homolog 2, a transport protein localised to the outer mitochondrial
membrane with an established role in apoptotic signalling281, and a repressor of oxidative phosphorylation
in haematopoietic stem cells282. MTCH2 knockout in mouse skeletal muscle protects against diet-induced
obesity through increased energy expenditure mediated by upregulation of oxidative phosphorylation and
increased mitochondrial mass, and also promotes resistance to hyperinsulinemia283. Correspondingly,
overexpression in rodents is correlated with diet-induced hyperglycaemia and lipid accumulation284. In
humans, the BMI-increasing allele (T) of rs3817334 is correlated with higher expression of MTCH2 in
skeletal muscle (pGTEx=1.05×10-5)165, providing directional consistency of MTCH2 transcript levels and
observed effect on adiposity and REE between functional models and our large population-based human
sample. Further, rs3817334 is in strong linkage disequibilibrium (r2 = 0.81 in Europeans) with a known
missense variant (rs1064608) in MTCH2, which is again an established eQTL for MTCH2
The common BMI signal in FTO (rs1558902 from Locke et al249) has recently been reported to influ-
ence adipocyte differentiation and regulate adipocyte browning and thermogenesis in animal models and
human cell lines241. The lack of association between this locus and REE in our data (REERES β=-2.14
kJ/24hr per BMI-increasing allele, p=0.92) provides a clear indication that these observations are not
translated to a meaningful correlation with REE at population level once REE has been normalised to
body size. In agreement with previous population-based work in smaller cohorts276, our findings do not
support the hypothesis that FTO influences adiposity via REE, after appropriate adjustment for body size.
Rather, given the body of evidence which supports a role for FTO variation in regulation of appetitive traits,
it would seem that the locus near FTO primarily confers risk for obesity through an increased behavioural
propensity for higher energy intake.
Equally, our observations for the BMI locus including MC4R (lead SNP rs6567160, REERES p=0.71) are
not consistent with the energy balance phenotype of MC4R characterised by loss-of-function variants in
Pima Indians in whom loss of MC4R predisposes to obesity through lower REE103. Discussion continues
over whether MC4R functional variants influence BMI through energy expenditure or hypothalamic control
of energy intake285: our findings for the common non-coding BMI-associated locus near MC4R contribute
to this debate.
Only a subset of the known BMI variants associate at statistical significance with BMI in our sample;
we are, therefore, likely underpowered to detect underlying associations with REE for some variants.
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For variants of large effect (including FTO and MC4R), which are associated with BMI in this sample,
it is reasonable to assume that we retain adequate power, and our results are informative, however.
Nonetheless, this sample represents the largest cohort with objectively assessed REE currently presented
in literature. To facilitate replication of our findings and increase power to investigate the aetiological role
of REE in genetic risk for obesity, additional work in other cohorts with REE measurements and pooled
analyses incorporating all available data will be required.
It should be noted that the association between REE and body size is complex and bidirectional: whilst
it is hypothesised that lower REE drives increased fat deposition through the creation of an energy sur-
feit, larger body size may conversely increase REE, possibly even masking an underlying aetiological
mechanism linking lower REE to adipose accumulation. The optimal approach to modelling REE inde-
pendent of body size remains a topic of debate in the literature276, but the lack of association between
REERES and BMI in our analyses provides some confidence that our approach provides a measure of
REE independent of body size, which indicates whether an individual has a high or low REE for their
size. The bidirectional relationship between REE and body size also makes mediation analyses partic-
ularly challenging, as formal assessment of mediation requires there to be an association between the
hypothesised mediating phenotype and the outcome phenotype of interest. In a model in which REE is
adjusted for BMI, therefore, it is impossible to consider REE as a mediator for genetic risk for higher BMI
directly. Instead, in this chapter, I have applied DXA-derived body fat percentage to allow the mediating
effect of REE normalised to body size in genetic predisposition to increased adiposity to be examined.
BMI variants drive body size substantially through adiposity286, and the two phenotypes are correlated.
Given that a reduction in REE resulting in energy surfeit is hypothesised to induce weight gain through
increased fat deposition, considering BFP as an outcome is arguably superior to an aggregated measure
such as BMI. Our results should, however, be interpreted with care and in the context of further work due
to the risk of collinearity and other statistical artefacts. In addition, the extent of mediated effect described
here (13% of genetic risk for adiposity at one SNP) is small, and, whilst informative, must be judged
cautiously pending independent replication and expanded analyses. This work demonstrates for the first
time in a large human population-based sample that known genetic risk for adiposity (modelled as BFP)
may operate partly through decreased REE, and informs current debate on the mechanistic role of BMI
risk loci in energy balance. We additionally demonstrate in the largest sample of objectively-measured
REE to date that the previously-suggested mechanistic basis by which MC4R and FTO influence obe-
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T he Y chromosome is frequently lost in haematopoietic cells, representing the single most commonsomatic aneuploidy amongst men, and is increasingly recognised as a biological marker of age-
ing. Recent reports suggest that mosaic loss of chromosome Y (mLOY) is a risk factor for malignancies
and cardiometabolic dysfunction, yet the mechanisms that regulate mLOY, and its clinical relevance, are
unknown. In this chapter, Y chromosome intensity data, as well as sequence reads from 85,542 men
were applied to identify 19 genomic regions (p≤5×10-8) associated with mLOY. Cumulatively, these loci
predicted X chromosome loss in women (n = 96,123; p=4.0×10-6). Additional epigenome-wide methyla-
tion analyses using whole blood highlighted 36 differentially-methylated sites associated with mLOY. The
genes identified converge on aspects of cell proliferation and cell cycle regulation, including DNA synthe-
sis (NPAT ), DNA damage response (ATM), mitosis (PMF1, CENPN and MAD1L1) and apoptosis (TP53).
We highlight the shared genetic architecture between mLOY and cancer susceptibility, in addition to in-
ferring a causal effect of smoking on mLOY. Collectively, our results demonstrate that intensity data from
commercial genotyping arrays in extensive use enables a measure of cell cycle efficiency at population
scale, offers a novel indicator of biological ageing, and identifies genes implicated in aneuploidy, genome
instability and cancer susceptibility. This chapter contains work completed in collaboration with a number




Post-zygotic errors in cell division that result in too few or too many chromosomes in somatic daughter
cells have been described for over a century: a cytogenetic feature known as aneuploidy. Although a
well-established feature of human cancer cells287,288, it remains unclear whether aneuploidy is a cause
or consequence of tumorigenesis287–291. Research into the molecular mechanisms of aneuploidy has
focused largely on the role of mitosis and mitotic checkpoint signaling, primarily in cellular and animal
models287,292. Recent human genomic studies have shown that aneuploidy can be estimated using chro-
mosome intensity data derived from standard genotyping arrays; an approach that has been validated
by DNA sequencing131,132,293. These population-based studies have demonstrated that mLOY is more
frequent than other mosaic chromosomal and structural alterations, exceeding the frequency of X chro-
mosome mosaicism, the next most-common aneuploid event, by an order of magnitude. Detectable Y
mosaicism in blood correlates with chronological age comparably to mean leukocyte telomere length
(LTL)294, with prevalence reaching 20% amongst men aged >80 years131. Such prevalence clearly re-
flects the capacity of some somatic cells to survive without the Y chromosome, and highlights mLOY as a
potential model system of severe yet well-tolerated aneuploidy in blood, and a novel biological marker for
ageing.
Although mLOY is a common feature in the general population, whether it is relevant to disease suscep-
tibility, or whether cells in tissues other than peripheral blood undergo similar rates of chromosomal loss,
remains unclear. Population studies have identified correlations between mLOY and smoking status, an
association that seems to be transient and reversible after smoking cessation135. Such epidemiological
studies have also identified associations with non-haematological cancers131,293, Alzheimer’s disease127
and type 2 diabetes134; however, these observations are inconsistent132 and possibly subject to confound-
ing or reverse-causality.
The ability to assay a common measure of aneuploidy in large array-genotyped populations could facili-
tate the systematic identification of variants and genes involved in cell division errors. This would, in turn,
enable a better understanding of the mechanisms involved and of the potential causal consequences of
aneuploidy on cancer risk and other morbidities, which may subsequently be inferred using Mendelian ran-
domisation approaches. To date, a single genetic association with mLOY near TCL1A has been reported
(n = 12,369), suggesting that germline variation influencing mosaic chromosome loss can be detected132.
Here, we used data from up to 85,542 men in UK Biobank and two further European cohorts to high-
light widespread genomic, transcriptomic and epigenetic signatures of mosaic Y chromosome loss, and
demonstrate that this approach concordantly identifies genes implicated in cell cycle regulation, genome
instability and cancer susceptibility.
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6.2 Methods
Estimation of Y chromosome mosaicism mLOY was estimated in the May 2015 genotyping release
of UKB by calculating the normalised average signal intensity of all SNPs on the male-specific region
of the Y chromosome (MSY)295. Signal intensity, genotype call and confidence files from genotyping
(Affymetrix Power Tools) were analysed using the PennCNV-Affy pipeline296 to generate a log-R ratio
(LRR) for each SNP. SNPs without LRR calculable on both arrays, or those flagged by UKB as QC failures,
were excluded. Fluorescence signal of the whole Y chromosome was summarised as the mean LRR
across all Y chromosome SNPs (mLRR-Y). After omission of monomorphic variants and of genotyping
and QC failures, 253 SNPs were available across all participants for the calculation of mLRR-Y.
Genetic discovery and signal selection Autosomal SNPs were analysed for linear association with
the derived mLRR-Y phenotype by linear mixed models implemented in BOLT-LMM, adjusting for age
and an indicator of genotyping array as covariates. This method has particular advantages regarding
robustness to cryptic relatedness and population structure, as previously discussed. Analyses were re-
stricted to white Europeans as defined using a K-means clustering approach applied to the first four
genomic principal components, and ratified by self-reported ancestry. A maximum of 67,034 men with
intersecting genotyping and mLRR-Y were available for analysis. SNPs with imputation quality <0.4 or
MAF <0.1% were excluded after analysis. Independent loci were defined on the basis of proximity using
a 1Mb window centred on the index. Fifteen independent loci were omitted from further consideration in
downstream analyses due to concerns of technical artefact. Each of these 15 loci fulfilled at least two of
the following criteria: (i) singletons in regional association plots, (ii) statistically significant association with
genotype array status, and/or (iii) association with mLRR-Y in female samples, suggesting that the associ-
ation observed in men was primarily with technical background intensity, as opposed to true physiological
variation.
Signal follow-up & replication Replication was performed in two large independent populations us-
ing techniques complimentary to the discovery effort. The first comprised 9,793 men drawn from the
EPIC-Norfolk subcohort, in whom mLRR-Y was derived from array intensity data as detailed above for
UKB. Secondly, genome sequences from 8,715 Icelandic men in the deCODE study297 (age range 41-
105 years, mean 63 years) who had provided whole blood for sequencing (Illumina) to a mean depth of
37× were analysed. In the deCODE sample, the average read depth over chromosome Y (restricted to
X-degenerate regions295) was interpreted as an estimate of Y copy number. Read depth was calculated
by our Icelandic colleagues in SAMtools298 using PLINK .bam-files aligned to hg38 and normalised rela-
tive to genome-wide sequencing coverage within each participant. Twelve individuals with copy number
estimates >1.25 for chromosome Y were excluded. Y chromosome copy number was strongly negatively
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correlated with age at blood draw (Spearman’s ρ=0.50). For individuals older than 60 years at the time of
sample collection, the distribution of chromosome Y copy-number had a heavy negative skew, with copy
numbers as low as 0.08.
Genome-wide association adjusted for chronological age at blood draw was run in BOLT-LMM for both
replication samples. deCODE copy number estimates were inverse normalised prior to analysis, and
effect sizes for log2(Y copy number) were estimated via robust linear regression (rlm funtion from MASS R
package299) to enable comparison with effect estimates obtained from array intensity-derived mLRR-Y in
UKB and EPIC-Norfolk. The fraction of variation explained by a given variant was calculated as 2fa2(1−
f) where f denotes the minor allele frequency of the variant,and a is the additive effect expressed in
standard deviations. An upper limit of heritability for Y mosaicism was estimated in deCODE as the
Spearman rank correlation of derived Y copy number (as opposed to mLRR-Y) between sibling pairs
(n=1,488), an approach commonly applied in this cohort300–302.
Determinants of X chromosome loss Female X chromosome mosaicism was estimated by an equiv-
alent protocol to mLOY, using array intensity data in UKB (n=75,595) and EPIC-Norfolk (n=11,248), in
addition to sequence reads in 9,302 deCODE women with a mean sequencing depth of 36×. As for Y,
X chromosome copy number was estimated from average read depth over the X chromosome, excluding
the pseudoautosomal regions PAR1 and PAR2, the X-transposed region295, and the centromere. This es-
timate was normalised against the participant’s sequencing coverage across the genome and adjusted for
sequencing protocol. Twenty-two outliers with non-physiological copy numbers (X copy number >2.5, or
<1.5) were excluded. X Copy number was negatively correlated with age at blood sampling (Spearman’s
ρ = -0.28).
Methylation analyses DNA methylation in whole blood was measured in EPIC-Norfolk (n=1,378) us-
ing the Human Methylation 450k BeadChip (Illumina), a widely-applied array covering 96% of human
genes with multiple probes, and 99% of characterised CpG islands across the genome, to facilitate high-
throughput hypothesis-free analysis of the human methylome303. After setting methylation markers with
detection p-value ≥ 0.01 to missing, methylation beta values were calculated for each marker. Quantile
normalisation of methylation betas was applied separately to different marker groups based on colour
channel, probe type and M/U subtypes304. Samples with a sample call rate ≤0.99 were removed (n=77).
Methylation beta value distributions of the X, Y and autosomal chromosome markers were analysed sep-
arately and a further 11 sample outliers were excluded. Within each sample, markers with a marker call
rate ≤0.95 were excluded (n=4,423).
All downstream analyses were restricted to autosomal methylation markers. Signal detection of methy-
lation intensities can be affected by several factors, including SNPs on the probe, repetitive DNA, and
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cross-reactive probes. We thus calculated the proportion of missing data at each CpG site (marker call
rate); 8,775 CpGs with a call rate ≤0.95 were excluded. 3,295 CpGs with multimodal distributions of
methylation intensities, identified by the R package ENmix305, which typically arise from technical arte-
facts were also excluded. A further 18,874 CpG sites which were previously identified as mapping to more
than 1 genomic location306 were also excluded. The final cleaned dataset comprised 442,920 autosomal
CpG sites. To account for cell composition variability, we estimated counts of T lymphocyte subtypes,
natural killer cells, monocytes, granulocytes and B lymphocytes using the minfi R package307,308. These
were included as covariates in subsequent epigenome-wide regression models.
To examine the association between methylation markers and mLOY, we performed an epigenome-wide
association analysis in all male EPIC-Norfolk methylation samples (n=569). mLRR-Y was regressed
separately on each methylation marker, adjusted for type 2 diabetes status, age, current smoking status,
estimated cell counts, and sample plate. Bonferroni correction was applied, accounting for the number of
markers tested (p=1×10-7). Furthermore, we checked that no significant CpG sites had sequences which
also mapped to the Y chromosome.
Association statistics for genetic variants within the probe vicinity and corresponding methylation levels
(i.e cis-meQTLs) were available from the BIOS QTL browser (http://www.genenetwork.nl/biosqtlbrowser/)
Genetic susceptibility to all-cause cancer To understand the shared genetic architecture of mLOY
and cancer, an ’any prevalent cancer’ variable was defined in UKB using linked NHS cancer registrations.
The UK’s system of mandatory cancer registration provides not only complete and systematic ascertain-
ment of cases, but also a rigorous case definition, minimising potential for ascertainment biases. Cases
were defined as individuals with a recorded date of diagnosis and corresponding diagnostic codes; con-
trols as individuals with neither a cancer registration nor self-reported cancerous condition. Participants
with inconsistent diagnostic details (e.g. a recorded diagnostic code, but no corresponding age at diagno-
sis) were set to missing to avoid heterogeneity of definition. GWAS analysis was performed in BOLT-LMM,
including age, sex, and genotyping array as covariates.
Bidirectional associations with ageing, cancer and cardiometabolic risk Genetic correlations (rg)
between mLRR-Y and summary statistics for (i) cancer risk defined from UKB, (ii) hand grip strength,
parental longevity and multi-site BMD as indicators of functional and biological ageing, and (iii) type II
diabetes status, CHD risk, basic anthropometric traits and continuous intermediate glycaemic phenotypes
as markers of cardiometabolic dysfunction, were calculated by LD-score regression. Hand grip strength
analyses leveraged the summary statistics generated in Chapter 3. Summary statistics for other traits
were obtained from the latest publicly-available European consortium meta-analyses, prioritising sample
size over latest date of publication where multiple efforts existed. References for each phenotype are
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detailed in the main text, Table 6.2
To assess the possible causal links between mLOY and cancer, and establish directionality in the po-
tentially confounded associations with cardiometabolic conditions, two-sample summary statistic MR was
applied using the 15 biallelic replicated mLOY signals as an additive (per-allele) instrument to model
mLRR-Y as a causal exposure. Due to the complexities of applying insertion-deletion variants in MR
either directly or via an assigned proxy, these variants were omitted. In bidirectional analyses, fasting
insulin (17 variants)309, fasting glucose (29 variants)309, HbA1c (11 variants)310, BMI (96 variants)249 and
type 2 diabetes case-control status (49 variants)311 were modelled as causal exposures for mLOY us-
ing previously reported biallelic risk loci at p≤5×10-8. Due to the considerable heterogeneity of cancer
pathologies and the relative lack of genome-wide summary statistics for site and tissue-specific cancers,
bidirectional cancer analyses were restricted to considering prostate cancer as a causal exposure, based
on 90 published susceptibility loci312,313. Main IVW models, as well as sensitivity estimators robust to
heterogeneity, partial invalidation of instrumental variable assumptions, and directional pleiotropy, were
run as previously detailed (Chapter 2.
Further analyses for biological insight Replicated loci were looked up in HaploReg for eQTL associa-
tions and other functional annotations, and imputed expression analyses leveraging genetically-predicted
gene expression were run in whole blood and multiple GTEx tissues using the three methods - SMR,
MetaXcan and TWAS - previously described. Hypothesis-free GSEA was implemented in MAGENTA
using the canonical pathways and GO Terms downloaded from mSigDB. Study-wise significance was de-
termined when an individual pathway reached a false discovery rate (FDR) <0.05 in either MAGENTA’s
95% or 75% significance threshold (see Chapter 2. In total, 3216 pathways from Gene Ontology, PAN-
THER, KEGG and Ingenuity were tested for enrichment of multiple modest associations with mLRR-Y.
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Table 6.1 | Nineteen mLOY loci reaching genome-wide significance in combined analyses
UK Biobank EPIC-Norfolk deCODE
n=67,034 n=9,793 n=8,715
rsID Chr. EA AA EAF Effect A p Effect A p Effect B p pCombined Gene
rs17758695 18 C T 0.97 -0.010 6.4E-21 -0.014 3.7E-04 -0.020 9.1E-13 1.3E-33 BCL2
rs1122138 14 C A 0.84 -0.005 3.6E-23 -0.006 4.3E-04 -0.007 1.5E-04 6.3E-31 TCL1A
rs78378222 17 G T 0.01 -0.013 1.3E-15 -0.032 1.8E-06 -0.026 3.8E-10 3.4E-28 TP53
rs59633341 3 D I 0.16 -0.004 2.6E-18 -0.009 7.5E-07 -0.007 1.1E-05 4.1E-28 TSC22D2
rs2736609 1 T C 0.36 -0.003 1.9E-12 -0.003 4.9E-02 -0.006 2.5E-07 2.0E-19 PMF1
SEMA4A
rs13191948 6 C T 0.54 -0.002 1.2E-11 -0.006 5.4E-06 -0.005 3.8E-05 2.2E-19 SMPD2
CCDC162P
rs60084722 20 I D 0.79 -0.003 6.6E-13 -0.002 2.5E-01 -0.006 9.4E-05 1.6E-17 TPX2
BCL2L1
HM13
rs381500 6 C A 0.55 -0.002 5.7E-11 -0.002 1.9E-01 -0.005 1.1E-07 5.0E-16 QKI
rs56084922 5 G A 0.08 -0.005 2.9E-13 -0.004 1.2E-01 -0.005 1.6E-03 3.0E-15 NREP
rs137952017 14 D I 0.85 -0.003 1.2E-09 -0.010 1.3E-07 -0.004 4.0E-04 4.0E-15 DLK1
rs4721217 7 T C 0.4 -0.002 6.5E-10 -0.005 2.8E-04 -0.003 1.1E-05 3.5E-14 MAD1L1
rs35091702 8 D I 0.74 -0.002 4.2E-10 -0.004 6.0E-03 -0.002 3.9E-02 9.5E-12 RBPMS
rs4754301 11 A G 0.55 -0.002 1.3E-09 -0.001 5.4E-01 -0.002 2.8E-02 6.5E-11 NPAT
ATM
ACAT1
rs12448368 16 C T 0.13 -0.003 9.8E-10 -0.002 2.5E-01 -0.003 2.4E-02 7.1E-11 CENPN
ATMIN
rs11082396 18 C T 0.13 -0.003 3.3E-09 -0.004 6.7E-02 -0.003 1.2E-01 1.2E-10 SETBP1
rs13088318 3 G A 0.34 -0.002 4.1E-09 0.000 7.7E-01 -0.003 1.7E-02 2.7E-10 SENP7
rs77522818 17 A T 0.96 -0.005 1.3E-09 -0.004 3.0E-01 -0.002 2.4E-01 8.8E-10 FAM117A
rs10687116 13 I D 0.8 -0.002 2.6E-08 -0.001 5.8E-01 -0.003 5.8E-02 8.8E-10 WBP4
rs115854006 3 C T 0.96 -0.006 3.7E-08 -0.007 5.4E-02 0.002 9.3E-01 4.5E-08 TREX1
PLXNB1
A Change in mLRR-Y per additional effect allele; B Change in copy number-transformed log2(Y copy number) per additional
effect allele. Results are ordered by combined p-value, which reflects meta-analysis of associations across all studies. Insertion-
deletion variant alleles are denoted I/D. Unless otherwise specified, gene shown is nearest gene to the index variant, or a
candidate gene falling within the locus. Red highlight, index or one of its proxies (r2≤0.8) is a non-synonymous coding variant in
the gene. Blue highlight, expression of gene is mediated by mLRR-Y associated SNPs. EA, effect allele; AA, alternative allele,
EAF, effect allele frequency
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6.3 Results
As a proxy for mLOY, mean intensity log-R ratio of all array-genotyped Y-chromosome SNPs (mLRR-Y)
was estimated in a sample of 67,034 male participants from the interim genotyping release of UKB138.
Further details of this derivation can be found in Methods. A normal distribution centred around zero was
observed (standard deviation = 0.067), with negative values indicating reduced Y chromosome abundance
in the clonal blood cell population (Supplementary Figure 11).
Consistent with previous reports132,135,294, a strong negative correlation was observed between mLRR-Y
and age (r=-0.21). ’Ever smoking’ status (defined as self-reported current or former tobacco smoking) was
also observationally associated with lower mLRR-Y (i.e. higher mLOY; p=3.05×10-82), and in combination
with age explained 4.74% of the trait variance (age alone = 4.45%). To demonstrate the causal relationship
between smoking and mLOY, we applied the principles of Mendelian randomisation, using an established
and widely-utilised genetic instrument for smoking frequency314. By modelling genetic variants robustly
associated with smoking volume (cigarettes per day) at the CHRNA5-CHRNA3-CHRNB4 locus, which
encodes various subunits of the major cholinergic nicotine receptor, we inferred a causal effect of smoking
on decreased mLRR-Y in UKB (rs1051730 p=0.03; pnever-smokers=0.41; pever-smokers=0.04). This genetic
association was confirmed in independent replication samples (EPIC Norfolk plus deCODE; combined
n=18,508, replication p=0.009, discovery plus replication overall p=0.004).
6.3.1 Many autosomal variants are associated with mLOY
To identify novel genetic variants associated with mLOY, we performed a genome-wide association study
of mLRR-Y as a quantitative trait in UKB. After stringent quality control (see Methods), the most significantly-
associated SNPs were located at the previously reported132 mLOY locus, TCL1A (p=3.6×10-23). We
additionally identified a further 18 novel signals at genome-wide significance (p≤5×10-8), with no evi-
dence for significant inflation of test statistics genome-wide (λGC=1.05, Supplementary Figures 12 and
13). Replication was subsequently performed in an independent set of 9,793 men with array intensity
data, in addition to 8,715 men from deCODE with Y loss estimated using sequence read abundance (see
Methods). Both replication datasets provided strong statistical support for the identified loci, with all 19
loci retaining genome-wide significance in a combined model (Table 6.1). As evaluated in the deCODE
data, these loci cumulatively explained 2.7% of total variance in Y chromosome copy number. Overall her-
itability was estimated at 34% (95% CI 25.2%, 42.4%), suggesting many additional associated variants of
modest or small effect remain to be discovered.
HaploReg247 and sequence data from the deCODE cohort were next applied to functionally annotate iden-
tified variants and genes. Four genes containing missense variants in strong linkage with the index signal
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were highlighted, implicating MAD1L1 (rs1801368, r2>0.98), PMF1 (rs1052053, r2=1), NREP (rs11559,
r2=0.74) and NPAT (rs2070661, r2=0.97) as potential functional candidates.
Genome-wide pathway analyses conducted on association results for continuous mLRR-Y highlighted
five pre-defined biological pathways enriched for association (FDR<0.05), the most significant of which
was ’Apoptosis’, defined per the Kyoto Encyclopaedia of Genes and Genomes (KEGG). Other significant
pathways (all defined from KEGG) included susceptibility to colorectal, prostate and thyroid cancers, and
progesterone-mediated oocyte maturation.
6.3.2 Identified variants determine Y loss rather than gain
To ascertain whether mLRR-Y signals more likely reflect gain or loss of Y chromosome material, two
analyses were run, comparing the bottom and top 5% of mLRR-Y ranked individuals to the median 25%
(i.e. those falling between the 37.5th and 62.5th percentiles), as a dichotomous indicator of extreme Y-
chromosome loss or gain, respectively. All nineteen loci exhibited consistently stronger associations with
the odds of falling within the bottom 5% of mLRR-Y (i.e. greatest degree of mLOY) than the top 5%
(Supplementary Table 27), suggesting that their effect is predominantly on mosaic Y chromosome loss.
Analysis of mLRR-Y as a continuous trait across all individuals, however, remained the most powerful
approach for variant discovery, as only two of the signals reached genome-wide significance in the di-
chotomised analysis (Supplementary Table 27).
6.3.3 mLOY variants influence X chromosome loss in women
To establish whether mlRR-Y signals acted only on the Y chromosome in a male-specific manner, or
more generally promoted aneuploidy across chromosomes and the sexes, we considered the combined
effect of the mLOY variants on mosaic loss of X chromosome (the next most common aneuploidy at
population-level) in women. Using a combined sample of 96,123 women from the three study cohorts,
and an equivalent approach to that used to ascertain mLOY, we quantified X chromosome loss both via
array intensity data modelled as mean log-R ratio of X (mLRR-X; n=86,843 from UKB and EPIC-Norfolk),
and sequence reads in deCODE (n=9,280, Figure 6.1). Heritability of X chromosome copy number was
estimated at 26% (95% CI 17.4%, 36.2%) in deCODE; comparable to that of mLOY. Cumulatively, the 19
mLOY variants (aligned to mLRR-Y increasing allele dosage) significantly predicted mLRR-X in women





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 6.1: Estimated X and Y chromosome abundance with age in the Icelandic deCODE cohort. (A) Average Y chromosome
copy number in 8,703 males. (B) Average X chromosome copy number in 9,280 females. In each case, copy number is
estimated from whole genome sequencing in whole blood. Black line indicates line of best fit with age at blood collection as a
linear predictor.
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Figure 6.2: Cumulative effect of the 19 mLOY variants on X chromosome loss (higher mLRR-X) in women. 19 variants are
modelled as an additive genetic score, aligned to mLRR-Y increasing (mLOY-decreasing) allele dosage
6.3.4 Transcriptomic and epigenetic signatures of mLOY
To identify potential functional transcripts mediating Y chromosome loss, summary statistic approaches to
infer gene expression associations were applied, using three analytical imputation approaches168,169,315,
each based on independent whole-blood expression datasets (see Methods). Across these datasets,
transcript abundance of eight genes (HM13, SMPD2, TCL1A, SENP7, NPAT, ATM, ACAT1, CENPN)
was significantly associated with mLRR-Y after conservative Bonferroni correction. All expression signals
identified in this way mapped near to one of the 19 associated genetic signals from GWAS (Table 6.1).
Using directly-assessed methylation data in 569 whole blood samples from EPIC-Norfolk, 36 differentially-
methylated CpG positions (DMPs) correlated with mLRR-Y were additionally identified (Supplementary
Table 28). Of note, all significant DMPs were in genomic regions distinct (>500kb distant) from the 19
original genetic loci, with the single exception of four correlated methylation probes within the TP53 gene
region. To investigate whether the observed DMPs represented causal drivers of mLOY, cis-methylation
quantitative trait loci (meQTLs) were identified for all associated probes in publicly-available data316. In
total, 20 probes had one or more genetic variants in cis which were associated with methylation levels of
the corresponding site (Supplementary Table 29). None of these genetic variants were correlated with the
19 genomic loci; however, one cis-meQTL survived multiple test correction for association with mLRR-Y
(rs7208523; CpG position cg20116579; meQTL p=5.6×10-31, mLRR-Y p=9×10-4). rs7208523 is 280kB
from the GWAS index variant identified at the TP53 locus (rs78378222), but is in total linkage equilibrium
with this variant in 1000G Europeans (r2=0.0021). This finding suggests that genetic variation at the TNK1
locus, a gene with known involvement in tumor growth and survival317, may be associated with increased
mLOY via an epigenetic mechanism.
6.3.5 Genetic overlap with cancer susceptibility
Three mLOY signals are correlated with signals previously reported for basal cell carcinoma318, glioma319,
neuroblastoma320 (TP53), or testicular cancer321,322 (SEMA4A/PMF1 and MAD1L1). In each case, the
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Table 6.2 | Genetic correlations of mLRR-Y with selected ageing, cardiometabolic and anthropometric traits
Trait Author Ref rg SE Z -score p-value
Fasting Insulin Manning, 2012 309 0.3396 0.0949 3.5791 0.0003
BMD (Femoral Neck) Zheng, 2015 205 -0.1649 0.0739 -2.2302 0.0257
Paternal Lifespan Pilling, 2016 324 0.2555 0.1219 2.0963 0.0361
BMI Locke, 2015 249 0.045 0.0397 1.142 0.2534
Body Fat Lu, 2016 252 0.0776 0.0695 1.1157 0.2646
Fasting Pro-insulin Dupuis, 2010 325 0.151 0.1482 1.0187 0.3083
Waist Circumference Shungin, 2015 251 0.052 0.0519 1.0011 0.3168
Fasting Glucose Manning, 2012 309 0.0685 0.0762 0.8989 0.3687
BMD (Lumbar Spine) Zheng, 2015 205 -0.0641 0.0757 -0.8465 0.3973
Type 2 Diabetes Morris, 2012 311 0.0526 0.0788 0.6678 0.5043
Maternal Lifespan Pilling, 2016 324 -0.07 0.1157 -0.6054 0.5449
Parental Lifespan Pilling, 2016 324 0.0816 0.1429 0.5708 0.5681
Hand Grip Strength Willems, 2017 326 0.0286 0.0627 0.456 0.6484
BMD (Forearm) Zheng, 2015 205 -0.0672 0.1694 -0.3967 0.6916
HbA1c Soranzo, 2010 310 0.0384 0.1073 0.3578 0.7205
Coronary Heart Disease Nikpay, 2015 204 -0.0152 0.0585 -0.2606 0.7944
Waist-Hip Ratio Shungin, 2015 251 -0.0026 0.0506 -0.0514 0.959
rg, genetic correlation; SE, standard error of correlation; BMD, bone mineral density; HbA1c, circulating glycated haemoglobin.
Note data reflects correlation of the trait with mLRR-Y, for which higher values indicates lower mLOY.
mLRR-Y decreasing allele (i.e increased mLOY) was associated with increased cancer susceptibility.
We performed a reciprocal lookup of 90 loci previously reported for prostate cancer susceptibility312,313
(Supplementary Table 30), the most common male non-skin cancer in western populations. There was
no obvious enrichment of signal across these loci and no apparent dose-response relationship between
the allelic effects on prostate cancer and mLOY (pMR-Egger = 0.26, Supplementary Figure 14). Under the
hypothesis that susceptibility to many types of cancer may have a common basis in mitotic error, GWAS
was run in UKB, defining men with any diagnosed cancer on the basis of linked UK cancer registrations
as a case (n= 7,745 cases, 58,562 controls). This approach was recently used for multiple reproductive
cancers, yielding several novel loci323. Applying the 19 mLRR-Y signals as an additive genetic instrument,
there was no evidence of a dose-response relationship between genetically-modelled mLOY and cancer
risk in men (pMR-Egger = 0.94, Supplementary Figure 15). To test the relationship between cancer risk and
mLOY more comprehensively, the extent of shared genetic architecture across the whole genome was
estimated using LD score regression. This revealed an overall significant inverse relationship between
mLRR-Y and cancer risk (rg=-0.42, p=0.02), which was not significant when considering only female
cancer cases (rg=-0.06, p=0.64).
6.3.6 Genetic overlap with ageing and cardiometabolic indicators
Given that Y chromosome mosaicism is a recognised correlate of age, implicated in cancer, and has
been associated with type 2 diabetes, further genetic correlations were run to inform the potential for
bidirectional causal inference between mLOY and existing markers of biological/functional ageing and
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cardiometabolic dysfunction (Table 6.2). After accounting for multiple testing, we observed some evidence
of shared genetic architecture between mLRR-Y and fasting insulin, based on MAGIC Cosortium data
(rg=0.3396, p=3×10-4), suggesting that a greater degree of mLOY shares a common genetic basis with
lower fasting insulin.
To investigate directionality of association in the previously-reported association between large clonal
mosaicism and diabetes risk134, two-sample bidirectional MR was applied between mLRR-Y and diabetes
status, as well as BMI, and a selected number of intermediate glycaemic markers (fasting insulin, fasting
glucose, HbA1c; Supplementary Table 32). No evidence was observed in support of a causal association
in either direction between mLOY and diabetes risk or continuous glycaemic status. Lower genetically-
predicted mLRR-Y (higher Y loss) was associated with lower BMI (βIVW = -1.15kg/m2 per unit decrease
in mLRR-Y, pIVW=0.016, MR-Egger Intercept p=0.610). A penalised weighted median estimator of the
causal effect offered confidence that this association was robust to potential heterogeneity in the mLOY
instrument (pHET=0.005, βPWM=-1.29kg/m2 per unit decrease in mLRR-Y, pPWM=0.034, Supplementary
Figure 16), though it should be noted that this association only reached nominal statistical significance
(p≤0.05) and did not survive adjustment for multiple testing (p=0.05/10). BMI was not a reciprocal causal
exposure for mLOY in these data (pIVW=0.923)
6.4 Discussion
Our findings, together with previous reports, demonstrate that loss of the Y chromosome in peripheral
blood represents a promising new proxy trait for cell cycle fidelity and cellular ageing in large-scale
population-based studies, which is highly prevalent and can readily be estimated as a continuous phe-
notype from sequencing reads or array genotyping data. The nature of the genes identified by these
analyses suggests that genetic determinants of mLOY reflect general mechanisms of aneuploidy, which
we speculate most frequently manifests as mLOY due to the higher capacity of haematopoietic cells to
tolerate Y-chromosome loss. This hypothesis is supported by the observation that these same SNPs also
predicted X chromosome loss in women, the second most frequent large-scale mosaic event327.
Pathway analyses identified enrichment of mLOY associations across the genome for cancer and apop-
tosis pathways. This is further supported by the many well-established cell cycle regulation genes which
we observed either as the closest gene to the association signal, or which were implicated via altered
expression or protein coding changes. Major mechanistic aspects of the cell cycle, and key regulators
of cell-cycle progression were represented by these findings (Figure 6.3), including elements of three
major cell cycle checkpoints, and several genes with complementary functional roles in mitosis. TPX2,
CENPN, PMF1 and ATMIN are involved in aspects of chromosome alignment during metaphase, spindle























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































cruits the crucial mitotic enzyme, Aurora Kinase A, to the spindle330, whilst ATMIN regulates expression
of a dynein motor component (DYNLL1) which critically mediates spindle positioning331–333 and also mod-
ulates Nek9 kinase signalling, required for correct spindle formation and function334. Similarly, Rho-GEF
10 (ARHGEF10, for which we observe a nearby methylated signal) regulates centrosome duplication
and prevents formation of multipolar spindles335. We identified a missense variant in MAD1L1 (MAD1
mitotic arrest deficient like 1), a major component of the spindle assembly checkpoint (SAC). This rep-
resents a key cellular safeguard against chromosome mis-segregation (and subsequent ploidy errors),
supressing metaphase-anaphase progression until chromatids are bi-orientated on a bipolar spindle at
the metaphase plate287. During cytokinesis, SEPT5 (septin 5, implicated in our methylation analysis) en-
codes a conserved cell cycle regulator required for effective cell division336, while activation of signalling
by Rho-GEF 10 (ARHGEF10) facilitates contractile ring ingression to separate the two daughter cells337.
We also implicated a number of genes with established roles in the replication and stability of nuclear DNA
in interphase: replication errors are a key cause of genomic instability and chromosomal fragility338–340.
G1 to S-phase transition is dependent on NPAT, at least in part through it promoting histone gene transcription341,
while ATM, in association with ATMIN42, acts as major cell cycle checkpoint kinase dedicated to maintain-
ing genome stability throughout interphase, with particular importance at the G1/S and G2/M checkpoints340.
In response to double-stranded DNA breaks (DSBs) indicative of genomic instability, ATM promotes vari-
ous responses via p53 and other factors to promote DNA repair, arrest cell-cycle progression, or otherwise
initiate cell cycle exit strategies including apoptosis and senescence338–340,342. TREX1 encodes 3’ Repair
Exonuclease 1, which digests aberrant replication intermediates and single stranded DNA from geno-
toxic stress to prevent chronic checkpoint activation343. Predicted deleterious missense variants in this
gene were recently identified in a mouse GWAS for micronucleus formation, a biomarker of chromosomal
breaks, whole chromosome loss and extranuclear DNA344.
At the later stages of the cell lifespan, several genes implicated by our GWAS findings - including TP53,
TCL1A, SMPD2, BCL2 and BCL2L1 - functionally impact on apoptotic events345–349. Apoptosis is a prime
mechanism by which cells with detected DNA damage or ploidy errors may be eliminated350: indeed,
p53 drives multiple cell-cycle exit responses in response to aberrant mitosis, including G1 arrest342,351,352.
The TP53 variant associated with mLOY in our analyses is the one previously reported for basal cell
carcinoma: for this trait, the risk allele changes the AATAAA polyadenylation signal to AATACA, result-
ing in impaired 3’-end processing of TP53 mRNA318. Our findings also implicated genes involved in
spermatogenesis353,354 (HENMT1 and DAZAP1), and cellular growth and differentiation355 (DLK1).
The genes directly involved in mitotic prophase-metaphase and the SAC have clear roles in averting
chromosomal mis-segregation and preventing mis-segregated cells from persisting unchecked; however
the mechanisms by which the broader set of genes implicated here may act to promote mLOY remains
less clear. We speculate that either many of these genes act in ways that are not currently recognised, or
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alternatively that the other highlighted processes outside of cell cycle control and mitosis are important. In
particular, as a major mode of cell-cycle exit, the observed enrichment of genes and cascades regulating
and effecting apoptosis may play a more passive, permissive, role in enabling mis-segregated cells to
survive with ploidy errors, rather than being directly causative of the initial aneuploid event.
Although an initial defect during the cell cycle process is required to generate an aneuploid daughter
cell, clonal expansion of the affected progenitor(s) is likely required to drive the lineage to a detectable
frequency in the circulating white blood cell population. It is possible that mLOY in haematopoietic precur-
sors confers a proliferative advantage to such cells, leading to a relative enrichment of assayable mLOY
progeny. We, therefore, speculate that some loci may operate through this pathway to further facilitate or
promote clonal expansion of these cells. Additional functional experimentation in cellular and animal sys-
tems is ultimately required to fully elucidate this issue and the role individual associated genes may play
in determining mLOY. It is also important to acknowledge that there are likely other, currently unknown,
mechanisms by which our associated loci exert their effects.
We observed a substantial shared genetic architecture between mLOY and cancer susceptibility, sug-
gesting that bivariate analyses of these two traits may help to prioritise novel cancer susceptibility loci
and elucidate their functions. We were not, however, able to find evidence of a dose-response relation-
ship between these two traits on the basis of MR analyses and reciprocal look-ups. This is perhaps not
surprising given that findings from mouse studies in which mitotic checkpoint components are experi-
mentally down-regulated demonstrate an inconsistent relationship between aneuploidy and spontaneous
tumorigenesis287. It is possible, therefore, that some of our identified genes may promote benign aneu-
ploidy, whereas others may play a role more generally in genome instability. This makes the use of genetic
variants associated with mLOY difficult within a Mendelian randomisation framework, as genes with gen-
eral roles in instability may have different phenotypic consequences to genes that promote aneuploidy in
a more stable way.
This of course does not preclude identifying causal risk factors for mLOY. The utility of understanding the
underlying genetics of mLOY is exemplified by our positive causal inference for smoking on mLOY, using
a genetic instrument for cigarettes per day. More generally, the association between smoking and mLOY
suggests that care should be taken to avoid confounding influences such as socioeconomic patterning in
epidemiological observations between mLOY and disease. Assuming that the potential for heterogeneity
and pleiotropy in the instrument is kept in mind, however, it would seem reasonable to assume that
such environmental confounders will be randomised relative to genotype across the 19 mLOY variants.
The implication of greater mLOY as a causal exposure for decreased BMI in MR analyses which are (i)
robust to heterogeneity and (ii) show no evidence of pleiotropy suggests that our mLOY instrument can be
appropriately applied. In this particular case, however, the results should be interpreted cautiously based
on its nominal significance (p≤0.05), which does not survive adjustment for multiple testing. Assuming
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that the association is true, it should also be considered that it may to some extent reflect the shared
biology of changing body composition, deterioration of muscle mass and the general frailty phenotype
which accompanies older age.
In conclusion, our study highlights that estimation of mLOY using genotype array intensity data may serve
as a useful quantitative measure of cell cycle efficiency and genome stability, and may thereby add a new
approach to the study of cellular ageing and its associations with disease, particularly cancer. In addition
to fully evaluating the broader disease relevance of mLOY, future epidemiological studies should look to
assess the differential rates at which mLOY changes in individuals over time, its relevance in other tissue
types, and further non-genetic modifiable factors which may influence it.
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7.1 Summary of Objectives and Findings
Ageing is a composite process of multiple interacting phenotypes spanning from the cellular to whole-
organism level, and including changes in muscle tropism, functional indices, aspects of metabolism, ge-
nomic stability, and cellular physiology. As well as being informative markers of ageing, many of these
phenotypes are also important endpoints in their own right. On the basis that direct study of the compos-
ite phenotypes of ageing might allow more direct biological insight into the association between ageing
and disease, this PhD set out to conduct the first large-scale population-based genetic discovery of three
important but little-studied markers of ageing: hand grip strength as a marker of overall muscle condition
and frailty, resting energy expenditure as an indicator of metabolism and energy balance, and mosaic loss
of the Y-chromosome, a potential novel marker of genomic instability and replicative capacity with age.
Having conducted these discovery efforts, I applied a host of downstream analytical approaches incorpo-
rating gene expression, epigenetics, genetic correlations, pathway-based work and partitioned heritability
to maximise biological insight, and to understand the shared and separate aetiology of these phenotypes,
and their role in cardiometabolic dysfunction.
Through concerted international collaboration and the use of very large population-based cohorts, this
thesis has robustly implicated the first variants identified for grip strength (n=16) and mLOY (n=19) in
the global literature. In each case, loci identified correspond to genes with a convergent and highly
plausible role in the phenotype. Through European and transethnic analyses of REE, three loci of potential
interest to this phenotype have additionally been identified. Downstream analyses dramatically enhance
our understanding of the basic biology underpinning variation in these traits at population level.
From a translational perspective, the work on grip strength has proved perhaps the most illuminating. Tar-
geted interrogation of the associations with HGS across the genome provided genetic evidence in support
of a monoclonal antibody - Bimagrumab (Novartis) - currently being pursued in Phase III trials as a treat-
ment for pathological muscle deterioration233, and already licensed as an early breakthrough therapy for
Sporadic Inclusion Body Myositis (sIBM), an inflammatory condition characterised by progressive wasting
of proximal and distal muscles) . Our identification of grip strength as a causal exposure for fracture risk
using data from the GEFOS consortium underlines the importance of muscle strength to the maintenance
of functional independence and mobility with advanced age. In mLOY, we have demonstrated that major
genes implicated in cell cycle control and progression, apoptosis and genomic stability can be identi-
fied using this readily-quantifiable and widely-available phenotype, which this thesis highlights as a new
parameter to facilitate the study of genome stability and associated conditions at very large population-
based scale. The finding that mLOY is inversely correlated with all-cancer risk at population level further
underlines this.
The analyses outlined in this work additionally contribute to ongoing high profile discussions in the litera-
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ture. For example, this thesis suggests that the genetic influence of MTCH2 on adiposity is mediated in
part through lower REE, but does not support the recently-reported role of FTO in thermogenesis241, or
the importance of MC4R in REE observed amongst Pima Indians103. This PhD does not support a causal
role for grip strength in CHD, suggesting that recent work outlining grip strength as a clinical predictor of
CHD incidence in low resource settings is not based on an underlying causal relationship, but, rather, on
other correlated factors. Whilst the nature of MR analyses precludes a conclusive finding in the case of a
null result, one would anticipate that a causal effect would be observed in this instance, if such an effect
existed.
This chapter places the work presented throughout this thesis in a wider context; technically, scientifically,
and in terms of its application and translational relevance. I firstly assess how the findings of this work
might be limited or influenced by major considerations including chance, bias, confounding and error, and
specific analytical limitations such as collider bias, whilst outlining the measures that have been applied
throughout to mitigate their potential effect. Before drawing final conclusions, I outline in some detail how
the findings of this thesis have contributed to the field, discuss their translational and applied relevance,
and suggest avenues for further work based on the foundations established by this thesis.
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7.2 Possible Limitations and Considerations
7.2.1 Limitations to REE Derivation
Despite the widespread clinical application of indirect calorimetry, consensus protocols for the testing
procedure and post-test processing and interpretation of data do not exist57, and best practice guidelines
are geared to the clinical setting. These guidelines typically stipulate rest periods of 30 minutes preceding
the test, disregard an initial period at the outset of calorimetry, and define steady state exchange according
to strict criteria which often necessitate extended testing durations. Their implementation is restrictive,
and a particular challenge in large-scale research environments in which testing procedures must strike
a balance between accuracy and throughput whilst minimising participant inconvenience. Working from
first principles of calorimetry interpretation, and in collaboration with colleagues, I optimised a framework
for cleaning of Fenland calorimetry data to generate a time-series of steady-state breaths physiologically
representative of underlying cellular respiration.
During testing, best-practice was applied wherever possible, but one notable deviation was the shortened
testing duration required to achieve acceptable throughput in Fenland baseline visits. Whilst the six-minute
period is considerably truncated from the recommended duration to achieve steady state356, a recent
systematic appraisal of guidelines has concluded that an overall test duration of five-minute acclimation
followed by a five-minute period of steady-state is sufficient to attain representative parameters57. Whilst
the five-minute steady-state requirement is widely advocated in literature, Reeves and colleagues357 ar-
gue that it is not evidence-based, and suggest that steady-state durations of three minutes generate REE
values which differ from five-minute steady-state estimates by less than 3%. It follows, therefore, that
observations over the last 120s of our six minute protocol tend towards steady-state, and that residual
error is random rather than systematic. In addition, the fasting requirement of REE assessment was tech-
nically contravened by the administraion of an oral glucose tolerance test (OGTT) prior to calorimetry. The
standardised (75g) glucose dose across all participants mitigates any potential systematic error in REE
introduced by pre-test glucose consumption.
Overall, derived REE used in these analyses has high face validity against known correlates including
age, sex and fat-free mass, as discussed in Chapter 4. Whilst our reported mean VO2 over the last 120s
of rest is lower than the standard metabolic equivalent of task (MET, 3.5mL/kg/min), this reference value
is often considered unrepresentative248, and a lower observation is in line with the findings of previous
studies in healthy populations of similar age248,358. Outliers of absolute REE fall within the expected
demographics in terms of sex and body mass. Efforts taken throughout data collection and processing
give us confidence that estimates are free of systematic error and provide a good indication of absolute
REE. Even in the presence of random error, derived phenotypes will correctly capture true inter-individual
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variance in RMR, and appropriately rank participants within the population-level distribution. In future,
however, the validity of our testing and derivation procedure could be examined by comparison to direct
calorimetry as a criterion measure in a representative subset of the Fenland cohort.
7.2.2 Internal and External Validity
Sound epidemiological inference is dependent on a study combining both internal and external validity:
that is, the study design and analytical processes are statistically robust, and the findings are generated
in a sample which is representative of the population of interest and are generalisable to the real-world
setting. Chance, confounding, error and bias can detract from validity, and best efforts have been taken
throughout this work to minimise their effect.
Chance Standard p-value thresholds and methods to account for family-wise error rate (FWER) have
been applied throughout to fix the risk of type I error (α, the likelihood of declaring a false positive as-
sociation) at ≤5%, in line with standard practice. As is convention, p≤5×10-8was applied universally as
the threshold for association at statistical significance in genome-wide discovery efforts for MAF ≥1%,
and Bonferroni correction used to conservatively account for multiple testing, assuming that all tests were
statistically independent even in situations (such as multiple tissue expression associations) where this
may not strictly be true. Replication of genetic associations from discovery-stage analyses in indepen-
dent, ancestry-matched cohorts, minimises the likelihood that reported associations are due to chance,
and mitigates the risk of statistical phenomena such as ’Winner’s Curse’. This term is used to refer to
the fact that effect sizes (and statistical significance) are often over-estimated at the discovery stage due
to the definition of statistical significance based on a binary p-value threshold359. Given that effect sizes
tend to regress to the mean during stage two follow-up, our exclusive use of effect sizes from combined
discovery plus replication analyses moderates the adverse influence of Winner’s Curse in downstream
MRs in which they are applied as instruments.
Confounding The need to systematically account for confounding issues which limit the capacity for
epidemiological inference in standard observational approaches was central to the objectives of this PhD.
By applying genetic instruments to model theoretically unconfounded exposures, we were able to estimate
causal effects according to Mendelian randomisation. A fuller discussion of the strengths and limitations
of these analyses can be found below. To account for population stratification in discovery efforts (con-
founding by underlying sub-structure in allele frequencies due to ancestry or relatedness), we primarily
restricted to individuals of European ancestry as defined by self-report, and applied a linear mixed model
(BOLT-LMM) as standard. By empirically accounting for genetic covariance between all samples (based
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on a genomic relatedness matrix), LMM have the distinct advantage of mitigating sub-continental ances-
tral structure, as well as overt and cryptic relatedness, without the necessary need for prior knowledge of
this structure. This offers power advantages over the conventional approach of including genomic principal
components as covariates to condition for variance attributable to ethnicity. Principal components-based
adjustment has, however, been the de facto standard since the inception of GWAS and is widely recog-
nised as effective. The majority of replication samples across the analyses provided association statistics
according to their standard procedure and thus accounted for population structure using a components-
based approach PCs. Systematic assessment of test statistic inflation by λGC and LD score regression
intercept provided confidence that our main discovery models were not residually confounded.
Error and Bias Whereas error, in an epidemiological sense, is used to refer to the random, uncorre-
lated error occurring in, for example, phenotype measurement within and across studies, bias denotes
systematic error which is intrinsic in the study design. The use of standardised protocols for phenotype
assessment within studies contributing to this work - as exemplified by UKB138 provide confidence that the
risk of measurement biases is appropriately mitigated. As error is random, it is largely an inverse function
of sample size, and is minimised with the increased statistical power offered by the large population-
based samples leveraged here. Error may become meaningful if it is structured between stage one and
two cohorts. Standard fixed-effect inverse variance-weighted methods was applied in this work to ensure
that cohorts contributed appropriately to overall meta-analyses, inversely proportional to the uncertainty
surrounding the point estimate of the association of each variant. Formal assessment of heterogeneity
across studies suggested that estimates were directly comparable and not subject to differential error by
cohort. The potential limitation of residual cohort effects should, however be considered.
As with all cohort-based work, these analyses are prone to healthy volunteer effect360; a bias introduced
by the phenomenon that, on average, individuals who enrol in population-based cohorts which do not
enforce selection criteria based on outcome status are more likely to be healthier and have better health
outcomes than their contemporaries. The overall recruitment response rate of 5.5% in UK Biobank141 is
indicative of the likely presence of healthy volunteer effect. By reference to the general population, UKB
participants are less socio-economically deprived, older, less likely to smoke or be obese, and suffer 50%
less mortality at age 70-74 years141. Whilst the healthy cohort effect reduces the representativeness of
studies and makes them unsuitable for derivation of descriptive prevalence and incidence rates or popula-
tion norms, valid assessment of exposure-disease relationships are widely generalisable and do not nec-
essarily require a representative sample given that sufficient phenotypic variability is observed136,141,361.
Continuing debate in this area should, nonetheless, be acknowledged here.
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7.2.3 Collider Bias
In the context of genetics, statistical collision occurs when discovery analyses are adjusted for a heritable
covariate which is itself causally influenced by the outcome of interest (a collider); the resulting ’collider
bias’ may cause spurious genetic associations to be observed. Specifically, variants associated with the
collider will be erroneously identified as genetic determinants of the outcome of interest, with a direction
of effect which is (a) physiologically implausible and (b) the inverse of the effect observed in analyses
not adjusting for the collider. This phenomenon has most clearly been demonstrated in a recent proof-
of-concept by Day and colleagues362, in which autosomal determinants of biological sex were artificially
induced in GWAS analyses by adjustment for standing height (which is itself influenced by sex). All
identified variants at genome-wide significance were known height-increasing loci, and were associated
with odds of being female; the opposite of what would be expected biologically. The implausibility of
these associations is self-evident, and clearly illustrates the statistical implications which may arise from
inappropriate adjustment of GWAS analyses, or interpretation of adjusted GWAS results without due
thought to the risk of statistical collision, even in cases for which the adjustment appears physiologically
sensible. Further work has expanded on this, highlighting BMI as a problematic covariate in GIANT meta-
analyses363.
The mLOY discovery (and the main discovery analyses for REE) presented in this PhD are adjusted only
for age, sex and other non-heritable covariates, and, therefore, have a very low prior for collision. The hand
grip strength discovery, however, is adjusted for BMI and standing height to account for the possibility that
strength may scale with muscle size. Given that height is fixed post-adolescence, it is conceptually unlikely
that height can be causally influenced by strength variation in adulthood. We were mindful, however, of
real possibility of collision by BMI, and took steps to assess its presence by systematically considering
the association of known BMI loci249 with HGS in models including or omitting BMI as a covariate. As
discussed more fully in Chapter 3, comparison of the direction of effect of known BMI variants in the main
HGS model (age, sex, height and BMI) and a sensitivity GWAS not adjusting for BMI did not provide
evidence of collider bias attributable to adjustment for BMI, and suggested its inclusion as a covariate was
appropriate.
7.2.4 Limitations to Inferring Causality
Mendelian randomisation offers a powerful solution to deal with many of the issues of observational epi-
demiology, yet causal inference is only robust if prerequisite assumptions hold. These assumptions have
been discussed in some detail in Chapter 2: briefly, the association between the instrument and the out-
come of interest must act only via the modelled exposure, free of pleiotropy or heterogeneity. Current
best-practice approaches to identifying and subsequently accounting for directional pleiotropy (MR-Egger
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Figure 7.1: Statistical collision illustrated by contrast to confounding. In the association of an exposure X with an outcome Y,
a confounder U is a correlate or causal exposure for X, which is also a determinant of Y, but does not lie on the X-Y causal
pathway. If the covariate is a causal outcome of Y, it is classed as a collider, C. Adjustment for C will generate a spurious
association between X and Y. Unidirectional arrow, causal association; bidirectional arrow, correlation
estimator) or heterogeneity (weighted median estimators) were applied throughout this thesis. Based
on a method first described to detect heterogeneity in meta-analyses, MR-Egger allows the intercept
term of the MR regression to deviate from zero, providing a quantitative estimate of the presence of di-
rectional pleiotropy and a causal β robust to this. Weighted median estimators seek to address issues
of heterogeneity and scores comprising a proportion of variants which contravene instrumental varaible
assumptions. The contribution of particularly heterogeneous variants to the overall causal estimate is
penalised, allowing robust estimates to be generated when as many as half of the variants used to model
the exposure are invalid.
A large proportion of the MR estimates presented in this thesis were inconclusive, providing a non-
statistically significant association, and highlight a particular limitation of the MR approach. Whereas
a statistically significant causal estimate can be interpreted as such, a null estimate cannot be interpreted
as absence of a true causal effect. The understanding of power calculations in MR is a developing field,
and methods described to date364,365 are only appropriate in restricted scenarios (for example when con-
sidering binary outcomes). Moreover, in two-sample MR, power calculations must inherently be post-hoc,
and by convention are not undertaken.
Power in MR is primarily a function of the variance explained in the modelled exposure by the instrument,
but a fine balance exists between maximising this variance (by expansion of the score), and the accompa-
nying risk of introducing variants which violate instrumental variable assumptions364. Use of two-sample
approaches conservatively shifts the causal estimate toward the null in the case of this weak-instrument
bias, assuming that the effect estimates for the modelled exposure and outcome of interest are drawn
from demographically and ethnically similar populations. However, variant choice remains of importance.
To minimise weak instruments, MR approaches conventionally restrict to variants robustly associated with
the modelled intermediate at genome-wide significance: we followed this convention throughout.
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7.3 Implications and the Future
A common criticism of genetic discovery analyses is that conclusions drawn are abstract and cannot be
readily translated to clinical or policy settings in a timely manner366. This criticism only holds if genetic
work is approached with inappropriate expectation of immediate clinical impact, however. In reality, trans-
lation may take a number of years, and begins with the major strength of hypothesis-free discovery to
empirically elucidate the underlying biology and aetiology of a phenotype. The importance of fully under-
standing this biology, and the value of genetic evidence in prioritising drug targets, is now recognised as
an important measure in improving the efficiency of drug development pipelines and the translation to the
clinic367.
Through the application of genetic discovery in the largest possible population-based samples to date,
and the application of downstream work to prioritise functionally-relevant genes, this thesis provides much
biological insight into the mechanisms involved in variation in hand grip strength, mosaic loss of Y and
resting energy expenditure.
In the case of grip strength, we demonstrate that common genetic variation in proximity to genes impli-
cated in severe monogenic neuromuscular syndromes is associated with normal variation in strength in
the population at large. Additionally, we observed important genetic evidence in support of the Novartis
compound BYM338, a candidate activin receptor type II (ActRII) antagonist monoclonal antibody being
investigated for its hypothesised utility in preserving muscle mass and function in a range of clinical and
frailty settings, and licensed (Bimagrumab) as an early breakthrough treatment for the rare degenerative
condition, sporadic inclusion body myositis (sIBM)233. In recent months, BYM338 has been repositioned
as a putative treatment for T2D, on the hypothesis that improvement of body composition amongst the
obese could favourably influence insulin sensitivity. Initial results are concordant with this theory368, and
highlight the shared biology between muscle function and metabolic parameters which has been investi-
gated in part in this thesis.
Work presented in Chapter 6 expands on the current literature linking increased mLOY to age, and pro-
vides substantial new evidence on the potential of mLOY as marker of basic physiological and ageing
processes. The convergence of loci identified by GWAS on diverse aspects of the cell cycle, apoptosis
and DNA replication highlight its relevance as a novel quantitative phenotype to assess cell cycle efficiency
and genomic instability in large-scale human populations. Whilst we were not able to demonstrate mLOY
as a causal exposure for cancer risk, positive genetic correlations indicated a clear shared genetic archi-
tecture, and suggest that wider study of this phenotype could offer new insights into processes pertinent
to cancer, and possibily drive prioritisation and validation of new targets for intervention. Our demonstra-
tion that mLRR-Y can be accurately estimated from commercial genotyping arrays makes this phenotype
particularly permissive to further high-impact genetic work with very high power in a comparably short
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timeframe. For both mLOY and hand grip strength alike, the imminent release of a further 350,000 geno-
typed samples from UK Biobank offers an immediate avenue to fundamentally expand discovery analyses,
and should be pursued as a priority. In the medium term, initiatives such as the United States’ ’All of Us’
programme (Precision Medicine Initiative)369,370 will allow momentum to be maintained in genetic discov-
ery of these traits over coming years. Given that mLOY requires no additional phenotyping - only access
to array genotyping - this phenotype is also uniquely placed to leverage the vast repositories or genome-
wide genotyping held by commercial direct-to-consumer vendors such as 23andMe and Ancestry.com,
and to perform discovery in large non-European populations (e.g., the China-Kadoorie Biobank371) with
relative ease. Even now, this transition to highly-powered and robust transethnic analyses remains a bar-
rier to the majority of phenotype discovery, which have conventionally been monopolised by European
efforts.
Chapter 5 informs the ongoing and often polarising debate surrounding the mechanism of action by which
known BMI variants exert their effect on body composition. In contrast to recent work in animal models
and human cell lines which implicates FTO in pro-thermogenic response and the regulation of adipose
browning, and established work implicating MC4R in lower REE, our analyses did not support the conclu-
sion that common variants in either gene increases BMI via modulation of REE at population scale. We
did, however, identify lower REE as a partial mediator of the adiposity-increasing effect of MTCH2.
Whilst some promising initial signals were identified, the REE discovery effort presented in Chapter 4 was
underpowered. Nonetheless, this analysis represents the largest discovery effort for REE conducted to
date, and combines the majority of available data on a global scale. We report that genetic associations
for REE are enriched for major respiratory processes, and confirm that known associations between body
size and REE are reflected in the shared genetic architecture of these traits. It was disappointing that no
genetic instrument for REE was robustly identified, but the international collaboration established during
this project sets the foundations for future expanded discovery analyses of REE, which will ultimately
implicate sufficient variants to create an instrument. The route to enhanced discovery is not so clear cut
for this phenotype as for HGS and mLOY, and will require concerted additional genotyping efforts in new
or existing cohorts, but must be pursued in the interests of improving our understanding of this trait and its
role in health. Functional work in human cells line and rodent models is likely to offer the greatest potential
to inform our knowledge of the role of genes implicated in REE in the short term.
Combined, the discovery analyses described here contribute significantly to our understanding of the
genetic aetiology of three functional ageing traits, and will facilitate hand grip strength and mLOY to be
modelled as causal exposures by others. MRs must be interpreted with care however. For example,
we implicate lower HGS as a ’causal’ risk factor for fracture risk, but this association only holds given
that HGS is a true proxy of overall muscular strength; i.e. isolated training of grip cannot be used as an
intervention to reduce fracture risk. Rather, this finding should be interpreted as a reinforcement of the
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need to maintain physical activity and overall strength through general and targeted means in middle and
older age.
I n conclusion, the work presented here significantly advances our understanding of the role of ageingphenotypes in health and disease. Through considering alternative functional and biological markers
of ageing, I have gained insight into the shared genetic aetiology of these traits and their underlying
biology, presenting the first large-scale genetic discoveries in each case, and characterising novel genetic
variants. The findings of this work have broad relevance to translational and basic science, but efforts
must continue to further enhance our knowledge and understanding of these complex topics.
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Supplementary Figure 1: Manhattan and QQ-plot of stage one grip strength associations in UK Biobank. Independent loci
reaching genomewide significance in combined stage one + two analyses are highlighted bright green. λGC=1.31, LD score
regression intercept = 1.02 (95% CI 0.998-1.042), suggesting that apparent inflation evident in the QQ-plot can be attributed to
polygenicity of grip strength. On Manhattan, genomewide significance threshold is indicated; on QQ-plot, red line indicates null
effect.
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Supplementary Figure 2: Regional association plots of sixteen loci reaching genomewide significance in combined stage one
plus two analyses for grip strength. Outlined plot characters denote a variant at suggestive significance (p=5×10-6) with coding
consequences. Square, non-deleterious; inverted triangle, stop-gain; triangle, missense; diamond, splice region
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Supplementary Figure 2: Continued
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Supplementary Figure 2: Continued
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Supplementary Figure 3: Evidence of non-additive genetic association with HGS at two loci. Data shown are predicted mean
hand grip strength by best-guess genotype expressed as HGS-increasing allele dosage. Upper: rs2273555 in GBF1; Lower:
rs10861798 in SYT1. Bars denote 95% confidence interval.
Supplementary Figure 4: Hand grip strength heritability partitioned by major tissue classes. Data shown are log p-values for
enrichment in each curated tissue class from LD Score Regression, based on genomewide grip strength association results
(adjusted for age, sex, BMI, standing height). Red line indicates Bonferroni-corrected threshold for statistical significance.
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Supplementary Figure 5: Effect of nonsense mutation in ACTN3 (R577X) on hand grip strength. Data are predicted mean hand
grip strength by dosage of the previously-described stop-gain allele at rs1815739 (R577X mutation) in ACTN3. Bars denote 95%
confidence interval.
Supplementary Figure 6: Heterogeneity in effect of variants for insulin phenotypes on HGS in MR analyses. Funnel plots
indicate the effect of variants included in the scores for two insulin traits on hand grip strength (kg), versus the standard error
of this effect. Upper: Insulin resistance; Lower: Fasting Insulin. The highlighted funnel indicates the expected 95% confidence
interval of effect, assuming that the variants in combination have an effect on the trait under an MR framework (black line). The
null is indicated by the red dashed line.
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Supplementary Figure 7: Derivation of REE from observed respiratory exchange data
Respiratory exchange parameters measured in participants were processed to ensure they were stable and representative of
underlying cellular respiration. VO2, Oxygen consumption; RER, respiratory exchange rate; TIN, inspiratory duration per breath;
TEX, expiratory duration per breath; pEtCO2, end-tidal partial pressure of CO2; PaCO2, arterial partial pressure of CO2
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Supplementary Figure 8: Frequency density distribution of REE in Fenland. Data are shown for all 9,372 participants passing
quality control for valid breaths and phenotype stability. Upper: crude REE. Lower: REE normalised to body mass. Kernel
density curve generated using Epanechnikov kernel function. Red, male; Blue, female.
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Supplementary Figure 9: QQ-plots of REE associations in combined European meta-analyses. Upper: Age and sex-adjusted,
λGC = 1.04, LD score regression intercept = 1.01 (95% CI 0, 1.02). Lower: Age, sex and body mass-adjusted, λGC = 1.01, LD
score regression intercept = 1.01.
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Supplementary Figure 10: GOT2 locus regional plots for major anthropometric traits. Associations are taken from current
GIANT European meta-analyses and elsewhere; details are provided in the main text. Plot character colour indicates linkage
disequilibrium with the locus index. (A) Regional association in REE-Gen European discovery, age + sex adjusted (B) BMI (C)
Standing height (D) Hip circumference (E) Waist circumference (F) Body fat percentage.
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Supplementary Figure 13: Quantile-quantile plot of genome-wide test statistics for mLRR-Y. Line of null effect is shown in black.
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Supplementary Figure 14: Prostate Cancer-mLOY Mendelian randomisation: dosage plot. Each variant previously published
for prostate cancer risk is plotted with regard to its additive effect on mLRR-Y. Black lines around each data point, 95% CI of
each effect. Coloured lines represent estimates from main and sensitivity MR analyses. Red, IVW (p=0.349); Blue, MR-Egger
(p=0.263); Yellow, weighted median (p=0.782); Green (aligned with yellow), penalised weighted median (p=0.772).
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Supplementary Figure 15: mLRR-Y-cancer Mendelian randomisation: dosage plot. Each variant identified for mLRR-Y is
plotted with regard to its effect on any-cancer risk (log-OR) in UKB . Black lines around each data point, 95% CI of each effect.
Coloured lines represent estimates from main and sensitivity MR analyses. Red, IVW (p=0.0576); Blue, MR-Egger (p=0.938);













Supplementary Figure 16: mLRR-Y-BMI Mendelian randomisation: dosage plot. Each variant identified for mLRR-Y is plotted
with regard to its effect on BMI in GIANT Consortium European Meta-analysis (Locke et al., 2012). Black lines around each data
point, 95% CI of each effect. Coloured lines represent estimates from main and sensitivity MR analyses. Red, IVW (p=0.016);
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































n males 4,561 1,392
n females 5,192 1,706
Age (years) (SD) 48.46 (7.46) 71.77 (7.47)
Lean Mass Index (kg/m2) 16.71 (2.22) 16.18 (2.04)
Fat Mass Index (kg/m2) (SD) 9.22 (3.49) 9.62 (3.28)
Supplementary Table 2: LMI and FMI GWAS cohort characteristics. Data shown are mean (SD) unless otherwise specified
180
HGS ( Height) HGS ( Height + BMI) BMI
rsID Chr Pos EA AA Beta SE p-value Beta SE p-value Beta SE p-value
rs13107325 4 103188709 C T 0.191 0.050 1.20E-04 0.200 0.050 5.30E-05 -0.048 0.007 1.83E-12
rs2207139 6 50845490 G A -0.120 0.035 5.00E-04 -0.129 0.035 1.90E-04 0.045 0.004 4.13E-29
rs17724992 19 18454825 A G -0.090 0.030 2.30E-03 -0.095 0.030 1.40E-03 0.019 0.004 3.41E-08
rs9374842 6 120185665 T C -0.086 0.031 5.30E-03 -0.089 0.031 4.10E-03 0.019 0.004 9.67E-08
rs7599312 2 213413231 G A 0.084 0.030 4.50E-03 0.080 0.030 6.80E-03 0.022 0.003 1.17E-10
rs3817334 11 47650993 C T 0.061 0.026 0.020 0.067 0.026 0.011 -0.026 0.003 5.14E-17
rs12446632 16 19935389 A G -0.099 0.037 7.50E-03 -0.092 0.037 0.013 -0.040 0.005 1.48E-18
rs1928295 9 120378483 C T 0.058 0.026 0.026 0.061 0.026 0.019 -0.019 0.003 7.91E-10
rs3888190 16 28889486 A C -0.055 0.027 0.038 -0.061 0.027 0.021 0.031 0.003 3.14E-23
rs17405819 8 76806584 C T -0.067 0.028 0.018 -0.064 0.028 0.024 -0.022 0.003 2.07E-11
rs16851483 3 141275436 G T -0.124 0.052 0.018 -0.118 0.052 0.025 -0.048 0.008 3.55E-10
rs17203016 2 208255518 G A 0.064 0.033 0.047 0.061 0.032 0.059 0.021 0.004 8.14E-08
rs6465468 7 95169514 G T -0.053 0.028 0.060 -0.053 0.028 0.060 -0.017 0.004 2.32E-06
rs7141420 14 79899454 T C 0.054 0.026 0.041 0.049 0.026 0.062 0.023 0.003 1.23E-14
rs7164727 15 73093991 T C -0.046 0.028 0.093 -0.051 0.028 0.068 0.018 0.003 6.83E-08
rs9400239 6 108977663 C T -0.048 0.029 0.094 -0.052 0.029 0.069 0.019 0.003 1.61E-08
rs977747 1 47684677 T G 0.051 0.026 0.052 0.047 0.026 0.073 0.017 0.003 8.65E-08
rs2245368 7 76608143 T C 0.056 0.035 0.110 0.061 0.035 0.078 -0.032 0.006 3.19E-08
rs7903146 10 114758349 T C -0.054 0.029 0.060 -0.049 0.029 0.087 -0.023 0.003 1.11E-11
rs10182181 2 25150296 A G 0.037 0.026 0.150 0.044 0.026 0.091 -0.031 0.003 8.78E-24
rs7899106 10 87410904 A G -0.106 0.060 0.078 -0.100 0.060 0.094 -0.040 0.007 2.96E-08
rs29941 19 34309532 A G -0.049 0.028 0.077 -0.045 0.028 0.100 -0.018 0.003 2.41E-08
rs16951275 15 68077168 C T -0.058 0.031 0.062 -0.051 0.031 0.100 -0.031 0.004 1.91E-17
rs1460676 2 164567689 T C -0.059 0.036 0.099 -0.056 0.036 0.120 -0.020 0.004 8.98E-07
rs6477694 9 111932342 C T -0.040 0.027 0.140 -0.042 0.027 0.120 0.017 0.003 2.67E-08
rs2365389 3 61236462 C T 0.046 0.027 0.086 0.039 0.027 0.140 0.020 0.003 1.63E-10
rs4740619 9 15634326 T C 0.042 0.026 0.110 0.038 0.026 0.140 0.018 0.003 4.56E-09
rs7239883 18 40147671 G A -0.035 0.027 0.200 -0.038 0.027 0.160 0.016 0.003 1.63E-07
rs3810291 19 47569003 A G -0.033 0.028 0.230 -0.039 0.028 0.160 0.028 0.004 4.81E-15
rs2033732 8 85079709 C T 0.039 0.030 0.190 0.038 0.030 0.200 0.019 0.004 4.89E-08
rs205262 6 34563164 A G 0.029 0.029 0.320 0.036 0.029 0.220 -0.022 0.004 1.75E-10
rs11191560 10 104869038 T C -0.065 0.049 0.180 -0.060 0.049 0.220 -0.031 0.005 8.45E-09
rs11057405 12 122781897 A G 0.043 0.042 0.300 0.051 0.042 0.230 -0.031 0.006 2.02E-08
rs9925964 16 31129895 G A -0.031 0.024 0.180 -0.028 0.024 0.230 -0.019 0.003 8.11E-10
rs4787491 16 30015337 A G -0.035 0.026 0.190 -0.031 0.026 0.240 -0.016 0.003 2.24E-06
rs17024393 1 110154688 C T 0.109 0.081 0.180 0.094 0.081 0.250 0.066 0.009 7.03E-14
rs2287019 19 46202172 C T 0.048 0.034 0.160 0.039 0.034 0.250 0.036 0.004 4.59E-18
rs12885454 14 29736838 C A -0.025 0.027 0.350 -0.029 0.027 0.290 0.021 0.003 1.94E-10
rs13078960 3 85807590 T G -0.039 0.032 0.230 -0.033 0.032 0.300 -0.030 0.004 1.74E-14
rs11165643 1 96924097 C T -0.031 0.026 0.240 -0.027 0.026 0.310 -0.022 0.003 2.07E-12
rs3736485 15 51748610 A G -0.023 0.026 0.380 -0.026 0.026 0.320 0.018 0.003 7.41E-09
rs1558902 16 53803574 A T 0.043 0.027 0.100 0.026 0.027 0.330 0.082 0.003 0
rs11847697 14 30515112 T C 0.066 0.064 0.300 0.061 0.064 0.330 0.049 0.008 3.99E-09
rs6567160 18 57829135 C T 0.041 0.031 0.180 0.029 0.031 0.340 0.056 0.004 0
rs2080454 16 49062590 A C 0.022 0.027 0.400 0.026 0.027 0.340 -0.017 0.003 6.55E-08
rs13191362 6 163033350 A G 0.042 0.039 0.280 0.038 0.039 0.340 0.028 0.005 7.34E-09
rs10733682 9 129460914 A G -0.020 0.027 0.440 -0.024 0.027 0.360 0.017 0.003 1.83E-08
rs758747 16 3627358 C T -0.028 0.029 0.350 -0.026 0.029 0.380 -0.023 0.004 7.47E-10
rs543874 1 177889480 G A -0.016 0.032 0.630 -0.027 0.032 0.400 0.048 0.004 2.62E-35
rs2650492 16 28333411 A G -0.017 0.029 0.550 -0.021 0.029 0.450 0.021 0.004 1.91E-09
rs9540493 13 66205704 G A 0.017 0.026 0.530 0.020 0.026 0.450 -0.017 0.003 1.42E-07
rs3849570 3 81792112 A C -0.017 0.027 0.530 -0.020 0.027 0.460 0.019 0.003 2.60E-08
rs11688816 2 63053048 A G 0.016 0.026 0.540 0.019 0.026 0.470 -0.017 0.003 1.89E-08
rs2121279 2 143043285 T C 0.029 0.039 0.460 0.028 0.039 0.480 0.024 0.004 2.31E-08
rs2075650 19 45395619 A G 0.028 0.035 0.430 0.025 0.035 0.480 0.026 0.004 1.25E-08
rs2820292 1 201784287 A C -0.023 0.026 0.380 -0.019 0.026 0.480 -0.020 0.003 1.83E-10
rs17094222 10 102395440 C T -0.019 0.032 0.550 -0.023 0.032 0.480 0.025 0.004 5.94E-11
rs6804842 3 25106437 A G 0.015 0.026 0.560 0.018 0.026 0.490 -0.019 0.003 2.48E-09
rs1167827 7 75163169 A G -0.022 0.026 0.400 -0.017 0.026 0.510 -0.020 0.003 6.33E-10
rs11126666 2 26928811 G A 0.019 0.030 0.510 0.019 0.030 0.510 -0.021 0.003 1.33E-09
Supplementary Table 3: Assessment of potential for collider bias by BMI variants in grip strength discovery. Part 1 of 2,
continued overleaf. The HGS effect size (kg) of each known BMI locus is shown in models with and without BMI as a covariate.
BMI association statistics (effect size in kg/m2) are taken from GIANT analyses restricted to Europeans - as a result some of the
displayed BMI p-values fall short of genomewide significance. All models are adjusted for age and sex.
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HGS ( Height) HGS ( Height + BMI) BMI
rsID Chr Pos EA AA Beta SE p-value Beta SE p-value Beta SE p-value
rs492400 2 219349752 T C -0.018 0.026 0.490 -0.017 0.026 0.520 -0.016 0.003 4.17E-07
rs1441264 13 79580919 A G -0.014 0.027 0.610 -0.017 0.027 0.520 0.018 0.003 6.04E-08
rs9641123 7 93197732 G C 0.015 0.026 0.580 0.017 0.026 0.530 -0.019 0.004 5.00E-07
rs2112347 5 75015242 G T -0.022 0.027 0.410 -0.016 0.027 0.540 -0.026 0.003 6.19E-17
rs10938397 4 45182527 A G -0.023 0.026 0.390 -0.016 0.026 0.550 -0.040 0.003 3.21E-38
rs4256980 11 8673939 G C -0.012 0.027 0.660 -0.016 0.027 0.550 0.021 0.003 2.90E-11
rs11030104 11 27684517 A G 0.026 0.032 0.430 0.017 0.032 0.600 0.041 0.004 5.56E-28
rs12566985 1 75002193 G A 0.017 0.026 0.530 0.014 0.026 0.600 0.024 0.003 3.28E-15
rs16907751 8 81375457 C T 0.026 0.045 0.560 0.022 0.045 0.620 0.035 0.007 1.25E-07
rs13201877 6 137675541 A G 0.017 0.039 0.650 0.019 0.038 0.620 -0.023 0.004 2.35E-07
rs1516725 3 185824004 T C -0.024 0.038 0.520 -0.018 0.038 0.630 -0.045 0.005 1.89E-22
rs7243357 18 56883319 G T -0.021 0.034 0.540 -0.016 0.034 0.630 -0.022 0.004 3.86E-08
rs1016287 2 59305625 T C 0.018 0.028 0.530 0.013 0.028 0.640 0.023 0.003 2.25E-11
rs7715256 5 153537893 G T -0.008 0.026 0.750 -0.012 0.026 0.650 0.016 0.003 1.70E-07
rs11583200 1 50559820 C T -0.007 0.027 0.800 -0.011 0.027 0.670 0.018 0.003 1.48E-08
rs11727676 4 145659064 C T -0.017 0.044 0.690 -0.018 0.044 0.680 -0.036 0.006 2.55E-08
rs2176598 11 43864278 T C -0.007 0.030 0.830 -0.012 0.030 0.700 0.020 0.004 2.97E-08
rs9914578 17 2005136 G C 0.011 0.032 0.730 0.010 0.032 0.750 0.020 0.004 8.99E-08
rs2176040 2 227092802 G A 0.007 0.027 0.800 0.008 0.027 0.770 -0.014 0.003 6.06E-06
rs10968576 9 28414339 G A -0.001 0.028 0.980 -0.006 0.028 0.830 0.025 0.003 6.61E-14
rs12429545 13 54102206 G A 0.001 0.039 0.980 0.008 0.039 0.840 -0.033 0.005 1.09E-12
rs17001654 4 77129568 C G -0.008 0.035 0.820 -0.006 0.035 0.860 -0.031 0.005 7.76E-09
rs12401738 1 78446761 A G 0.008 0.027 0.780 0.004 0.027 0.870 0.021 0.003 1.15E-10
rs1808579 18 21104888 T C -0.002 0.026 0.940 0.003 0.026 0.900 -0.017 0.003 4.17E-08
rs13021737 2 632348 A G -0.009 0.035 0.800 0.004 0.035 0.910 -0.060 0.004 0
rs10132280 14 25928179 A C -0.007 0.029 0.810 -0.003 0.029 0.910 -0.023 0.003 1.14E-11
rs1000940 17 5283252 G A 0.000 0.028 0.990 -0.003 0.028 0.910 0.019 0.003 1.28E-08
rs1528435 2 181550962 T C 0.006 0.027 0.820 0.002 0.027 0.940 0.018 0.003 1.20E-08
rs12286929 11 115022404 G A 0.000 0.026 0.990 -0.002 0.026 0.940 0.022 0.003 1.31E-12
rs6091540 20 51087862 C T 0.003 0.029 0.930 -0.002 0.029 0.940 0.019 0.004 8.02E-08
rs7138803 12 50247468 G A -0.007 0.027 0.790 -0.001 0.027 0.970 -0.032 0.003 8.15E-24
rs3101336 1 72751185 T C -0.007 0.026 0.800 -0.001 0.026 0.980 -0.033 0.003 2.66E-26
rs12940622 17 78615571 A G -0.004 0.026 0.870 -0.001 0.026 0.980 -0.018 0.003 2.49E-09
rs2836754 21 40291740 C T 0.004 0.027 0.880 0.000 0.027 0.990 0.016 0.003 4.16E-07






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Haplotype Class Variable Effect (kg) Robust SE p-value
Inversion H2 (vs. H1) -0.165 0.036 3.85×10-6
α/β/γ Copy Number α -0.066 0.030 0.027
β 0.015 0.039 0.712
γ -0.039 0.023 0.092
Structural Haplotype H1.β1.γ1 Ref.
H1.β1.γ2 -0.035 0.053 0.508
H1.β1.γ3 -0.058 0.047 0.216
H1.β1.γ4 -0.576 0.293 0.049
H1.β2.γ1 0.029 0.041 0.480
H1.β3.γ1 -0.273 0.428 0.523
H2.α1.γ2 0.287 0.222 0.196
H2.α2.γ1 -1.579 1.793 0.379
H2.α2.γ2 -0.182 0.042 1.24×10-5
Supplementary Table 6: Association of common structural haplotypes at 17q21.31 with grip strength. Effect is additive, in kg
per additional CNV/allele/as otherwise specified, and is adjusted for age, sex, BMI, height and genotyping array. H2 denotes





Neoplasms All malignant neoplasms
excl. benign skin cancers






Alveolitis (fibrosing/not otherwise specified)
Respiratory Failure
Endocrine Type 1 Diabetes
























Lateral Epicondylitis (Tennis Elbow)
Cerebrovascular Stroke (inc Ischaemic and Haemorrhagic)





Vasculitis (inc Polymyalgia Rheumatica)
Polyarteritis Nodosa
Supplementary Table 7: Exclusion criteria for grip strength sensitivity analyses in UKB. T1D was defined using an centrally-
curated, adjudicated algorithm1 based on the convergence of multiple indicators to robustly discriminate diabetes cases using
the self-reported phenotype data of UKB. Cancers were defined on the basis of a prevalent cancer registration in the UK at the





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Gene Tissue Z-Score pMetaXcan Expression Variance nVariants Gripstrength Locus
Index rsID Gene
ACTG1 Skeletal Muscle -5.38 7.50E-08 0.042272 10 rs6565586 ACTG1
ARHGAP27 Basal Ganglia - Caudate -5.73 1.02E-08 0.0253439 7 rs80103986 KANSL1
ARHGDIB Cerebral Cortex 5.08 3.78E-07 0.083278 31 rs11614333 ERP27
ARL17A Basal Ganglia - Caudate -5.39 7.10E-08 0.1644262 16
Cerebral Cortex -5.19 2.16E-07 0.2059632 42
Basal Ganglia - NAcc. -5.06 4.29E-07 0.2553275 27
Hypothalamus -5.02 5.26E-07 0.1405813 22
Cerebellar Hemisphere -4.95 7.53E-07 0.296909 47
ASB8 Testis -5.51 3.49E-08 0.0594337 24
CHRDL2 Basal Ganglia - Caudate -4.95 7.56E-07 0.0231122 13 rs72979233 POLD3
CRHR1 Basal Ganglia - Putamen 5.37 7.74E-08 0.0155817 14 rs80103986 KANSL1
ERP27 Tibial Nerve 6.00 1.98E-09 0.0573961 28 rs11614333 ERP27
Whole Blood 5.91 3.45E-09 0.0250218 11
FMNL1 Cerebellum 5.04 4.74E-07 0.110669 24 rs80103986 KANSL1
GFAP Tibial Nerve 5.53 3.25E-08 0.0130075 12 rs80103986 KANSL1
H2AFJ Basal Ganglia - NAcc. 6.52 7.26E-11 0.0148962 10 rs11614333 ERP27
KIF1B Whole Blood -5.79 7.10E-09 0.0730446 50 rs6687430 PEX14
LRPPRC Hippocampus 5.96 2.54E-09 0.0973548 16 rs10186876 LRPPRC
Cerebral Cortex 5.62 1.90E-08 0.1034959 17
Testis 5.60 2.16E-08 0.1418592 9
Basal Ganglia - Putamen 5.55 2.85E-08 0.0752171 14
Basal Ganglia - NAcc. 5.44 5.43E-08 0.0865671 10
Cerebellum 5.42 6.12E-08 0.0328546 9
Tibial Nerve 5.27 1.34E-07 0.1818902 49
Whole Blood 5.25 1.48E-07 0.0399471 21
LRRC37A Cerebellum -5.52 3.35E-08 0.3104757 37
Hypothalamus -5.43 5.64E-08 0.4599563 47
Skeletal Muscle -5.30 1.19E-07 0.1516158 39
Basal Ganglia - Caudate -5.12 3.02E-07 0.2969325 49
Cerebellar Hemisphere -5.12 3.04E-07 0.286255 24
Hippocampus -5.12 3.10E-07 0.0723494 10
Whole Blood -5.11 3.21E-07 0.192233 77
Tibial Nerve -5.06 4.19E-07 0.3424756 53
LRRC37A2 Hippocampus -5.55 2.80E-08 0.1788016 20
Skeletal Muscle -5.49 3.92E-08 0.3461513 36
Cerebellar Hemisphere -5.47 4.49E-08 0.2523477 43
Basal Ganglia - Caudate -5.35 8.69E-08 0.2170825 30
Tibial Nerve -5.32 1.02E-07 0.3305588 58
Basal Ganglia - NAcc. -5.28 1.27E-07 0.3082167 42
Cerebellum -5.23 1.71E-07 0.4771353 33
Hypothalamus -5.22 1.79E-07 0.4074591 50
MAPT Cerebral Cortex 5.88 4.22E-09 0.0264987 5 rs80103986 KANSL1
Cerebellum 5.53 3.24E-08 0.1219373 14
Cerebellar Hemisphere 5.41 6.44E-08 0.1216889 22
MGP Tibial Nerve 6.31 2.75E-10 0.0481746 24 rs11614333 ERP27
PLEKHM1 Skeletal Muscle -5.45 5.02E-08 0.0301035 13 rs80103986 KANSL1
Testis 5.23 1.73E-07 0.0280989 16
Cerebellar Hemisphere 5.15 2.57E-07 0.2780433 29
Cerebellum 5.07 4.04E-07 0.3692071 42
RAET1G Testis -5.12 3.14E-07 0.024732 17
RP11-182J1.16 Skeletal Muscle 4.98 6.51E-07 0.0340662 11
SLC35E2B Tibial Nerve 5.37 8.09E-08 0.2740872 30
Skeletal Muscle 5.07 4.06E-07 0.3103245 18
Basal Ganglia - Caudate 5.01 5.34E-07 0.1644098 7
Testis 4.99 6.04E-07 0.3714615 50
Basal Ganglia - Nucleus accumbens 4.93 8.03E-07 0.2226097 25
SLIT1 Skeletal Muscle 5.35 8.72E-08 0.0591131 25
SPPL2C Cerebellar Hemisphere -5.13 2.96E-07 0.0302724 14
WDR73 Cerebellum 4.94 7.82E-07 0.0649431 29
ZNF641 Tibial Nerve -4.92 8.53E-07 0.051986 10
Supplementary Table 9: Imputed transcriptome association results for grip strength (MetaXcan) in biologically-relevant tissues.
Analyses were restricted to imputed expression levels in all brain tissues, transformed fibroblasts, skeletal muscle, tibial nerve,
testis and whole blood. Only protein-coding transcripts associated with gripstrength at statistical significance after Bonferroni

















































































































































































































































































































































































































































































































































Custom Set Genes (Entrez ID)
Myostatin-Activin Signalling through ActRIIA 10468; 3624; 2660; 92; 91; 7046; 4087; 4088;
4089; 207; 2308; 2309; 4303; 114907; 84676;
10891
Myostatin-Activin Signalling through ActRIIB 10468; 3624; 2660; 93; 91; 7046; 4087; 4088;
4089; 207; 2308; 2309; 4303; 114907; 84676;
10891
Monogenic muscular dystrophies 58; 825; 859; 1120; 1291; 1292; 1293; 1605;
1674; 1756; 1785; 2010; 2218; 2273; 3679;
3908; 4000; 5339; 6442; 6443; 6444; 6445;
7273; 7415; 8291; 8557; 8813; 8818; 9215;
9499; 9987; 10049; 10329; 10585; 11041;
22954; 23224; 23345; 23347; 23534; 26092;
29925; 29954; 54344; 55624; 57190; 60684;
79147; 79188; 79868; 84197; 84892; 148789;
203859; 284119; 729920; 100288687
Monogenic myopathies 58; 90; 178; 274; 859; 1073; 1272; 1410; 1674;
1785; 2027; 2273; 2318; 2548; 2632; 2660;
2992; 2997; 3920; 3939; 4534; 4607; 4620;
4625; 4703; 5213; 5224; 5230; 5236; 5255;
5339; 5837; 6261; 7072; 7138; 7169; 7170;
7273; 7415; 8106; 8291; 9200; 9499; 9531;
9782; 10020; 10290; 10324; 10616; 11155;
22954; 23479; 51422; 55958; 57190; 131377;
203547; 203859; 246329; 390594
Monogenic myopathies and dystrophies Myopathies + dystrophies combined and de-
duplicated




































































































































































































































































































































































































































































































































































































































































































































































rsID EA/AA CEU JPT ACB ASW OR LCI UCI log(OR) SElog(OR) P-value PHET
rs6565586 A/T 0.29 0.76 0.22 0.31 0.98 0.79 1.21 -0.023 0.111 0.8355 0.240
rs6687430 G/A 0.44 0.22 0.79 0.66 0.79 0.48 1.30 -0.235 0.252 0.3516 1.000
rs2288278 A/G 0.60 0.80 0.46 0.54 1.29 0.95 1.76 0.259 0.157 0.1001 0.490
rs2110927 C/T 0.31 0.16 0.68 0.53 0.98 0.82 1.18 -0.016 0.094 0.8627 0.325
rs4926611 C/T 0.67 0.51 0.14 0.22 1.11 0.81 1.53 0.105 0.162 0.5156 0.911
rs2273555 A/G 0.58 0.77 0.55 0.61 0.99 0.84 1.18 -0.008 0.087 0.9293 0.820
rs958685 A/C 0.55 0.64 0.54 0.53 0.98 0.81 1.19 -0.019 0.097 0.8448 0.460
rs11614333 C/T 0.65 0.88 0.68 0.61 0.80 0.67 0.95 -0.225 0.089 0.01167 0.097
rs10186876 A/G 0.33 0.95 0.78 0.81 0.98 0.79 1.21 -0.020 0.109 0.853 1.000
rs72762373 A/G 0.04 NA NA 0.01 0.60 0.27 1.34 -0.511 0.410 0.2128 1.000
rs34845616 A/G 0.29 0.21 0.04 0.08 1.01 0.64 1.58 0.006 0.229 0.9785 1.000
rs72979233 A/G 0.77 0.64 0.95 0.90 0.84 0.63 1.13 -0.174 0.150 0.2451 1.000
Supplementary Table 13: Effect of strength-associated variants from stage I plus II analyses with odds of elite athletic status
in combined analyses of four ethnic groups. Results are aligned to the grip strength-increasing effect allele (EA). OR, odds
ratio of athletic status; AA, alternate allele; UCI and LCI, upper and lower limit of 95% confidence interval of OR. Effect allele
frequencies (EAF) are provided for each ancestral sub-group in these analyses (European, Japanese, Jamaican and African
American) based on the most closely-matched 1000G ancestral population. CEU, Utah residents with Northern and Western
European ancestry; JPT, Japanese in Tokyo; ACB, African Caribbean in Barbados; ASW, African ancestry in South-western
United States. For the low-frequency variant rs72762373, NA denotes that the variant is monomorphic for the alternate allele in
a sub-population, and was omitted from analyses. Full details of contributing cohorts are provided in the Supplementary Note.
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Model Effect Allele Effect SE p-value
Additive - lookup in stage 1 grip strength GWAS results T -0.062 0.026 0.018
Dominant - linear regression in unrelated UKB participants T -0.062 0.045 0.168
Recessive - linear regression in unrelated UKB participants T -0.033 0.053 0.528


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Variant Beta SE Beta SE
SHBG - ln(nmol)/L
rs10454142 0.023 0.0044 -0.085 0.028
rs17496332 0.028 0.0041 0.004 0.027
rs2411984 0.033 0.0044 -0.050 0.028
rs293428 0.019 0.0042 0.003 0.029
rs3779195 0.28 0.0051 0.053 0.033
rs440837 0.028 0.0047 -0.051 0.032
rs7910927 0.048 0.0039 0.089 0.026
rs8023580 0.03 0.0044 0.017 0.029
DHEA-S - ln(µmol)/L
rs11761528 -0.16 0.01 0.073 0.046
rs2637125 -0.09 0.01 -0.032 0.036
rs7181230 0.05 0.01 -0.003 0.027
rs2497306 -0.04 0.01 -0.063 0.026
rs2185570 -0.06 0.01 -0.040 0.038
Fasting insulin - ln(pmol)/L
rs10195252 0.018 0.003 0.035 0.026
rs1167800 0.015 0.003 0.001 0.026
rs1530559 0.013 0.003 -0.102 0.027
rs17036328 0.014 0.005 0.015 0.040
rs2126259 0.031 0.005 0.037 0.043
rs2745353 0.015 0.003 0.065 0.026
rs2943645 0.016 0.003 0.007 0.027
rs3822072 0.010 0.003 0.049 0.026
rs459193 0.019 0.003 0.089 0.030
rs4846565 0.015 0.003 0.103 0.027
rs4865796 0.016 0.003 -0.048 0.028
rs6822892 0.010 0.003 0.037 0.028
rs6912327 0.015 0.005 0.036 0.032
rs731839 0.017 0.003 0.062 0.028
rs780094 0.022 0.003 0.009 0.027
rs7903146 0.022 0.004 0.049 0.029
rs860598 0.012 0.004 -0.112 0.036
rs974801 0.016 0.003 -0.038 0.027
Insulin resistance - ln(pmol)/L
rs731839 0.017 0.003 0.062 0.028
rs17036328 0.014 0.005 0.015 0.040
rs4865796 0.016 0.003 -0.048 0.028
rs10195252 0.018 0.003 0.035 0.026
rs459193 0.019 0.003 0.089 0.030
rs3822072 0.010 0.003 0.049 0.026
rs2943645 0.016 0.003 0.007 0.027
rs4846565 0.015 0.003 0.103 0.027
rs2745353 0.015 0.003 0.065 0.026
rs6822892 0.010 0.003 0.037 0.028
Supplementary Table 17: Variants applied in MR analyses to model hormonal phenotypes as causal exposures for grip strength.
Part 1 of 2, continued overleaf. Reference details for each score are provided in the main text. Betas are expressed in the units
specified for each exposure. Grip strength data are from stage I analyses in UKB.
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Exposure Grip Strength
Variant Beta SE Beta SE
Insulin secretion - SD 30-min insulin
rs10811661 0.083 0.029 0.076 0.034
rs10830963 0.076 0.025 -0.020 0.029
rs10946398 0.061 0.023 0.003 0.028
rs11603334 0.051 0.028 0.015 0.036
rs11605924 0.069 0.021 0.047 0.026
rs11672660 0.130 0.034 0.030 0.033
rs12686676 0.015 0.021 0.008 0.026
rs12779790 0.068 0.028 -0.035 0.034
rs13266634 0.041 0.024 0.053 0.028
rs174550 0.031 0.022 -0.009 0.027
rs4502156 0.050 0.022 0.006 0.026
rs4607517 0.032 0.033 0.004 0.034
rs5015480 0.061 0.021 0.058 0.026
rs5215 0.038 0.022 0.014 0.027
rs560887 0.047 0.023 -0.025 0.028
rs7903146 0.060 0.025 0.049 0.029
rs7957197 0.062 0.027 -0.058 0.033
rs933360 0.079 0.024 0.005 0.029
IGF-I - SD IGF-I
rs1065656 0.053 0.009 0.056 0.028
rs2153960 0.051 0.009 -0.043 0.029
rs509035 0.049 0.009 -0.005 0.028
rs700753 0.089 0.009 -0.009 0.027
rs780093 0.064 0.009 0.007 0.027
rs934073 0.051 0.009 0.005 0.028
rs978458 0.059 0.009 0.091 0.030
Supplementary Table 17: Variants applied in MR analyses to model hormonal phenotypes as causal exposures for grip strength






































































































































































































































































































































Phenotype Source r2 z-score p-value
Coronary Heart Disease CARDIoGRAMplusC4D -0.045 -0.006 0.362
Fat Mass Index Fenland + EPIC-Norfolk -0.128 -1.943 0.052
Lean Mass Index Fenland + EPIC-Norfolk 0.258 4.189 2.80E-05
Bone Mineral Density (Forearm) GEFOS 0.164 1.558 0.119
Bone Mineral Density (Femoral Neck) GEFOS 0.123 2.595 0.0095
Bone Mineral Density (Lumbar Spine) GEFOS 0.156 3.441 0.0006
Supplementary Table 19: Genetic correlations of grip strength with selected phenotypes. Correlations shown are with UKB














































































































































































































































































































































































































































































n 4325 5047 9372
Age (years) 48.9 (7.6) 48.9 (7.4) 48.9 (10.0)
Body Mass (kg) 86.2 (13.9) 71.2 (14.6) 78.1 (16.1)
Body Mass Index (kg/m2) 27.3 (4.0) 26.4 (5.2) 26.8 (4.7)
Fat Mass (kg) 25.4 (8.2) 27.4 (10.2) 26.5 (9.3)
Lean Mass (kg) 57.4 (6.8) 41.5 (5.3) 48.8 (10.0)
Relative Body Fat Mass (%) 29.0 (5.8) 37.5 (7.0) 33.5 (7.7)
Relative Lean Mass (%) 67.3 (5.7) 59.3 (6.7) 63.0 (7.4)
Breaths passing QC 20.8 (7.1) 23.7 (7.3) 22.3 (7.4)
Breaths failing QC 5.5 (4.3) 4.9 (4.3) 5.2 (4.3)
Resting VO2 (mL/kg/min) 3.33 (0.55) 3.06 (0.59) 3.18 (0.59)
Resting VCO2 (mL/kg/min) 3.03 (0.60) 2.84 (0.56) 2.92 (0.59)
RER 0.91 (0.07) 0.93 (0.07) 0.92 (0.07)
REE (kcal/24hr) 2008.5 (384.15) 1525.1 (336.40) 1748.17 (432.55)
REE (kcal/kg/24hr) 23.5 (3.91) 21.7 (4.23)
Supplementary Table 21: Univariate characteristics of derived REE and associated traits in Fenland. Unless specified, data are
mean (SD). DXA data are available for 9296 participants of the final 9372 passing all quality control stages for REE derivation.
Data shown for lean and fat masses reflect this figure.
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Beta SE p-value
Model 1 (n = 7,689)
Age (per 10-year increase) -320.18 19.83 1.01E-57
Sex (Males vs Females) 1859.63 29.44 <5.00E-300
BMI (kg/m2) 777.74 14.78 <5.00E-300
Model 2 (n = 7,689)
Age (per 10-year increase) -279.85 20.64 2.15E-41
Sex (Males vs Females) 1412.84 51.34 4.63E-159
Total LM (kg) 747.15 43.99 1.55E-63
Total FM (kg) 461.70 18.73 3.11E-129
Total BM (kg) -307.74 35.94 1.33E-17
Supplementary Table 22: Association of REE with basic anthropometric covariates. For each model, associations are cal-
culated in participants with complete data available for REE, genotyping, and all covariates. Betas and SEs are change in
REE (kJ/day) per SD increase in exposure, unless otherwise stated. Models include all variables shown as covariates, and are


























































































































































































































































































































































































































































































Gene Set Size GSEA
Source Gene Set Original Effective p-value FDR Enrich.
KEGG Citrate Cycle/TCA Cycle 32 27 2.18E-02 2.50E-01 1.71
GO TCA Cycle Enzyme Complex 11 11 3.40E-02 1.93E-01 2.00
Biocarta ETC Pathway 12 9 4.99E-02 1.62E-01 2.50
Reactome Glycolysis 29 24 1.20E-01 4.31E-01 1.50
GO Negative Regulation of Release of Cytochrome C from Mitochondria 17 16 1.87E-01 5.33E-01 1.50
Reactome Pyruvate Metabolism 19 16 1.90E-01 4.63E-01 1.50
GO Oxaloacetate Metabolic Process 11 11 2.84E-01 5.70E-01 1.33
GO Proton Transporting ATP Synthase Complex 22 22 2.97E-01 6.01E-01 1.17
Reactome TCA Cycle and Respiratory ET 141 109 3.81E-01 7.67E-01 1.07
GO Respiratory Chain Complex IV Assembly 18 17 4.25E-01 8.32E-01 1.25
KEGG Glycolysis Gluconeogenesis 62 54 4.90E-01 8.21E-01 1.00
GO Regulation of Release of Cytochrome C from Mitochondria 44 43 5.17E-01 7.86E-01 1.00
Reactome Respiratory ET: ATP Synthesis by Chemiosmotic Coupling and Heat Production by UCP 98 77 5.63E-01 7.65E-01 1.00
GO Hydrogen Peroxide Metabolic Process 30 24 5.76E-01 7.96E-01 1.00
KEGG Pyruvate Metabolism 40 38 6.40E-01 7.74E-01 0.90
Reactome Respiratory Electron Transport 79 61 6.97E-01 7.76E-01 0.93
Biocarta Glycolysis Pathway 10 9 7.06E-01 8.16E-01 1.00
GO Positive Regulation of Release of Cytochrome C from Mitochondria 28 28 7.32E-01 7.48E-01 0.86
GO Respiratory Chain 80 74 7.79E-01 8.14E-01 0.84
GO Mitochondrial ET: Ubiquinol to Cytochrome C 14 13 8.75E-01 8.25E-01 0.67
GO Electron Transport Chain 94 87 9.08E-01 8.80E-01 0.77
Supplementary Table 24: Enrichment of REE associations for selected respiratory pathways. Gene set size is expressed in
number of genes - effective size denotes the gene set used in analysis after filtering of the input set based on gene size and
proximity. Results are sorted by enrichment p-value. Enrich indicates the fold-enrichment of REE associations in this pathways,
based on permutation. FDR, permutation-based false discovery rate; ET, electron transport; TCA, tricarboxylic acid
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REEAS
Trait PMID rG SE p-value
Height 20881960 0.5747 0.1038 3.10E-08
BMI 20935630 0.7076 0.1336 1.18E-07
Waist Circumference 25673412 0.9296 0.1994 3.14E-06
Waist-to-hip Ratio 25673412 0.6594 0.1461 6.41E-06
Hip Circumference 25673412 0.834 0.1864 7.68E-06
Body Fat Percentage 26833246 0.3834 0.12 0.0014
HOMA-IR 20081858 0.5554 0.1895 0.0034
Fasting Insulin 22581228 0.3931 0.1569 0.0122
Type 2 Diabetes 22885922 0.274 0.1218 0.0244
Parental age at death 27015805 -0.3959 0.2068 0.0556
Maternal age at death 27015805 -0.3366 0.1876 0.0727
Fasting Pro-insulin 20081858 0.3617 0.2062 0.0794
HOMA-B 20081858 0.2847 0.1788 0.1114
Fasting Glucose 22581228 0.2115 0.1335 0.113
Amyotrophic Lateral Sclerosis 27455348 0.2004 0.2056 0.3299
Paternal age at death 27015805 -0.1464 0.1738 0.3995
Femoral Neck BMD 26367794 0.0864 0.1157 0.455
Coronary Artery Disease 26343387 0.0583 0.0815 0.4743
Lumbar Spine BMD 26367794 0.0794 0.1157 0.4927
Adiponectin 22479202 -0.0641 0.1873 0.7323
HbA1C 20858683 -0.0418 0.1492 0.7791
Parkinson’s disease 19915575 0.0314 0.1121 0.7792
Sitting height ratio 25865494 0.0366 0.1521 0.8099
Alzheimer’s disease 24162737 -0.0283 0.1608 0.8603
Forearm BMD 26367794 0.0278 0.2698 0.918
Supplementary Table 25: Genetic correlations of REE with selected anthropometric, ageing and cardiometabolic phenotypes.
PMID indicates original source of GWAS summary statistics for trait. BMD, bone mineral density; HOMA-IR, ; HOMA-B
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REEAS (kJ/24hr) REERES (kJ/24hr) BMIAS (kg/m2) BFPAS (%)
rsID Beta SE p-value Beta SE p-value Beta SE p-value Beta SE p-value n
rs3817334 -43.44 24.59 0.077 -73.72 21.05 4.65E-04 0.19 0.08 0.013 0.24 0.11 0.023 7689
rs9641123 -43.25 24.64 0.079 -51.88 21.1 0.014 0.07 0.08 0.402 0.12 0.11 0.238 7689
rs7138803 102.6 24.94 3.93E-05 49.93 21.39 0.02 0.31 0.08 8.08E-05 0.32 0.11 2.96E-03 7671
rs7599312 -50.99 27.85 0.067 -47.38 23.87 0.047 -0.02 0.09 0.817 -0.01 0.12 0.951 7686
rs12566985 48.84 24.47 0.046 41.41 20.96 0.048 0.05 0.08 0.495 -0.07 0.11 0.482 7689
rs9400239 52.07 26.83 0.052 44.84 22.99 0.051 0.04 0.08 0.637 -0.08 0.12 0.508 7689
rs17094222 -55.01 30.41 0.071 -50.47 26.05 0.053 -0.01 0.1 0.88 0.02 0.13 0.863 7689
rs1808579 -17.28 24.39 0.479 -39.45 20.89 0.059 0.14 0.08 0.079 0.32 0.1 2.62E-03 7689
rs1528435 58.52 24.88 0.019 37.95 21.31 0.075 0.13 0.08 0.092 0.16 0.11 0.146 7689
rs12286929 -9.67 24.12 0.688 -36.72 20.66 0.076 0.17 0.08 0.023 0.27 0.1 0.01 7689
rs6804842 51.82 24.67 0.036 32.44 21.13 0.125 0.12 0.08 0.127 0.15 0.11 0.144 7689
rs543874 74.07 30.05 0.014 36.49 25.75 0.157 0.24 0.09 0.013 0.18 0.13 0.165 7689
rs6477694 41.21 25.35 0.104 29.53 21.71 0.174 0.07 0.08 0.351 0.13 0.11 0.228 7689
rs7243357 53.24 31.86 0.095 36.77 27.29 0.178 0.09 0.1 0.381 0.15 0.14 0.27 7689
rs12401738 59.03 25.18 0.019 28.32 21.58 0.189 0.19 0.08 0.018 0.16 0.11 0.137 7689
rs1928295 -13.83 24.29 0.569 -25.55 20.8 0.219 0.07 0.08 0.356 0.04 0.1 0.702 7665
rs11165643 37.02 24.52 0.131 25.08 21.01 0.233 0.08 0.08 0.309 0.13 0.11 0.222 7689
rs11126666 9.62 27.68 0.728 -28.13 23.7 0.235 0.22 0.09 0.012 0.14 0.12 0.244 7647
rs7164727 -1.17 25.69 0.964 -25.84 22 0.24 0.16 0.08 0.054 0.13 0.11 0.23 7689
rs3888190 36.45 24.94 0.144 24.5 21.37 0.252 0.07 0.08 0.346 0.18 0.11 0.088 7689
rs2365389 -15.16 24.51 0.536 -22.81 21 0.277 0.05 0.08 0.559 0.21 0.11 0.048 7689
rs492400 -42.03 24.51 0.086 -22.49 21 0.284 -0.12 0.08 0.123 -0.17 0.11 0.097 7689
rs9540493 -4.45 24.46 0.855 -21.91 20.95 0.296 0.11 0.08 0.153 0.18 0.1 0.094 7655
rs758747 -1.2 28.03 0.966 -24.4 24.01 0.31 0.14 0.09 0.111 0.16 0.12 0.178 7689
rs10968576 41.38 25.93 0.111 21.96 22.22 0.323 0.11 0.08 0.194 0.09 0.11 0.43 7689
rs2121279 -45.6 36.77 0.215 -30.37 31.5 0.335 -0.09 0.12 0.423 -0.02 0.16 0.882 7689
GRS95 13.85 2.79 7.21E-07 -2.29 2.4 0.339 0.1 0.01 2.08E-29 0.11 0.01 2.21E-19 7689
rs11847697 -18.53 58.4 0.751 -46.82 50.02 0.349 0.15 0.18 0.404 -0.03 0.25 0.903 7689
rs13021737 72.4 31.82 0.023 25.43 27.26 0.351 0.28 0.1 5.26E-03 0.22 0.14 0.114 7689
rs1167827 59.3 24.84 0.017 19.58 21.28 0.358 0.25 0.08 1.44E-03 0.17 0.11 0.12 7689
rs6091540 11.85 26.58 0.656 -20.39 22.77 0.371 0.19 0.08 0.021 0.21 0.11 0.063 7689
rs17203016 -24.74 30.94 0.424 -22.35 26.5 0.399 -0.03 0.1 0.783 -0.05 0.13 0.734 7689
rs12429545 50.4 37.25 0.176 26.14 31.91 0.413 0.14 0.12 0.228 0.01 0.16 0.969 7689
rs977747 27.84 24.66 0.259 16.51 21.12 0.434 0.08 0.08 0.319 0.25 0.11 0.019 7689
rs3736485 9.29 24.42 0.704 16.25 20.91 0.437 -0.03 0.08 0.715 0.07 0.1 0.486 7689
rs2033732 -19.2 27.53 0.486 -18.28 23.59 0.438 -0.01 0.09 0.923 -0.1 0.12 0.419 7689
rs1000940 7.18 26.1 0.783 -17.23 22.36 0.441 0.15 0.08 0.075 0.2 0.11 0.068 7689
rs10733682 21.31 25.55 0.404 16.4 21.89 0.454 0.03 0.08 0.71 0.01 0.11 0.917 7689
rs4256980 -10.33 25.28 0.683 -15.94 21.65 0.462 0.04 0.08 0.628 0.2 0.11 0.069 7689
rs3101336 29.24 24.94 0.241 -14.63 21.37 0.494 0.27 0.08 5.33E-04 0.18 0.11 0.098 7689
rs12446632 -6.14 35.22 0.862 -20.55 30.17 0.496 0.09 0.11 0.415 -0.14 0.15 0.342 7689
rs1516725 25.97 35.31 0.462 -20.32 30.24 0.502 0.28 0.11 0.011 0.22 0.15 0.15 7689
rs1441264 -17.89 25.01 0.474 -14.37 21.42 0.502 -0.02 0.08 0.817 -0.13 0.11 0.214 7689
rs7903146 -14.22 26.69 0.594 -14.88 22.86 0.515 0 0.08 0.995 0.02 0.11 0.865 7689
rs4787491 23.99 24.42 0.326 13.6 20.92 0.516 0.07 0.08 0.389 0.03 0.1 0.761 7689
rs11030104 41.81 29.65 0.159 16.31 25.4 0.521 0.16 0.09 0.084 0.17 0.13 0.174 7671
rs10182181 27.73 24.51 0.258 -13.01 20.99 0.535 0.25 0.08 1.35E-03 0.31 0.11 3.35E-03 7689
rs2245368 1.85 32.45 0.954 -15.22 27.79 0.584 0.08 0.1 0.407 -0.08 0.14 0.546 7689
rs16951275 12.02 28.65 0.675 13.42 24.54 0.585 -0.01 0.09 0.915 -0.03 0.12 0.83 7689
rs16851483 41.61 47.24 0.378 -21.76 40.46 0.591 0.4 0.15 8.03E-03 0.55 0.2 6.50E-03 7689
Supplementary Table 26: Association of 95 known BMI variants with REE in the Fenland cohort. Part 1 of 2, continued overleaf.
Effect shown is additive per BMI-increasing allele based on GIANT consortium data - effect size for BMI shown here may be
negative due to lack of power. Variants are sorted by p-value of association with REERES. GRS95 denotes the additive effect of
all 95 variants combined into a single dosage score. BMI and BFP are residualised for age and sex. REE is residualised for age,
sex, OGTT and technical parameters (see main text); REERES additionally residualised for BMI.
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REEAS (kJ/24hr) REERES (kJ/24hr) BMIAS (kg/m2) BFPAS (%)
rsID Beta SE p-value Beta SE p-value Beta SE p-value Beta SE p-value n
rs13078960 14.54 30.27 0.631 -13.78 25.93 0.595 0.18 0.1 0.062 0.2 0.13 0.132 7689
rs2080454 40.56 25.08 0.106 10.91 21.49 0.612 0.19 0.08 0.017 0.29 0.11 7.07E-03 7689
rs11583200 8.82 24.55 0.719 -10.64 21.03 0.613 0.12 0.08 0.125 0.23 0.11 0.029 7689
rs29941 2.95 26.24 0.911 -11.3 22.48 0.615 0.09 0.08 0.291 0.12 0.11 0.285 7689
rs7141420 2.61 24.34 0.915 -10.46 20.85 0.616 0.08 0.08 0.307 0.17 0.1 0.094 7687
rs2650492 3.51 27.55 0.898 -11.43 23.6 0.628 0.1 0.09 0.266 0.22 0.12 0.063 7689
rs1460676 -18.17 32.72 0.579 -12.6 28.03 0.653 -0.05 0.1 0.658 -0.04 0.14 0.802 7689
rs12940622 29.43 24.24 0.225 8.54 20.77 0.681 0.14 0.08 0.074 0.09 0.1 0.396 7689
rs7899106 -0.73 53.61 0.989 -18.27 45.92 0.691 0.11 0.17 0.512 -0.11 0.23 0.634 7687
rs2176040 3.08 25.06 0.902 -8.2 21.47 0.703 0.06 0.08 0.412 0.21 0.11 0.051 7689
rs6567160 50.36 28.37 0.076 -9.08 24.31 0.709 0.36 0.09 5.37E-05 0.36 0.12 2.96E-03 7689
rs2207139 33.13 32.53 0.309 -9.5 27.87 0.733 0.27 0.1 8.82E-03 0.22 0.14 0.119 7689
rs17024393 56.59 78.53 0.471 -22.72 67.27 0.736 0.49 0.25 0.05 0.74 0.34 0.027 7689
rs12885454 9.8 25.12 0.696 -7.19 21.52 0.738 0.1 0.08 0.2 0.22 0.11 0.043 7689
rs13191362 -3.03 36.63 0.934 10.22 31.38 0.745 -0.07 0.12 0.518 -0.16 0.16 0.302 7689
rs205262 40.19 27.17 0.139 6.58 23.28 0.777 0.2 0.09 0.017 0.15 0.12 0.21 7689
rs2836754 52.4 25.23 0.038 6.05 21.62 0.779 0.29 0.08 3.12E-04 0.28 0.11 0.011 7689
rs2176598 -1.22 28.43 0.966 6.46 24.35 0.791 -0.04 0.09 0.685 -0.05 0.12 0.684 7689
rs3849570 -29.99 25.33 0.236 -5.74 21.7 0.791 -0.14 0.08 0.072 -0.14 0.11 0.205 7689
rs16907751 54.85 40.83 0.179 8.8 34.98 0.801 0.28 0.13 0.032 0.19 0.18 0.277 7689
rs13201877 -17.21 35.82 0.631 -7.51 30.69 0.807 -0.05 0.11 0.654 -0.18 0.15 0.247 7689
rs9914578 4.21 29.88 0.888 6.2 25.59 0.809 -0.01 0.09 0.941 0.12 0.13 0.369 7689
rs11727676 18.35 41.71 0.66 -8.62 35.73 0.809 0.17 0.13 0.203 0.14 0.18 0.422 7689
rs11057405 41.06 40.38 0.309 7.9 34.59 0.819 0.21 0.13 0.104 0.26 0.17 0.128 7689
rs6465468 -8.44 26.84 0.753 5.14 23 0.823 -0.08 0.08 0.325 -0.06 0.12 0.629 7689
rs2112347 20.27 25.15 0.42 4.38 21.55 0.839 0.09 0.08 0.275 -0.03 0.11 0.747 7689
rs17001654 18.82 34.16 0.582 5.71 29.27 0.845 0.08 0.11 0.48 0.13 0.15 0.393 7689
rs13107325 50.57 46.19 0.274 7.71 39.57 0.846 0.26 0.15 0.073 0.09 0.2 0.647 7689
rs17724992 0.63 28.2 0.982 4.53 24.15 0.851 -0.03 0.09 0.748 -0.03 0.12 0.794 7689
rs10938397 27.4 24.65 0.266 -3.93 21.11 0.852 0.2 0.08 0.011 0.25 0.11 0.017 7689
rs17405819 9.79 26.67 0.714 -4.15 22.84 0.856 0.1 0.08 0.224 0.14 0.11 0.229 7689
rs2820292 -6.7 24.31 0.783 -3.66 20.83 0.861 -0.03 0.08 0.723 0.04 0.1 0.681 7689
rs9581854 -14.48 30.83 0.639 -4.51 26.41 0.864 -0.07 0.1 0.498 -0.12 0.13 0.371 7689
rs2033529 -54.31 65.47 0.407 -9.15 54.71 0.867 -0.27 0.23 0.249 -0.18 0.31 0.563 979
rs9925964 19.89 24.67 0.42 -2.49 21.13 0.906 0.14 0.08 0.074 0.27 0.11 0.011 7689
rs2287019 32.32 32.38 0.318 3.19 27.74 0.908 0.17 0.1 0.102 0.06 0.14 0.688 7689
rs2075650 24.08 36.07 0.504 3.36 30.9 0.913 0.12 0.11 0.288 0.1 0.15 0.532 7689
rs1558902 48.74 24.38 0.046 -2.14 20.89 0.918 0.3 0.08 7.95e-05 0.4 0.1 1.28E-04 7689
rs7715256 19.13 24.16 0.429 1.87 20.7 0.928 0.09 0.08 0.229 0.09 0.1 0.399 7689
rs4740619 -0.7 24.36 0.977 1.79 20.87 0.932 -0.01 0.08 0.877 0 0.1 0.991 7689
rs11688816 22.88 24.23 0.345 -1.63 20.75 0.937 0.14 0.08 0.061 0.12 0.1 0.249 7689
rs3810291 -3.8 25.85 0.883 -0.97 22.15 0.965 -0.01 0.08 0.855 -0.09 0.11 0.42 7689
rs7239883 23.6 24.88 0.343 0.71 21.32 0.974 0.13 0.08 0.089 0.13 0.11 0.233 7689
rs11191560 36.74 43.41 0.397 1 37.19 0.978 0.22 0.14 0.114 -0.06 0.19 0.736 7680
rs10132280 -0.04 26.53 0.999 0.38 22.73 0.987 0 0.08 0.993 -0.12 0.11 0.299 7689
rs9374842 25.11 28.5 0.378 -0.27 24.41 0.991 0.14 0.09 0.113 0.1 0.12 0.418 7689
rs1016287 19.61 26.48 0.459 0.19 22.68 0.993 0.12 0.08 0.166 0.09 0.11 0.44 7689
Supplementary Table 26: Association of 95 known BMI variants with REE in the Fenland cohort. Part 2 of 2.
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Bottom 5% mLRR-Y Top 5% mLRR-Y
rsID Chr. Pos. EA AA log(OR) SE p-value log(OR) SE p-value
rs1122138 14 96180242 C A 0.0417 0.0050 9.60E-17 -0.0083 0.0050 9.40E-02
rs17758695 18 60920854 C T 0.0576 0.0109 1.40E-07 -0.0385 0.0105 2.60E-04
rs59633341 3 150018880 D I 0.0334 0.0048 2.70E-12 0.0025 0.0049 6.10E-01
rs78378222 17 7571752 T G -0.0856 0.0161 1.10E-07 0.0205 0.0177 2.50E-01
rs2736609 1 156202640 C T -0.0196 0.0037 9.70E-08 0.0014 0.0038 7.10E-01
rs13191948 6 109634599 C T 0.0189 0.0036 1.60E-07 -0.0069 0.0037 5.90E-02
rs35091702 8 30279470 I D -0.0188 0.0041 4.20E-06 0.0085 0.0041 4.00E-02
rs4721217 7 1973579 C T -0.0185 0.0036 3.20E-07 0.0047 0.0037 2.00E-01
rs137952017 14 101176090 D I 0.0193 0.0052 1.90E-04 -0.0135 0.0052 9.30E-03
rs56084922 5 111061883 A G -0.0322 0.0067 1.50E-06 0.0099 0.0070 1.60E-01
rs60084722 20 30355738 I D 0.0221 0.0045 1.20E-06 -0.0118 0.0046 1.00E-02
rs381500 6 164478388 C A 0.0188 0.0036 1.80E-07 -0.0036 0.0037 3.20E-01
rs12448368 16 81044947 T C -0.0215 0.0053 5.00E-05 0.0036 0.0054 5.10E-01
rs4754301 11 108048541 G A -0.0163 0.0036 5.20E-06 0.0060 0.0036 9.80E-02
rs77522818 17 47817373 A T 0.0419 0.0091 3.60E-06 -0.0174 0.0089 5.10E-02
rs11082396 18 42080720 T C -0.0280 0.0052 7.60E-08 0.0140 0.0054 9.50E-03
rs13088318 3 101242751 A G -0.0193 0.0038 2.60E-07 0.0058 0.0039 1.30E-01
rs10687116 13 41678081 D I -0.0152 0.0045 8.10E-04 0.0080 0.0046 7.90E-02
rs115854006 3 48388170 C T 0.0394 0.0106 1.90E-04 -0.0213 0.0104 4.20E-02
Supplementary Table 27: Effect of the 16 mLOY variants on dichotomised mLRR-Y. Effects are shown for the topmost and
lowermost 5% of participants ranked by mLRR-Y, by comparison to the median 25% in each case. Insertion-deletion variants
are coded I/D. Only two variants reach statistical significance at p≤5×10-8in these dichotomised analyses (highlighted red),
illustrating the increased statistical power of considering mLRR-Y as a continuous trait in discovery analyses
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CpG Chr. Pos. Effect SE T -value p-value Nearest Gene GWAS Locus
cg24405270 7 141401010 -0.0421 0.0041 -10.17 2.73E-24 KIAA1147
cg06010724 5 79911547 0.0350 0.0042 8.24 2.22E-16 DHFR
cg24718722 10 129536818 0.0350 0.0044 8.01 1.11E-15 FOXI2
cg19509778 10 129537308 0.0346 0.0043 8.02 1.11E-15 FOXI2
cg07823670 1 35222618 0.0328 0.0046 7.20 6.04E-13 GJB5
cg07546011 2 233274509 0.0308 0.0043 7.13 1.03E-12 ALPPL2
cg02317313 12 122235206 0.0306 0.0045 6.82 8.79E-12 LOC338799
cg00691598 8 1810526 0.0344 0.0050 6.82 9.00E-12 ARHGEF10
cg01788994 4 96469264 -0.0288 0.0043 -6.63 3.30E-11 UNC5C
cg07159847 12 58122341 0.0285 0.0045 6.37 1.90E-10 AGAP2
cg11294269 12 132685428 0.0275 0.0044 6.24 4.24E-10 GALNT9
cg22585988 1 161059327 0.0273 0.0044 6.15 7.59E-10 PVRL4
cg24299740 11 134252804 0.0266 0.0044 6.10 1.06E-09 B3GAT1
cg05304393 16 1545405 0.0287 0.0047 6.08 1.24E-09 TELO2
cg08634229 6 169326603 0.0266 0.0044 6.05 1.48E-09 SMOC2
cg02307597 19 17402942 0.0291 0.0048 6.03 1.65E-09 ABHD8
cg25095973 10 48413850 0.0262 0.0044 5.96 2.51E-09 GDF2
cg13935577 12 107974897 0.0265 0.0045 5.96 2.57E-09 BTBD11
cg05796223 16 21532721 0.0273 0.0046 5.94 2.89E-09 SLC7A5P2
cg24843003 19 1409547 0.0280 0.0047 5.92 3.28E-09 DAZAP1
cg01303141 17 77952109 0.0262 0.0045 5.88 4.19E-09 TBC1D16
cg21468274 17 7339835 0.0255 0.0044 5.80 6.73E-09 TMEM102 TP53
cg20442078 2 27531360 0.0253 0.0044 5.75 8.75E-09 UCN
cg26315984 1 173176501 -0.0247 0.0044 -5.62 1.89E-08 TNFSF4
cg09911083 17 7754956 0.0314 0.0056 5.61 2.02E-08 KDM6B TP53
cg00328227 1 109204325 0.0274 0.0049 5.60 2.18E-08 HENMT1
cg13249146 12 132887349 0.0245 0.0044 5.58 2.39E-08 GALNT9
cg00317577 15 83239908 0.0297 0.0053 5.58 2.39E-08 CPEB1
cg03339609 19 34662636 0.0279 0.0050 5.54 2.98E-08 LSM14A
cg14644418 10 129536661 0.0242 0.0044 5.51 3.67E-08 FOXI2
cg20116579 17 7288001 0.0244 0.0044 5.50 3.81E-08 TNK1 TP53
cg06783429 7 127673038 0.0243 0.0044 5.48 4.24E-08 SND1
cg05726109 22 19709755 0.0243 0.0044 5.47 4.55E-08 SEPT5
cg16572910 1 43880657 0.0274 0.0051 5.40 6.48E-08 SZT2
cg14782678 17 7339721 0.0237 0.0044 5.39 7.23E-08 TMEM102 TP53
cg27529647 1 151300868 0.0240 0.0045 5.37 7.69E-08 PI4KB
Supplementary Table 28: Differentially-methylated CpG positions associated with mLRR-Y. Effect shown is change in mLRR-Y
per SD increase in methylation at the specified CpG. All CpGs are physically independent of GWAS signals for mLRR-Y, with the
exception of the four indicated sites falling within a 1mB window of TP53
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DMP cis-meQTLs Association with mLRR-Y (UKB)
CpG Chr. Pos. rsID Pos All. Z -score p-value EAF Effect SE p-value
cg00317577 15 83239908 rs185018922 83183986 A/C 4.39 1.12E-05 0.935 0.002 0.0007 5.40E-03
rs12438312 83363323 G/A 31.1 2.41E-212 0.412 0.000 0.0004 2.60E-01
rs28664062 83414429 C/T -8.54 1.37E-17 0.839 0.000 0.0005 5.10E-01
rs66500181 83459370 C/T -4.74 2.13E-06 0.530 0.000 0.0004 7.20E-01
rs140228545 83030117 G/A -5.91 3.33E-09
cg00328227 1 109204325 rs17025036 109150720 T/C 15.34 3.95E-53 0.935 -0.001 0.0007 4.20E-02
rs144231308 109200742 C/T -5.88 4.15E-09 0.918 0.000 0.0006 5.60E-01
cg01303141 17 77952109 rs73423941 77943468 T/C 4.41 1.05E-05 0.892 -0.001 0.0006 1.70E-01
rs3169601 77909438 C/T -9.95 2.44E-23 0.697 0.000 0.0004 5.80E-01
rs1542102 78003406 C/G 5.28 1.27E-07 0.792 0.000 0.0004 7.80E-01
rs1561812 78061027 C/T -4.16 3.20E-05 0.412 0.000 0.0004 9.80E-01
cg02307597 19 17402942 rs2288544 17337025 T/C -4.72 2.39E-06 0.778 0.000 0.0004 9.10E-01
cg02317313 12 122235206 rs2515729 122279333 T/A -4.6 4.14E-06 0.212 0.001 0.0004 1.80E-01
rs1168668 122227451 C/G 9.64 5.25E-22 0.189 0.000 0.0004 4.90E-01
cg03339609 19 34662636 rs872236 34685617 G/C -17.69 5.41E-70 0.805 0.001 0.0004 3.80E-02
rs74401830 34711072 A/G 8.82 1.12E-18 0.670 0.000 0.0004 2.50E-01
cg05726109 22 19709755 rs9680714 19571194 T/C -4.17 3.00E-05 0.860 0.000 0.0005 6.00E-01
cg06783429 7 127673038 rs7809182 127521056 G/C 9.36 7.77E-21 0.703 0.000 0.0004 7.90E-01
cg07159847 12 58122341 rs4760169 58118847 C/T -10.74 6.82E-27 0.870 0.000 0.0005 3.90E-01
rs7965287 58188696 C/G 5.92 3.26E-09 0.667 0.000 0.0004 7.10E-01
cg13935577 12 107974897 rs61648172 107813364 T/C 5.57 2.60E-08 0.924 0.002 0.0007 1.50E-02
rs7138971 107724891 T/G -20.6 2.98E-94 0.724 -0.001 0.0004 2.70E-02
rs6539329 107786705 G/A -5.13 2.92E-07 0.452 0.000 0.0003 2.40E-01
rs856887 107725814 G/A 8.62 6.71E-18 0.226 0.000 0.0004 4.50E-01
cg14644418 10 129536661 rs1926181 129586689 A/C -4.17 3.06E-05 0.203 0.001 0.0004 2.40E-01
rs77244569 129535455 A/G -19.75 8.82E-87 0.868 0.000 0.0005 9.90E-01
cg14782678 17 7339721 rs35894069 7395176 A/G 6.12 9.36E-10 0.640 0.000 0.0004 2.80E-01
rs117208279 7337862 A/G -28.31 2.32E-176 0.927 0.000 0.0007 5.90E-01
rs111269607 7367810 A/G 5.31 1.12E-07 0.925 0.000 0.0007 6.90E-01
cg20116579 17 7288001 rs7208523 7288228 T/C -11.57 5.57E-31 0.886 -0.002 0.0006 8.80E-04
rs60684900 7264760 T/C -5 5.71E-07 0.901 -0.001 0.0007 1.60E-01
rs114576150 7307950 G/T -4.38 1.18E-05 0.908 0.001 0.0006 2.80E-01
cg20442078 2 27531360 rs72817542 27526681 G/C -3.94 8.21E-05 0.792 0.000 0.0004 3.80E-01
rs61737373 27423913 A/G 5.12 2.98E-07 0.943 0.001 0.0007 4.90E-01
cg21468274 17 7339835 rs35894069 7395176 A/G 6.9 5.28E-12 0.640 0.000 0.0004 2.80E-01
rs4796305 7336055 G/T 5.45 5.02E-08 0.915 0.000 0.0006 4.80E-01
rs34662267 7333058 A/C -27.66 1.99E-168 0.927 0.000 0.0007 5.80E-01
cg22585988 1 161059327 rs11577230 161053644 T/C -5.6 2.17E-08 0.886 0.001 0.0005 2.00E-01
cg24299740 11 134252804 rs10894808 134256805 T/C -4.43 9.55E-06 0.874 0.001 0.0005 1.70E-01
cg24718722 10 129536818 rs12777108 129632527 G/A 6.19 5.88E-10 0.832 0.000 0.0005 5.20E-01
rs72843197 129590057 C/G 4.88 1.06E-06 0.814 0.000 0.0005 7.60E-01
rs72843150 129535239 T/C -24.75 3.49E-135 0.868 0.000 0.0005 9.70E-01
cg24843003 19 1409547 rs11881021 1441600 C/T -6.54 6.18E-11 0.697 -0.001 0.0004 1.70E-01
cg27529647 1 151300868 rs11204798 151273726 C/G -7.7 1.38E-14 0.233 0.001 0.0004 3.80E-02
rs34834099 151502427 T/C 9.9 4.05E-23 0.933 -0.001 0.0007 7.30E-02
rs6695344 151178491 G/A 9.64 5.57E-22 0.369 0.001 0.0004 1.40E-01
rs3811402 151119745 C/G -6.05 1.49E-09 0.920 0.001 0.0006 1.60E-01
rs3828054 151512895 G/A 3.96 7.57E-05 0.881 0.000 0.0005 8.60E-01
rs76061334 151182876 T/C -19.6 1.67E-85 0.891 0.000 0.0006 9.30E-01
Supplementary Table 29: cis-meQTLs for mLRR-Y differentially-methylated positions, with corresponding mLRR-Y association
statistics. Z -score reflects the direction and magnitude at which the meQTL effect allele is associated with methylation of the
CpG. For mLRR-Y, Effect is change in mLRR-Y per meQTL effect allele.
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Published PCa Risk LociA Lookup in mLOY (UKB)
rsID Chr. Pos. EA AA OR 95% CI GeneB EAF EffectC SE p-value
rs16901979 8 128124916 A C 1.79 (1.36âĂŞ2.34) 0.034 -0.0002 0.0010 0.830
rs1447295 8 128485038 A C 1.62 0.103 0.0001 0.0006 0.800
rs817826 9 110156300 C T 1.41 (1.29, 1.54) RAD23B-KLF4 0.146 -0.0006 0.0005 0.260
rs10486567 7 27976563 A G 0.74 (0.66, 0.83) JAZF1 0.234 0.0002 0.0004 0.580
rs12621278 2 173311553 A G 0.75 (0.70, 0.80) ITGA6 0.937 0.0004 0.0007 0.550
rs103294 19 54797848 C T 1.28 (1.21, 1.36) LILRA3 0.774 -0.0001 0.0004 0.900
rs11649743 17 36074979 G A 1.28 (1.07, 1.52) HNF1B 0.813 -0.0002 0.0005 0.630
rs1571801 9 124427373 A C 1.27 (1.10, 1.48) DAB21P 0.269 0.0000 0.0004 0.940
rs6983267 8 128413305 G T 1.26 (1.13, 1.41) 0.520 0.0001 0.0003 0.760
rs12653946 5 1895829 T C 1.26 (1.20, 1.33) IRX4 0.418 0.0001 0.0004 0.840
rs10993994 10 51549496 T C 1.25 (1.17, 1.34) MSMB 0.392 0.0003 0.0004 0.330
rs7127900 11 2233574 A G 1.22 (1.17, 1.27) 0.187 -0.0002 0.0004 0.600
rs4430796 17 36098040 A G 1.22 (1.15, 1.30) HNF1B 0.519 0.0000 0.0003 0.950
rs339331 6 117210052 T C 1.22 (1.15, 1.28) RFX6 0.693 -0.0001 0.0004 0.840
rs2735839 19 51364623 G A 0.83 (0.75, 0.91) KLK2/KLK3 0.854 0.0001 0.0005 0.910
rs2055109 3 87467332 C T 1.2 (1.13, 1.29) 0.243 -0.0001 0.0004 0.780
rs1859962 17 69108753 G T 1.2 (1.14, 1.27) 0.465 0.0001 0.0003 0.820
rs4962416 10 126696872 C T 1.2 (1.07, 1.34) CTBP2 0.289 0.0004 0.0004 0.290
rs7931342 11 68994497 G T 0.84 (0.79, 0.90) 0.511 -0.0004 0.0003 0.270
rs2660753 3 87110674 T C 1.18 (1.06, 1.31) 0.096 0.0001 0.0006 0.880
rs636291 1 10556097 A G 1.18 (1.12-1.24) PEX14 0.672 -0.0003 0.0004 0.410
rs1512268 8 23526463 A G 1.18 (1.14, 1.22) NKX3.1 0.584 -0.0001 0.0004 0.790
rs9600079 13 73728139 T G 1.18 (1.12, 1.24) 0.448 0.0001 0.0003 0.850
rs9364554 6 160833664 T C 1.17 (1.08, 1.26) SLC22A3 0.307 0.0001 0.0004 0.860
rs902774 12 53273904 A G 1.17 (1.11, 1.24) KRT8 0.144 -0.0004 0.0005 0.380
rs5759167 22 43500212 G T 0.86 (0.83, 0.88) BIL/TTLL1 0.504 -0.0003 0.0003 0.410
rs1938781 11 58915110 C T 1.16 (1.11, 1.21) FAM111A 0.210 0.0002 0.0004 0.570
rs2252004 10 122844709 G T 1.16 (1.10, 1.22) 0.091 0.0005 0.0006 0.400
rs1983891 6 41536427 T C 1.15 (1.09, 1.21) FOXP4 0.280 0.0004 0.0004 0.350
rs13385191 2 20888265 G A 1.15 (1.10, 1.21) C2orf43 0.232 -0.0001 0.0004 0.770
rs721048 2 63131731 A G 1.15 (1.10, 1.21) EHBP1 0.198 0.0005 0.0004 0.200
rs11650494 17 47345186 A G 1.15 (1.09, 1.22) SPOP,HOXB13 0.087 0.0006 0.0006 0.310
rs10086908 8 128011937 T C 0.87 (0.81, 0.94) 0.704 0.0003 0.0004 0.500
rs2242652 5 1280028 G A 0.87 (0.84, 0.90) TERT 0.805 0.0000 0.0004 0.990
rs2292884 2 238443226 G A 1.14 (1.09, 1.19) MLPH 0.254 0.0004 0.0004 0.320
rs76934034 10 46082985 T C 1.14 (1.10, 1.18) MARCH8 0.906 0.0003 0.0006 0.590
rs80130819 12 48419618 A C 1.13 (1.08, 1.17) RP1-228P16.4 0.920 -0.0018 0.0006 0.004
rs12480328 20 49527922 T C 1.13 (1.08, 1.17) ADNP 0.927 -0.0004 0.0007 0.580
rs8008270 14 53372330 G A 0.89 (0.86, 0.93) FERMT2 0.816 0.0001 0.0004 0.820
rs6062509 20 62362563 A C 0.89 (0.66, 0.92) ZGPAT 0.673 0.0000 0.0004 0.960
rs1933488 6 153441079 A G 0.89 (0.87, 0.92) RSG17 0.597 -0.0004 0.0004 0.320
rs11672691 19 41985587 A G 1.12 (1.03, 1.21) 0.251 -0.0003 0.0004 0.440
rs6465657 7 97816327 C T 1.12 (1.05, 1.20) LMTK2 0.465 -0.0002 0.0003 0.550
rs8102476 19 38735613 C T 1.12 (1.08, 1.15) 0.535 0.0005 0.0003 0.150
rs10934853 3 128038373 A C 1.12 (1.08, 1.16) EEFSEC 0.269 -0.0002 0.0004 0.690
rs3771570 2 242382864 A G 1.12 (1.08, 1.17) FARP2 0.163 -0.0001 0.0005 0.870
rs10936632 3 170130102 A C 0.9 (0.88, 0.93) CLDN11/SKIL 0.521 0.0008 0.0003 0.027
rs620861 8 128335673 C T 0.9 (0.84, 0.96) 0.365 -0.0006 0.0004 0.120
rs17021918 4 95562877 C T 0.9 (0.87, 0.93) PDLIM5 0.652 -0.0005 0.0004 0.150
rs12155172 7 20994491 A G 1.11 (1.07, 1.15) SP8 0.220 0.0001 0.0004 0.880
rs11135910 8 25892142 A G 1.11 (1.07, 1.16) EBF2 0.170 -0.0006 0.0005 0.160
rs684232 17 618965 G A 1.1 (1.07, 1.14) VPS53,FAM57A 0.356 0.0004 0.0004 0.260
rs17599629 1 150658287 G A 1.1 (1.07, 1.13) GOLPH3L 0.235 -0.0008 0.0004 0.038
rs17694493 9 22041998 G C 1.1 (1.06, 1.13) CDKN2B-AS1 0.136 -0.0004 0.0005 0.390
rs4245739 1 204518842 A C 0.91 (0.88, 0.95) MDM4,PIK3C2B 0.723 -0.0005 0.0004 0.230
rs1894292 4 74349158 G A 0.91 (0.89, 0.94) AFM,RASSF6 0.512 0.0002 0.0003 0.630
rs11568818 11 102401661 A G 0.91 (0.88, 0.94) MMP7 0.454 0.0001 0.0003 0.800
rs7611694 3 113275624 A C 0.91 (0.88, 0.93) SIDT1 0.597 -0.0008 0.0004 0.018
rs7679673 4 106061534 C A 0.91 (0.88, 0.94) TET2 0.629 0.0007 0.0004 0.063
rs3850699 10 104414221 A G 0.91 (0.89, 0.94) TRIM8 0.711 -0.0001 0.0004 0.830
rs7153648 14 61122526 C G 1.09 (1.04, 1.13) SIX1 0.087 0.0001 0.0006 0.910
rs7141529 14 69126744 G A 1.09 (1.06, 1.12) RAD51L1 0.503 0.0002 0.0003 0.590
Supplementary Table 30: Effect of published autosomal risk loci for prostate cancer on mLOY. Part 1 of 2, continued overleaf.
A Source detailed in main chapter. B Nearest gene. C Change in mLRR-Y per additional prostate cancer EA (risk-increasing).
PCa, prostate cancer excluding benign prostate hyperplasia. Six PCa risk loci falling on the X-chromosome, and three autosomal
variants with unacceptable imputation quality, are omitted from this look-up.
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Published PCa Risk Loci Lookup in mLOY (UKB)
rsID Chr. Pos. EA AA OR 95% CI GeneB EAF EffectC SE p-value
rs10009409 4 73855253 T C 1.09 (1.06, 1.12) COX18 0.289 -0.0002 0.0004 0.680
rs2238776 22 19757892 G A 1.09 (1.06, 1.12) TBX1 0.801 0.0000 0.0004 0.970
rs10187424 2 85794297 A G 0.92 (0.89, 0.94) GGCX/VAMP8 0.428 -0.0006 0.0003 0.066
rs7241993 18 76773973 G A 0.92 (0.89, 0.95) SALL3 0.306 0.0005 0.0004 0.160
rs1465618 2 43553949 A G 1.08 (1.03, 1.12) THADA 0.792 0.0004 0.0004 0.380
rs12543663 8 127924659 C A 1.08 (1.00, 1.16) 0.314 0.0001 0.0004 0.860
rs12500426 4 95514609 A C 1.08 (1.05, 1.12) PDLIM5 0.445 -0.0006 0.0003 0.061
rs11214775 11 113807181 G A 1.08 (1.05, 1.11) HTR3B 0.720 -0.0015 0.0004 0.000
rs3096702 6 32192331 A G 1.07 (1.04, 1.10) NOTCH4 0.401 -0.0008 0.0004 0.026
rs9287719 2 10710730 C T 1.07 (1.04, 1.09) NOL10 0.478 -0.0001 0.0003 0.680
rs1270884 12 114685571 A G 1.07 (1.04, 1.10) TBX5 0.483 -0.0003 0.0003 0.430
rs4713266 6 11219030 C T 1.07 (1.04, 1.09) NEDD9 0.514 -0.0004 0.0003 0.200
rs56232506 7 47437244 A G 1.07 (1.05, 1.09) TNS3 0.465 -0.0003 0.0003 0.320
rs8014671 14 71092256 G A 1.07 (1.05, 1.10) TTC9 0.596 -0.0002 0.0004 0.650
rs11902236 2 10117868 A G 1.07 (1.03, 1.10) TAF1B:GRHL1 0.278 0.0007 0.0004 0.068
rs10875943 12 49676010 C T 1.07 (1.04, 1.10) TUBA1C/PRPH 0.275 -0.0005 0.0004 0.170
rs6869841 5 172939426 A G 1.07 (1.04, 1.11) FAM44B 0.211 -0.0002 0.0004 0.700
rs2273669 6 109285189 G A 1.07 (1.03, 1.11) ARMC2,SESN1 0.145 -0.0003 0.0005 0.500
rs9443189 6 76495882 G A 1.07 (1.04, 1.11) MYO6 0.145 0.0003 0.0005 0.600
rs2427345 20 61015611 G A 0.94 (0.91, 0.97) GATAS,CABLES2 0.373 0.0003 0.0004 0.410
rs1775148 1 205757824 C T 1.06 (1.03, 1.08) SLC41A1 0.363 -0.0001 0.0004 0.710
rs1218582 1 154834183 G A 1.06 (1.03, 1.09) KCNN3 0.441 0.0009 0.0004 0.012
rs1041449 21 42901421 G A 1.06 (1.04, 1.09) TMPRSS2 0.446 -0.0002 0.0004 0.620
rs12051443 16 71691329 A G 1.06 (1.03, 1.08) PHLPP2 0.362 -0.0005 0.0004 0.160
rs2121875 5 44365545 G T 1.05 (1.02, 1.08) FGF10 0.673 -0.0005 0.0004 0.210
rs2928679 8 23438975 T C 1.05 (1.01, 1.09) SLC25A37 0.528 -0.0001 0.0003 0.880
rs130067 6 31118511 G T 1.05 (1.02, 1.09) CCHCR1 0.197 0.0005 0.0004 0.220
rs6763931 3 141102833 T C 1.04 (1.01, 1.07) ZBTB38 0.443 -0.0003 0.0003 0.340
Supplementary Table 30: Effect of published autosomal risk loci for prostate cancer on mLOY, Continued. Part 2 of 2
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mLOY SNPs All-Cancer excl. Skin
rsID EA AA EAF Effect p-value log(OR) SE p-value log(OR) SE p-value
rs1122138 C A 0.84 -0.005 3.6E-23 0.0026 0.0018 1.40E-01 0.0021 0.0016 1.90E-01
rs17758695 C T 0.97 -0.01 6.4E-21 -0.0023 0.0037 5.40E-01 -0.0030 0.0034 3.80E-01
rs59633341 D I 0.16 -0.004 2.6E-18 0.0026 0.0017 1.30E-01 0.0025 0.0016 1.20E-01
rs78378222 T G 0.99 -0.013 1.3E-15 -0.0267 0.0060 7.50E-06 -0.0166 0.0055 2.60E-03
rs2736609 C T 0.64 -0.003 1.9E-12 -0.0020 0.0013 1.30E-01 -0.0029 0.0012 1.80E-02
rs13191948 C T 0.54 -0.002 1.2E-11 0.0013 0.0013 3.20E-01 0.0009 0.0012 4.50E-01
rs35091702 I D 0.26 -0.002 4.2E-10 0.0004 0.0015 7.70E-01 0.0009 0.0013 4.90E-01
rs4721217 C T 0.60 -0.002 6.5E-10 -0.0040 0.0013 2.10E-03 -0.0030 0.0012 1.20E-02
rs137952017 D I 0.85 -0.003 1.2E-09 0.0004 0.0018 8.30E-01 -0.0004 0.0017 8.20E-01
rs56084922 A G 0.92 -0.005 2.9E-13 0.0020 0.0024 3.90E-01 0.0028 0.0022 2.00E-01
rs60084722 I D 0.79 -0.003 6.6E-13 -0.0013 0.0016 4.40E-01 -0.0018 0.0015 2.40E-01
rs381500 C A 0.55 -0.002 5.7E-11 0.0016 0.0013 2.00E-01 0.0008 0.0012 4.80E-01
rs12448368 T C 0.87 -0.003 9.8E-10 -0.0043 0.0019 2.40E-02 -0.0040 0.0017 2.20E-02
rs4754301 G A 0.45 -0.002 1.3E-09 -0.0003 0.0013 8.30E-01 -0.0002 0.0012 8.60E-01
rs77522818 A T 0.96 -0.005 1.3E-09 -0.0008 0.0032 8.00E-01 -0.0015 0.0029 6.10E-01
rs11082396 T C 0.87 -0.003 3.3E-09 -0.0011 0.0019 5.60E-01 -0.0008 0.0017 6.40E-01
rs13088318 A G 0.66 -0.002 4.1E-09 -0.0011 0.0013 4.00E-01 -0.0009 0.0012 4.60E-01
rs10687116 D I 0.20 -0.002 2.6E-08 -0.0001 0.0016 9.60E-01 0.0006 0.0015 6.80E-01
rs115854006 C T 0.96 -0.006 3.7E-08 0.0009 0.0037 8.00E-01 0.0005 0.0034 8.80E-01
Supplementary Table 31: Association of the 19 mLOY variants with cancer registrations in UKB. Effect is change in mLRR-Y per
effect allele. log(OR), odds of having received a registration for cancer vs. control status. For brevity, alleles at insertion-deletion







































































































































































































































































































































































































Hand Grip Strength: Stage II & Additional Cohorts
CHARGE Consortium
Fourteen cohorts contributed to the CHARGE grip strength GWAS:
AGES-Reykjavik The AGES-Reykjavik Study is a population-based study of older individuals from the
40-year long Reykjavik Study. Participants were aged between 66 and 96 years and were randomly
recruited between 2002 and 2006 from surviving Reykjavik Study members3. Informed consent was
obtained from all participants. Details of the investigations and local institutional review board approvals
are described in the study’s baseline article3.
Cardiovascular Health Study The CHS is a population-based cohort study of risk factors for CHD and
stroke in adults ≥65 years conducted across four field centers4. The original predominantly Caucasian
cohort of 5,201 persons was recruited in 1989-1990 from random samples of the Medicare eligibility lists;
subsequently, an additional predominantly African-American cohort of 687 persons was enrolled for a
total sample of 5,888. DNA was extracted from blood samples drawn on all participants at their baseline
examination in 1989-90. In 2007-2008, genotyping was performed at the General Clinical Research Cen-
ter’s Phenotyping/Genotyping Laboratory at Cedars-Sinai using the Illumina 370CNV BeadChip system
on 3980 CHS participants who were free of CVD at baseline, consented to genetic testing, and had DNA
available for genotyping.
Framingham Heart Study The Framingham Heart Study (FHS) was initiated in 1948 to study determi-
nants of cardiovascular disease and other major illnesses. The original cohort included 5,209 men and
women, aged 28-62 years at enrollment who have undergone routine biennial examinations5. In 1971,
Offspring of the original cohort participants and Offspring spouses including 5,124 men and women, aged
5 to 70 years, were enrolled into the Framingham Offspring Study. Offspring participants have been ex-
amined approximately every 4 years. In the 1990s, DNA was obtained for genetic studies from surviving
original cohort and Offspring participants. All participants provided informed consent for all assessments
through the Boston University Medical Center IRB.
Health ABC Between March 1997 and July 1998, 3,075 black and white men and women aged 70 to
80 were recruited to participate in the Health, Ageing and Body Composition (Health ABC) Study; charac-
teristics of the cohort have been described elsewhere6. Medicare beneficiary listings were used to recruit
in metropolitan areas surrounding Pittsburgh, Pennsylvania, and Memphis, Tennessee. Eligibility criteria
included having no difficulty walking one-quarter of a mile, climbing 10 steps, or performing activities of
daily living (transferring, bathing, dressing, and eating); no history of active treatment for cancer in the
prior 3 years; and no plans to move from the area within 3 years.
Health & Retirement Study The Health and Retirement Study (HRS) is a longitudinal survey of a repre-
sentative sample of Americans over the age of 50. The current sample is over 26,000 persons in 17,000
households. The study interviews respondents every two years about income and wealth, health and
use of health services, work and retirement, and family connections7. DNA was extracted from saliva
collected during a face-to-face interview in the respondents’ homes. These data represent respondents
who provided DNA samples and signed consent forms in 2006 and 2008.
InCHIANTI The study participants consisted of men and women, aged 65 and older, who participated
in the Invecchiare in Chianti (Aging in the Chianti Area, InCHIANTI) study, conducted in two small towns
in Tuscany, Italy. The rationale, design, and data collection have been described elsewhere, and the main
217
outcome of this longitudinal study is mobility disability8. Briefly, in August 1998, 1270 people aged 65
years and older were randomly selected from the population registry of Greve in Chianti (pop. 11,709)
and Bagno a Ripoli (pop. 4,704), and of 1,256 eligible subjects, 1,155 (90.1%) agreed to participate. Par-
ticipants received an extensive description of the study and participated after written, informed consent.
The study protocol complied with the Declaration of Helsinki and was approved by the Italian National
Institute of Research and Care on Aging Ethical Committee and by the Institutional Review Board of the
Johns Hopkins University School of Medicine.
Lothian Birth Cohorts The Lothian Birth Cohort 1921 (LBC1921) cohort consists of 550 relatively
healthy individuals, 316 females and 234 males, assessed on cognitive and medical traits at 79 years of
age. They were born in 1921, most took part in the Scottish Mental Survey of 1932, and almost all lived
independently in the Lothian region (Edinburgh City and surrounding area) in Scotland. When tested, the
sample had a mean age of 79.1 years (SD = 0.6). A full description of participant recruitment and testing
can be found elsewhere9. Ethics permission for the study was obtained from the Lothian Research Ethics
Committee (LREC/1998/4/183). The research was carried out in compliance with the Helsinki Declaration.
All subjects gave written, informed consent.
The Lothian Birth Cohort 1936 (LBC1936) consists of 1,091 relatively healthy individuals assessed on
cognitive and medical traits at 70 years of age. They were born in 1936, most took part in the Scottish
Mental Survey of 1947, and almost all lived independently in the Lothian region of Scotland. The sample
of 548 men and 543 women had a mean age 69.6 years (SD = 0.8). A full description of participant
recruitment and testing can be found elsewhere10. Ethics permission for the study was obtained from the
Multi-Centre Research Ethics Committee for Scotland (MREC/01/0/56) and from Lothian Research Ethics
Committee (LBC1936: LREC/2003/2/29). The research was carried out in compliance with the Helsinki
Declaration. All subjects gave written, informed consent.
Sydney Memory and Aging Project The Memory and Aging Project (MAP) is a longitudinal clinical-
pathologic cohort study of aging. The study enrolls older adults without known dementia who agree to an
annual assessment of risk factors, blood donation and a structured clinical evaluation11. All participants
sign an Anatomical Gift Act and agree to the donation of brain, the entire spinal cord and selected nerve
and muscles at the time of death. Study participants are primarily recruited from retirement communities
throughout northeastern Illinois. Since October 1997, about 1,650 participants have completed their
baseline evaluation. The follow-up rate of survivors exceeds 90%, and the autopsy rate exceeds 80%.
Religious Orders Study The Religious Order Study (ROS) is a longitudinal clinical-pathologic cohort
study of aging. The study enrolls older adults without known dementia who agree to an annual assess-
ment of risk factors, blood donation and a detailed evaluation12. All participants sign an Anatomical Gift
Act and agree to donation of brain at the time of death. Study participants are primarily Catholic priests,
nuns and brothers from about 40 groups in 12 states. Since January 1994, over 1,100 participants com-
pleted their baseline evaluation. Both the follow-up rate among survivors and the autopsy rate exceed
90
Osteoporotic Fractures in Men Study The Osteoporotic Fractures in Men Study (MrOS) is a multi-
center prospective, longitudinal, observational study of risk factors for vertebral and all non-vertebral
fractures in older men, and of the sequelae of fractures in men13,14. The original specific aims of the
study include: (1) to define the skeletal determinants of fracture risk in older men, (2) to define lifestyle
and medical factors related to fracture risk, (3) to establish the contribution of fall frequency to fracture risk
in older men, (4) to determine to what extent androgen and oestrogen concentrations influence fracture
risk, (5) to examine the effects of fractures on quality of life, (6) to identify sex differences in the predictors
and outcomes of fracture, (7) to collect and store serum, urine and DNA for future analyses as directed
by emerging evidence in the fields of aging and skeletal health, and (8) define the extent to which bone
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mass/fracture risk and prostate diseases are linked. From March 2000 to April 2002, 5994 community
dwelling ambulatory men aged 65 years or older were recruited from six communities in the United States
(Birmingham, AL; Minneapolis, MN; Palo Alto, CA; Monongahela Valley near Pittsburgh, PA; Portland,
OR; and San Diego, CA). Inclusion criteria were designed to provide a study cohort that is representative
of the broad population of older men. The MrOS inclusion criteria were: (1) ability to walk without the
assistance of another, (2) absence of bilateral hip replacements, (3) ability to provide self-reported data,
(4) residence near a clinical site for the duration of the study, (5) absence of a medical condition that
(in the judgment of the investigator) would result in imminent death, (6) ability to understand and sign
an informed consent, and (7) 65 years or older. To qualify as an enrollee, the participant had to provide
written informed consent, complete the self-administered questionnaire (SAQ), attend the clinic visit, and
complete at least the anthropometric, DEXA, and vertebral X-ray procedures. The institutional review
board at each center approved the study protocol, and written informed consent was obtained from all the
participants.
Study of Health in Pomerania The Study of Health in Pomerania (SHIP) is a population based in West
Pomerania, the north-east area of Germany15,16. A sample from the population aged 20 to 79 years was
drawn from population registries. First, the three cities of the region (with 17,076 to 65,977 inhabitants)
and the 12 towns (with 1,516 to 3,044 inhabitants) were selected, and then 17 out of 97 smaller towns
(with less than 1,500 inhabitants), were drawn at random. Second, from each of the selected communities,
subjects were drawn at random, proportional to the population size of each community and stratified by
age and gender. Only individuals with German citizenship and main residency in the study area were
included. Finally, 7,008 subjects were sampled, with 292 persons of each gender in each of the twelve
five-year age strata. In order to minimize drop-outs by migration or death, subjects were selected in
two waves. The net sample (without migrated or deceased persons) comprised 6,267 eligible subjects.
Selected persons received a maximum of three written invitations. In case of non-response, letters were
followed by a phone call or by home visits if contact by phone was not possible. The SHIP population
finally comprised 4,308 participants (corresponding to a final response of 68.7%). This study includes
data of 320 individuals with complete GWAS data who participated in the 10-year follow-up examinations
(SHIP-2).
Study of Osteoporotic Fractures The Study of Osteoporotic Fractures (SOF) is a prospective multicen-
ter study of risk factors for vertebral and non-vertebral fractures17. From 1986 to 1987, 9704 community
dwelling women aged 65 years or older were recruited from population-based listings in four U.S. areas:
Baltimore, Maryland; Minneapolis, Minnesota; Portland, Oregon; and the Monongahela Valley, Pennsyl-
vania. The SOF participants were followed up every four months by postcard or telephone to ascertain
the occurrence of falls, fractures and changes in address. The SOF inclusion criteria were: 1) 65 years
or older, (2) ability to walk without the assistance of another, (3) absence of bilateral hip replacements,
(4) ability to provide self-reported data, (5) residence near a clinical site for the duration of the study, (6)
absence of a medical condition that (in the judgment of the investigator) would result in imminent death,
and (7) ability to understand and sign an informed consent. To qualify as an enrollee, the participant had
to provide written informed consent, complete the self-administered questionnaire (SAQ), attend the clinic
visit, and complete at least the anthropometric measures. The institutional review board at each center
approved the study protocol, and written informed consent was obtained from all the participants.
Tasmanian Study of Cognition & Gait TASCOG is a study of cerebrovascular mechanisms underlying
gait, balance and cognition in a population-based sample of Tasmanian people aged at least 60 years18.
Individuals aged 60âĂŞ86 years (n = 395) living in Southern Tasmania, Australia, were randomly selected
from the electoral roll between 2006 and 2008 to participate in the study. Individuals were excluded if they
lived in a nursing home, had a contraindication for magnetic resonance scanning (MRI) or were unable to
walk without a gait aid. Participants underwent brain MRI scans and genotyping. DNA was extracted from
peripheral blood samples by proteinase K digestion following cell lysis, then phenol-chloroform purifica-
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tion. DNA was genotyped using Illumina Hap370CNV chips at the University of Queensland Diamantina
Institute, Princess Alexandra Hospital, Brisbane, Australia, for 370 participants, and call rates were greater
than 97% for all samples. Genotypes for 22 individuals were excluded, either because they were closely
related to other individuals, they were outliers in a population ancestry analysis or their sex predicted from
genotypes did not match sex as recorded in the database. Among the 348 remaining participants with
available genome-wide data, after exclusion of 2 participants with dementia, 3 with posterior circulation
infarcts on MRI and 3 with insufficient MRI image quality, 340 individuals were available for the present
analysis on hippocampal volume.
TwinsUK The TwinsUK registry now consists of about 12,000 monozygotic (MZ) and dizygotic (DZ)
twins aged 18 to 103 years. About 83% of the registry is female (mean age of 55 years). The registry
now contains 51% MZ and 49% DZ twins. Between 1992 and 2004, twins were invited for a full com-
prehensive visit and several project-led studies. More than 7,000 twins responded to some of the annual
questionnaires and 5,725 attended a comprehensive visit. Apart from a lifelong lower weight in MZ twins
of around 1 kg, all other age-matched characteristics of these volunteer twins were found not to differ
from a singleton population-based cohort of British women19. Between April 2004 and May 2007, all the
6,740 active twins on the registry were invited for a 1-day clinical visit, of whom 3,725 twins attended
and 1,299 twins posted their blood DNA samples via their general practitioners. The age of participants
ranged between 18 and 82 years (mean 52.5 Âś 13 years) and 3,299 of the clinic attendants (89%) were
female.
Further Stage II Samples
Erasmus Rucphen Family Study The Erasmus Rucphen Family genetic isolate study (ERF) is a
prospective family based study located in the southwestern Netherlands20. This young genetic isolate
was founded in the midâĂŘeighteenth century and minimal immigration and marriages occurred between
surrounding settlements due to social and religious reasons. The ERF population includes 3,465 indi-
viduals that are living descendants of 22 couples with at least six children baptized. The study protocol
was approved by the medical ethics board of the Erasmus MC Rotterdam, the Netherlands. The baseline
demographic data and measurements of the ERF participants were collected around 2002 to 2006. All
the participants filled out questionnaires on socio-demographics, disease and medical history and lifestyle
factors, and were invited to the research center for an interview and blood collection for biochemistry and
physical examinations. In the main follow-up of the study by May, 2016 (follow up from 9 to 14 years),
1,940 baseline participants’ records were scanned in the general practitionerâĂŹs database.
Health 2006 and 2008 Cohorts The Health2006 study is a general population-based study (started
in 2006) designed to investigate lifestyle-related chronic diseases such as coronary heart disease, dia-
betes, musculoskeletal disorders, asthma, allergy, chronic lung diseases and mental disorders in men and
women aged 18 to 69 years. The Health2008 study (started in 2008) is an extension of the Health2006
study using essentially similar collection methods, investigating men and women aged 30 to 60 years,
living in the same municipalities as participants from Health2006. A random sample of potential vol-
unteers was obtained from the Danish Civil Registration system. All participants were Danish adults
living in 11 municipalities in the south-western part of the greater Copenhagen area, Denmark. Preg-
nant women were excluded. All participants had measurements done at the Research Centre for Pre-
vention and Health at the Copenhagen University Hospital in Glostrup. Participants were asked to be
fasting at the day of examination for a detailed clinical examination when blood samples were collected.
Written informed consent was obtained from all participants and the study was approved by the Ethical
Committee of Copenhagen County and the Danish Data Protection Agency. The study is registered at
www.clinical.trials.com.
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Hunter Community Study The HCS21 is a population-based study comprised of middle-aged to older
adults aged 55-85 years from Newcastle, Australia. Voting registration in Australia is compulsory and
participants were recruited randomly from the electoral roll. Potential participants were excluded if they
could not speak English and/or if they lived in an aged-care facility. The final sample included 3207 par-
ticipants. Ethics approval was obtained from the Hunter New England Local Health District and University
of Newcastle Human Research Ethics Committees and written informed consent was obtained from all
participants. Comprehensive data was collected including samples for genetic analyses.
Sydney Memory & Ageing Study The Sydney MAS22 is a longitudinal population-based study, which
recruited community-dwelling adults aged 70-90 years at baseline from Sydney. In Australia voting regis-
tration is compulsory and participants were recruited randomly from the electoral roll. Exclusion criteria
included a diagnosis of dementia, schizophrenia or bipolar disorder and medical or psychological condi-
tions that would prevent them from completing assessments. The final sample was comprised of 1,037
participants at baseline. Ethics approval for Sydney MAS was granted by the Human Research Ethics
Committees of the University of New South Wales and the South Eastern Sydney and Illawarra Area
Health Service. Written informed consent was provided by all participants. A wide range of data was
collected including samples donated for genetic analyses.
TwinsUK Additional Samples In addition to the TUK sample contained within CHARGE, Twins UK
contributed 3009 additional genotyped grip strength samples that were not included in the pre-existing
CHARGE GWAS discussed above. The TwinsUK cohort (www.twinsuk.ac.uk) is an adult twin British
registry shown to be representative of singleton populations and the United Kingdom population19. The
mean age of the 3009 individuals was 52.5 (Âś10.9) years. Ethical approval was obtained from the
GuyâĂŹs and St. ThomasâĂŹ Hospital Ethics Committee. Written informed consent was obtained from
every participant to the study.
Athlete case-control studies
European Athletes The European Athlete study consists of white European sprint and power athletes
(n=395) and approximately geographically-matched white European controls (n=726). Participant DNA
was whole genome amplified and normalised before SNP-based genotyping at each of the sixteen grip
strength SNPs identified in combined analyses (Sequenom). Genotyping was conducted at the Australian
Genome Research Facility (AGRF). 12 SNPs passed quality control (HWE pâL’ě0.05) and genotype as-
sociations between cases and controls were assessed using conditional logistic regression with country
as a covariate (conducted in R). All participants supplied written informed consent, which was approved
by each respective cohortâĂŹs institution. This includes approval by the institutional review boards of
the the ChildrenâĂŹs Hospital at Westmead (2003/086), The Royal ChildrenâĂŹs Hospital Human Re-
search Ethics Committee (35172), the Pomeranian Medical University Ethics Committee, Universidad
Pablo Olavide, The Lithuanian National Committee of Biomedical Ethics, Aristotle University of Thessa-
loniki Research Committee, The Ethics Committee of the University of Cagliari, Ghent University Hospital,
Belgium and the Nottingham Trent University Ethical Review Committee.
Japanese Athletes The Japanese cohort is comprised of 54 international sprint/power track and field
athletes and 406 geographically matched controls. Total DNA was isolated from venous blood and saliva
by QIAamp DNA Blood Maxi Kit (QIAGEN, Hilden, Germany) and OrageneÂůDNA (DNA genotek, On-
tario, Canada), respectively. DNA Samples from all subjects were genotyped on the HumanOmniExpress
BeadChip (Illumina). Ten of the sixteen replicated SNVs associated with grip strength in the present
study were available in this Japanese population either directly or by proxy (r2âL’ě0.8). Genotyping qual-
ity of each polymorphism was checked by visually in GenomeStudio (Illumina). This study is part of the
Japanese Human Athlome Project, focusing on the study of genes associated with physical performance
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and its related phenotypes23. Written consent was obtained from each subject, and the study was ap-
proved by the Ethics Committees of Juntendo University, the Japanese National Institute of Health and
Nutrition and the Japan Institute of Sports Sciences.
Jamaican and US Athletes This cohort is comprised of high-level black athletes (n=167) and geograph-
ically matched controls (n=478). Samples were genotyped using the HumanOmniExpress or Omni1-Quad
BeadChips (Illumina). Standard GWAS quality control was applied to the genotype data. Genetic associa-
tions were evaluated by logistic regression with adjustment for population structure. Genotype imputation
with IMPUTE2 using the 1000G phase 3 reference panels was then conducted to increase power of GWA
scans. This investigation aims to understand the influence of common genetic variants on performance
through the use of athletic populations enriched with high-level competitors. All participants supplied writ-
ten informed consent, which was approved by the UHWI/UWI/FMS Ethics Committee, University of West
Indies, Jamaica and participating institutions in the United States.
Genetic Factors for Osteoporosis (GEFOS) Consortium
The GEFOS consortium is an international collaboration of investigators dedicated to identify the ge-
netic determinants of osteoporosis (http://www.gefos.org/). The original any-type of fracture GWAS meta-
analysis comprised 24 GWA studies (20,439 cases, 78,843 controls) from populations across North Amer-
ica, Europe, East Asia and Australia, with a variety of epidemiological designs and patient characteristics.
Cases were individuals (>18 years) with fractures confirmed by medical, radiological or questionnaire
reports. When possible, fractures of the fingers, toes and skull were excluded from analyses. GWAS
genotyping was done by each study following standard manufacturer protocols followed by imputation to
2.5 million SNPs from HapMap Phase II.
Muscle Histology
The muscle histology study was performed on 656 men from three independent cohorts of Swedish an-
cestry. These cohorts included Uppsala Longitudinal Study of Adult Men (ULSAM, n=482)24, Malmö Men
(MM, n=128)25 and Malmö Exercise Intervention (MEI, n=46)26. The ULSAM cohort included non-diabetic
males of age 71.0 Âś 0.64 years and body-mass index (BMI) 26.3 Âś 3.4 kg/m2. The MM cohort consists
of non-obese males aged 65.9 Âś 2.0 years and with BMI 26.4 Âś 3.4 kg/m2, including 50 individuals
with diagnosed Type II diabetes (T2D). The MEI cohort consists of male subjects aged 37.7 Âś 4.3 years,
VO2MAX 32.0 Âś 5.0 ml/kg/min and BMI 28.0 Âś 3.1kg/m2 with (n=22) and without (n=24) a first degree
family member with T2D. The primary phenotypes included in the GWA-analysis were percentage of (i)
type I, (ii) type IIa, and (iii) Type IIx fibres, as well as capillary density, calculated as number of capillaries
divided by total number of fibres. Phenotypes were inverse-normalised for analysis. Genotype data in
each cohort were imputed up to 35 million variants from the 1000 Genomes âĂIJall ancestriesâĂİ refer-
ence panel (March 2012). Prephasing of haplotypes and imputation were performed using ShapeIT and
IMPUTE2, respectively. The association within each cohort was performed using SNPTEST frequentist
score additive model test.
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Resting Energy Expenditure GWAS Analysis Plan (1000G Imputed) 
 
Version 2.1, distributed 9th March 2016. 
 
Prepared by the Resting Energy Expenditure Genetics Consortium (REE-Gen).  







1 Genotyping & Imputation 
 
 
We request that all studies are imputed to 1000G, Phase III. If your study is imputed to a different reference panel, 
please let us know.  We can meta-analyse results using different imputation strategies, including HapMap.   
 
We presume that pre-imputation sample QC was performed to account for call rate, heterozygosity, relatedness 
(unless participants are related by study design) and outlying ethnic ancestry.  If you have questions, would like to 




2 Association Analyses 
 
 
GWAS of REE will be conducted using z-score standardised residual REE (after adjustment for covariates) as the 
outcome.  Follow the steps detailed in 2.1 to 2.3 to generate the residuals and conduct the analyses.  Please bear in 
mind the following points: 
 
 
Derivation of REE  The trait of interest is total daily REE (kJ / 24hr).  For consistency, this should have been generated 
via the abbreviated Weir Equation using VO2 and VCO2 from steady-state resting calorimetry in thermoneutral, 
fasted participants. If an alternative derivation equation has been used, please recalculate the REE using the Weir 
approach if possible: 
 
REE (kJ / 24hr) = 4.184 (1.44 (3.9 VO2 + 1.1 VCO2)) 
 
Note that VO2 and VCO2 in this equation are mL/min, not mL/min/kg 
 
The original abbreviated Weir equation (shaded green) calculates the REE in kcal / 24hr. An adjustment factor has 
been included in the above formula to convert this kcal result to kJ, based on 1 kcal = 4.184 kJ.  Please double-check 
that your REE phenotype is expressed as kJ / 24hr, not kcal.  Contact us with any questions.   
 
 
Population Stratification  In the Fenland Study, we have conducted initial genome-wide analyses using BOLT-LMM, 
which implements GWAS using linear mixed models.  LMM have the particular benefit of not being liable to sub-
ethnic population stratification when applied to a population of known continental ancestry (e.g. white Europeans), 
precluding the need to include genomic PCs as indicators of underlying structure.  The method also confers power 
benefits in large population-based studies.  If convenient, please consider using this tool (available from 
http://www.hsph.harvard.edu/po-ru-loh/software/).  Dan will be happy to discuss and share scripts.  If using linear 
regression-based software for the association analyses (e.g. SNPTest), please adjust for underlying population 
structure using your standard approach (e.g. genomic PCs, the number of which can be defined by each study).   
 
 
Known Relatedness  Some of the contributing cohorts use family-based recruitment.  In these cases, please take 
any usual steps to account for relatedness within the sample (whilst maximising sample size for REE).  This will 
usually involve conditioning the analyses on a kinship matrix.  Note that BOLT-LMM can also help here .     
 
 
Indels, CNVs and Multiallelic SNPs If available in your genotyping data, please retain all such variants for analysis 
alongside biallelic SNPs. Depending on naming, we may be able to standardise these centrally and retain for meta-
analysis.  
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In All Models:  Assume additive genetic effect.  Please do not impute missing phenotypes or omit true outliers (i.e. 
those which correspond to a real observation).  Do not apply genomic correction to results, nor filter results based 
on imputation quality; we can do so centrally.  
 
 
Standard Covariates:  All models should be adjusted for age at calorimetry (years) and biological sex.  Age squared 
can also be included as a covariate if this is usual for your study, explains additional variance, or a non-linear age-REE 
association is expected.  Depending on your study design, adjust for study-specific covariates as required; e.g. for 
study site if a multi-centre study, or device ID if calorimetry was measured using different devices for different 
participants.  As discussed on the TC, ambient air temperature during calorimetry (°C) should be included as a 
covariate where available.   
 
 
2.1  Generate Residuals of REE 
 
- Trait is total daily REE (kJ / 24hr) 
- Derived (where possible) via the Abbreviated Weir Equation using steady-state VO2 and VCO2 from resting 
calorimetry in fasted, thermoneutral participants (see above). 
 
Using linear regression, generate a set of crude REE residuals for each of the three models: 
 
Model 1 (Baseline):     REE (kJ/24hr) ~ Standard Covariates 
Model 2 (Weight-Adjusted):    REE (kJ/24hr) ~ Standard Covariates + Weight (kg)  
Model 3 (Weight and Height-Adjusted):   REE (kJ/24hr) ~ Standard Covariates + Weight (kg) + Height (m)  
 
 
2.2 Standardise REE Residuals 
 
Standardise each set of residuals from 2.1 by applying a z-score transformation – i.e. to produce a distribution with 
mean = 0 and standard deviation = 1. 
 
This step can be easily run in STATA using the zscore command or in R using the scale function     
 
 
2.3 Genome-Wide Association 
 
Conduct genome-wide association for all three sets of standardised residuals:  
 
A) Standardised REE residuals from Baseline Model ~ Population Structure 
B) Standardised REE residuals from Weight-adjusted Model ~ Population Structure 
C) Standardised REE residuals from Weight and Height-adjusted Model ~ Population Structure  
 
 
We encourage you to consider using BOLT-LMM for these analyses, but please feel free to apply your current 
pipeline if more convenient.  Apply your normal approach (e.g. inclusion of genomic PCs) to account for population 
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3.1 File Format 
 
Results for each model should be returned as a separate tab-delimited text file including both typed and imputed 
variants, one variant per line (multiple lines may be required if the variant is multiallelic, see below).  For each variant, 
please provide the variables shown in the table.  The first line of the file should contain these variable names as a 




Variable Name Details Format 
snp Unique SNP identifier, e.g. rsID   rsID 
chr Chromosome Integer 
pos Base pair coordinate, build 37 (hg19) Integer 
effect_allele Allele to which effect estimate corresponds String (see below) 
other_allele Alternative allele at this position String (see below) 
n Number of individuals analysed Integer 
eaf Observed frequency of effect_allele in study cohort Numeric  
hwe_p Hardy-Weinberg p-value for variant (NA if imputed) Numeric 
beta Effect size corresponding to effect_allele Numeric 
se Standard error of effect size (uncorrected for GC) Numeric 
pval p-value of association (uncorrected for GC) Numeric 
info Imputation quality (0-1) Numeric 




Flagging Typed Variables  The typed indicator is not included in BOLT-LMM output; please flag typed variants 
manually.  As BOLT provides separate output files for typed and imputed loci, typed loci can be quickly flagged by 
reading in the typed results and generating typed ==1 for all observations, before appending the imputed results file.   
 
 
Hardy-Weinberg Equilibrium  For variant QC during meta-analysis, we ask that HWE p-values are returned.  In 
SNPTEST, HWE p-values can be outputted by specifying the –hwe option.  BOLT cannot currently output HWE p-
values, which will need to be merged in from another source.  Should you need to calculate these from scratch, exact 
Hardy-Weinberg tests can be run in PLINK using the --hardy option.  Please calculate p-values using the exact (as 
opposed to asymptotic) Hardy-Weinberg test for all participants.  Contact Dan if you have any queries.  
 
 
Allele Coding  For biallelic SNPs, the effect allele and other allele should be specified as A/C/T/G.  For other variant 
types, please report alleles using your normal practice.   All biallelic variants should be reported one variant per line 
in the returned file.  For multiallelic variants, more than one line may be reported for the same genomic coordinate 
(i.e. chromosomal position) to represent the different combinations of alleles at the site.  We will harmonise variant 














Provide all values for all analysed variants exactly as displayed in association output. 
 
Do not correct for genomic control  
 
Please do not apply any filtering to results (for example, based on MAF or imputation quality) 
 
Please include HWE p-value to facilitate variant QC during meta-analysis 
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Ancestry  EUR for White European, AFR for Black African descent, PIM for Pima Indian. 
Model  as for baseline, asw for weight-adjusted, aswh for weight and height-adjusted  
Study  Study Abbreviation:  QFS, NEO, ICSHIB, BLSA, PIMA etc. 
Software  Software used to run GWA analyses (e.g. BOLT, SNPtest etc.) 
Date  Analysis date (DDMMYY) 
Initials  Initials of person uploading file 
 
e.g. EUR_GWAS_residREE_zstand_as_Fenland_BOLT_150316_DW.txt  
 
 
3.3 Cohort Details 
 
Please provide descriptive statistics of your cohort using the spreadsheet distributed with this analysis plan 
(REEGen_Additional_Information_Sheet_V2_March2016_Final.xlsx).   
 
Descriptives should be restricted to the individuals included in the GWAS. 
 
Please additionally provide histograms for each set of standardised residuals generated, plus the non-residualised 
crude REE phenotype (kJ / 24hr) – i.e. four histograms in total.  Please provide each histogram as a separate image 








Name the non-residualised REE phenotype distribution as  
 
Distribution_REE_crude_[Study].png 
   
 
 
3.4 Data Upload 
 
An SFTP site hosted by the MRC Epidemiology Unit is provided for return of results.  
 
Host  sftp.mrc-epid.cam.ac.uk 
Username sftp-REE-Gen 
Password E-mail Dan when you are ready to upload; he will provide password by phone. 
 
Unix and MacOS X:  Use sftp or scp at the terminal 
 
Windows:  We suggest using FileZilla (http://sourceforge.net/projects/filezilla).  Connect your client to the host.  
 
 
To minimise upload size, please compress all files being returned into a zip archive or similar (named with the study 
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